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Abstract
This Dissertation is divided into five chapters reporting various aspects of the
background to my field of study and the results obtained during my research program.
Chapter 1 gives a very brief introduction to photodynamic therapy including the
mechanism of the treatment, the localization of photosensitizer in tumor cells, the
pathways leading to tumor death and characteristics of various photosensitizers such as
porphyrin-based photosensitizers and non-porphyrin based photosensitizers.
Chapter 2 reports a total synthesis of zinc(II) isoporphyrins by cyclization of b-bilene salt
using α-keto esters for the macrocyclization carbon. Functionalization of the resulting
zinc(II) isoporphyrins was attempted using different strategies such as direct
functionalization of the isoporphyrin after cyclization of the b-bilene salt and introduction
of the functional group during the cyclization of b-bilene salt.
Chapter 3 desrcibes a different total synthesis of zinc(II) isoporphyrins by way of the
MacDonald 2+2 condensation approach. A serial of zinc(II) isoporphyrins were obtained
and further functionalization of these compounds was also attempted by use of various
hydrolytic reactions. Functionalization of dipyrromethanes before cyclization was also
investigated through hydrolytic and amination reactions.
Chapter 4 explores novel syntheses of BODIPYs using pyrroketones as starting
materials. Reactions of pyrroketoned including electropholic alkylation with Meerwein’s
salt, chlorination using phosgene, and protonation with acids were investigated. The
reactivity of the derivatives, especially, 5-chloro-dipyrromethenes and 8-chloro-BODIPYs
were also investigated by using replacement (substitution/elimination) and modern

x

organometallic coupling reactions. Some meso-substituted BODIPYs were obtained and
their photophysical properties were studied, including absorption, fluorescence and
quantum yields.
Chapter 5 presents a synthesis of tri-chloro-BODIPYs. Global and regioselective Stille
coupling reactions were investigated using tri-chloro-BODIPYs. A novel series of new
symmetrical and unsymmetrical BODIPYs s were synthesized using this method.

xi

Chapter 1: Introduction
1.1 Photodynamic Therapy (PDT)
Photodynamic therapy (PDT) was discovered in the 19 th century and matured as a
viable medical technology in the 1980s at several institutions throughout the world,
in countries such as Canada, USA and Japan. This treatment involves the use of
photochemical reactions mediated by the interaction of a photosensitizing agent,
light, and oxygen, to kill malignant tumor cells. Depending on the part of the body
being treated, the drug is either injected into the bloodstream or applied to the skin;
over time, the drug is preferentially absorbed by cancer cells and clears from
normal cells. Then a specific wavelength of light is applied to initiate a
photochemical reaction and produce singlet oxygen, the active form of oxygen, and
other active oxygen spevcies which can damage the cancer cell (Figure 1.1).1

xii

Figure 1.1: The application of photodynamic therapy.1
A simplified Jablonski diagram (Figure 1.2) is used to explain what actually happens
during the treatment. Once photosensitizers are exposed to a specific wavelength of
light, they are promoted from the ground state S0 to the spin-allowed excited singlet
states Sn; from this point, the photosensitizers can undergo several electronic changes.3
Radiationless deactivation of photosensitizer from upper-lying excited states to the
lowest excited state is a very fast process on the picosecond time scale. From the lowest
excited state, the photosensitizers can release energy in the form of fluorescence and
return to ground state. The pathway which involves intersystem crossing from the lowest
excited singlet state to triplet state is the key process for PDT and a high population of
triplet state is required to produce toxic 1O2; if the triplet state population is too low, the
photosensitizer will return to its ground state with the emission of light as
phosphorescence. From triplet state, the photosensitizer can transfer the energy to the

Figure1. 2: Jablonski diagram.
http://www.chemicool.com/img1/chem-ed/quantum/graphics/jablon.gif
2

nearby molecule triplet oxygen through spin exchange and generate the highly reactive
singlet oxygen, which is believed to be one of the key species toxic to cancer cells. The
half life of singlet oxygen is less than 0.04 µs and it thus has a migrating radius smaller
than 0.02 µm2, therefore making PDT a very local treatment.
1.2 Localization of Photosensitizer in Tumor Cells
It was discovered that some compounds, especially porphyrins and porphyrin derivatives,
can selectively localize in tumor cells compared with normal cells.4 Although intensive
studies have been done to find out the mechanism, there is still no clear result so far.
However, it has been found that all the different photosensitizers are bound to serum
protein to some degree after injection into the bloodstream.5 Based on pharmacokinetic
studies of photosensitizers,6 one of the proposals is that photosensitizers prefer to bind
to albumin and heavy proteins such as HDL, LDL and VLDL. The assumption in this
theory is that the tumor cell can overexpress heavy proteins such as LDL-receptors
compared with normal cells since tumor cells grow faster than normal cells and they
need more cholesterol to permit the rapid growth of cellular membranes. Therefore,
when the photosensitizers circulate in a patient’s body, most are absorbed by the tumor
cells instead of normal cells. There are some other theories, more related to the
structural difference between cancer cells and normal cells. It was found that tumor cells
usually have a lower pH environment than do normal cells, and they therefore have
affinity for anionic photosensitizers. For example, Thomas and Girotti7 found that
decrease of pH by admistrating glucose into tumor cells can result in a greater
accumulation of the sensitizer hematoporphyrin derivatives (HpD). The assumption is
that negatively charged photosensitizers are neutralized once protonated and therefore
become more lipophilic, which is a very important property during localization since the
membrane of tumor cells is also lipophilic. Another theory is related to the vascular
3

permeability of photosentizers to tumor cell and lymphatic drainage of tumor cells. It is
well known that photosensitizers behave as macromolecules because they are either
bound

to

large

proteins or form intermolecular aggregates.8 Vasculature

is

nonproliferative for adults while the vasculature of tumors has some embryonic vessels
and neovasculature which are highly proliferative; the photosensitizers usually have an
affinity for proliferative neovaculature9 over nonproliferative vasculature, therefore
increasing the permeability of the photosensitizers to the neovasculature of the tumor.
Additionally, the tumor cells have poorly developed lymphatic drainage ; the
photosensitizers which extravasate from the hyperpermeable tumor neovasculature tend
to remain in the extravascular space.
There are some relationships between the structures of photosensitizers and selectivity
for the tumor, specifically, in different organelles of tumor cells (Figure 1.3). According to
the structures of the photosensitizers, they could be classified into three categories:
hydrophilic photosensitizers (such as tetra-sulfonated derivatives of tetraphenylporphine),
amphiphilic photosensitizers (like benzoporphyrin derivative monoacid) and hydrophobic
photosensitizers (such as unsubstituted phthalocyanines). According to whether or not
the photosensitizers carry charges, they could be classified into anionic, cationic or
neutral photosensitizers. Depending on the properties of photosensitizers, they can
diffuse across the plasma membrane and selectively relocate in one of the organelles of
the tumor cell or several of them including mitochondria, lysosomes, Golgi and
Endoplasmic Reticulum (ER) or plasma. Some correlations between the characteristic of
photosensitizers and their localizations in tumor cell were found through years of studies.
The photosensitizers with net negative charges (anionic photosensitizers) tend to
localize in the lysosomes, while the photosensitizers with positive charges (cationic
photosensitizers) prefer to localize in mitochondria.10 For example, Woodburn et al.
reported the intracellular localization of a series of porphyrin
4

Figure 1.3: The configuration of cell.
Taken from: http://www.enchantedlearning.com/subjects/animals/cell/
derivatives with different properties (Table 1.1) such as hydrophobic, anionic or cationic
characters in V79 Chinese hamster lung fibroblasts and C6 glioma cells.11 The
localization results are listed in Table 2. One can see that anionic photosensitizers 2, 8,
and 10 mainly localized in lysosomes and cationic photosensitizer 4, 6, 7 and 9 preferred
to localize in mitochondria. Lysosomes, and mitochondria are the main subcellular
compartment PDT targets. Some photosensitizers localized in the Golgi apparatus and
endoplasmic reticulum (ER) instead of lysosomes and mitochondria. For instance,
Foscan12 predominantly localized in Golgi and ER with very weak accumulation in
mitochondria. For the amphipathic photosensitizers, there should be a balance between
hydrophobic and hydrophilic properties. Hydrophilicities can facilitate the delivery of the
photosensitizers through the bloodstream and hydrophobic properties can help with the
permeability of the membrane of tumor cells.

5

Table 1.1. Photosensitizers with Different Properties.

Compound
1 (HpD)
2
3
4
5
6
7
8
9
10

R

R’

HC(CH3)OH
HC(CH3)OCH3
CH=CH2
HC(CH3)O(CH2)2OCH2CH3
HC(CH3)O(CH2)2OCH2CH3
HC(CH3)SCH2CONH(CH2)2N(CH3)2
HC(CH3)S(CH2)2NO
HC(CH3)S(CH2)2NO
HC(CH3)O(CH2)2N(CH3)2

OH
OCH3
NH(CH2)2N(CH3)2
OH
NH(CH2)2N(CH3)2
NH(CH2)2N(CH3)2
OH
NH(CH2)2N(CH3)2
OH

*

Table 1.2. The Localization of Photosensitizers in Different Organelles.
R

R’

2

hydrophilic

Anionic

3

hydrophobic

Hydrophobic

4
5

hydrophobic
hydrophobic

cationic
Anionic

6

hydrophobic

Cationic

7

Amphipathic

catioic

8

amphipathic

Anionic

Compound
1(HpD)

6

Localization
Diffuse cytoplasmic plus
perinuclear
Diffuse cytoplasmic plus
lysosomes
Diffuse cytoplasmic plus
lysosomes
mitochondria
Diffuse cytoplasmic
C6; mitochondira
lysosomes
V79; mitochondria
lysosomes(vacuolation)
mitochondira
cytoplasmic
lysosomes
lysosome engorgement

Table 1.2 continued
.
Compound

R

R’

9

amphipathic

Cationic

10

amphipathic

Anionic

Localization
C6; mitochondria
lysosomes
V79; mitochondria
cytoplasmic
lysosomes
lsysosome
engorgement

1.3 The Pathways Leading to Tumor Cell Death

The outcome of PDT depends on numerrous factors such as the localization of
photosensitizers, tissue types, and PDT dose, etc. There is no single pathway leading to
cell death; a combination of factors is necessary to achieve the optimum tumor cures.
There are three main independent pathways leading to tumor cell death: (1) subcellular
localization-induced apopotosis and necrosis, which is the direct tumor cell death effect
of PDT; (2) vasculature destruction is another way to kill tumor cell; and (3) immune
system response is the impact after the PDT is completed, and is therefore called the
post-PDT effect. Apoptosis is an energy-consuming process through activation of a
death receptor or the mitochondrial release of cytochrome;13 both of these pathways
could activate caspase which can cause damage to subcellular organelles such as
mitochondira, lysosomes and ER, or initiate DNA fragmentation and cell shrinkage.
Apoptosis is the dominant, rapid and intermediate form of tumor cell death during
photodynamic therapy. Another pathway that can lead to direct tumor cell death is
necrosis. Necrosis14 has been considered an uncontrolled process caused by physical or
chemical damage. It is an intense and rapid form of degeneration that can cause
cytoplasmic swelling, damage to organelles and dysfunction of plasma membrane.
Therefore the necrosis process really depends on the PDT dose such as high
photosensitizer concentration or a high light fluence, or both; the pathway of cell death
can switch from apoptotic to necrotic when the PDT dose is excessive. The localization
7

of photosensitizer can also play a role in the cell death pathway. Mitochondria localizing
photosensitizers

usually

induce

apoptosis

while

plasma

membrane

localizing

photosensitizers are most likely to induce necrosis, which can damage the plasma
membrane integrity due to acute inflammation. There are another two pathways leading

Figure 1.4: The formation of angiogenesis15 (a) photosensitizer in the vessel at the
beginning; (b) photosensitizer diffused into the surrounding tissue gradually as time
increases; (c) vascular endothelial growth factor (VEGF); (d) The emergence of new
blood vessels accompanied by endothelial cell proliferation and migration.

8

to tumor cell death beside apoptosis and necrosis. One of them is vascular damage; as
was mentioned in discussion of localization in tumor cells, the blood is the medium to
deliver the nutrient and oxygen to cells through vessels. Damage to the neovasculature
can lead to thrombosis, hemorrhage and tissue hypoxia. Nutrient deprivation and
eventual starvation can also cause death of tumor cells15 (Figure 1.4).
Photodynamic therapy is a local treatment. However, this treatment can also have some
systemic attributes since it can induce response of the immune system. PDT induced
anti-tumor immunity is due to the acute inflammatory response, exposure and
presentation of tumor-specific antigens.16 With the PDT-induced destruction of the tumor
cells, a strong inflammatory reaction occurs locally at the same time and enables the
influx of non-affected immune cells into the PDT-site from elsewhere and result in the
development of a systemic anti-tumor immune response.17 In summary, the effect of
PDT is the combination of various factors such as subcellular localization of
photosensitizers, PDT dose and tissue targets, and these factors cannot be localized
independently.
1.4 Lights and Penetration of Tissue.
Light is one of the non-toxic components of photodynamic therapy and is used as an
energy form to activate the photosensitizers. Therefore, it is very important to develop
light resources in parallel with photosensitizers. Lasers are the mostly common light
source used in photodynamic therapy18 due to their capability of generating a coherent
light beam. The light could be directed to the site need to be treated through optical
fibers with a 200-400 µm diameter. Figure 1.5 shows the correlation between
wavelength of light and the depth of penetration into tumor.19 Semiconductor lasers such
as LED lights will be the preference in the future because they are cheap and easy to
handle.
9

Figure 1.5: The wavelength dependence of depth of penetration of light into a tumor.19
1.5 Advantages and Limitations of PDT.
Photodynamic therapy is a very selective treatment of tumor cells over normal cells. It
can target the tumor cell very precisely without damage to surrounding tissues due to the
short-lived 1O2, which only can migrate within the cell about 0.02 µm. Compared with
traditional cancer treatments such as chemotherapy,

radiation, and

surgery,

photodynamic therapy is less invasive, the only invasive operation being the technique
that is used with the optical fiber, which is very small and is used to penetrate the tissue
to direct the incoming light. Therefore, there is little or no scar left after treatment of
superficial tumors. Another advantage of PDT is that this treatment can be used at the
same site repeatedly until all cancer cells are killed.
Of course, there are some limitations with this PDT treatment. The main drawback of
PDT is that it can be only used to treat early stage cancers. Once the tumor cells spread,
it is hard to target any metastases. It cannot be used to treat larger tumors due to the
problem of light penetration though tissues. Another inconvenience of this treatment is
10

that the delay time after injection of photosensitizer can be fairly long from 24 hours to
72 hours. Another complication is that the patients can remain photosensitive after
treatment for some time depending on the photosensitizer used. Investigators are
developing more mature photodynamic therapies to solve these issues.
1.6. Ideal Photosensitizers
To be an ideal photosensitizer, the compound should meet the following requirements to
achieve a good outcome in photodynamic therapy:
1. The compound should have preferential tumor localization over normal cells. The
better localization can be achieved by conjugation of biomolecule such as amino acids
or sugars to the molecule.
2. The photosensitizer candidate should be able to generate singlet oxygen (1O2)
efficiently which is mostly responsible for the tumor cell death in photodynamic therapy.
This requires the compound to have a high quantum yield of the triplet state (φT > 0.4)
with a long lifetime ( t > 100 µs).
3. The photosensitizers should have an absorption region between 630-800 nm (Figure
1.6) with high extinction coefficient. The energy gap between 3O2 and 1O2 can be
measured by observing its 1270 nm phosphorescence. By detection of the 1270 nm
phosphorescence emission, theoretically, a photosensitizer with a triplet state energy
higher than 94kJ/mol (1270 nm) can transfer its energy to ground state 3O2. However,
the photosensitizer with long wavelength absorption cannot efficiently generate singlet
oxygen. For example, a reported 34-π conjugated porphyrin with absorption at 940 nm
did not produce singlet oxygen.20
4. The photosensitizer should be nontoxic in the absence of light and have minimal
residual skin photosensitivity.

11

5. The sensitizer should be photostable and biologically stable, and easily to soluble in
injectable solvents. This requires the photosensitizer should have some amphiphilic and
hydrophobic groups attached.
6. The photosensitizers should be chemically pure so that the subsequent studies such
as pharmacokinetics and dose-response correlation can be performed easily.

Figure1.6: The therapeutic window of photodynamic therapy.
http://www.photobiology.info/Hamblin.html

1.7. Porphyrin-based Photosensitizers
Porphyrins and their derivatives21 are a class of very important biological products in
nature. Porphyrins are the building blocks of hemoglobin and myoglobin which are the
two major oxygen binding proteins in blood. These aromatic macrocyles possess 18-π
electrons and have very interesting optical spectra with a Soret absorption band around
400 nm belonging to the π-π* transition and four small Q bands in the visible region.
When porphyrins are reduced by breaking a cross-conjugated double bonds without
12

interruption of the aromaticity of macrocycle, the Q-band is red shifted with a high
extinction coefficient19 (Figure 1.7). This is probably due to perturbation introduced to the
planar and symmetrical porphyrin ring and the energy of the HOMO orbital is raised and
therefore reduces the energy gap between the HOMO and LUMO orbitals.22 From the
optical spectrum of porphyrins and their derivatives, one can see that their absorption in
the visible and IR areas make these molecules very good candidates as potential
photosensitizers. Porphyrins also possess some other potentially advantageous features
including their localization in tumor cells, ability to produce singlet oxygen, their
florescence, low-dark toxicity and high chemical stability. All these properties make
porphyrin-based compounds extremely useful for PDT. So far, several porphyrin
derivatives have been developed and some of them have been approved in countries
such as Canada, the USA, Europe and Japan, for treating various cancers.
Hematoporphyrin derivatives (HpD) and photofrin 23-25 (Figure 1.8) were discovered to
have the ability to selectively accumulate in neoplastic tissue and function in various
malignant tissues such as carcinomas of the breast, colon, prostate and malignant
melanomas. Photofrin is a purified version of hematoporphyrin derivative (HpD) and has
been approved by the US FDA to treat lung cancer, esophageal cancer, malignant and
nonmalignant skin diseases, and early-stage cervical cancer.26 Due to the low extinction
coefficient of the Q bands, significant dosage or a high concentration of Photofrin was
needed to achieve tumor eradication. This caused serious side effects. Chemical
modification of hematoporphyrin was performed to overcome the chemical complexity of
Photofin by functionalization of the benzylic hydroxyl groups or by introducing different
substituents.27,28 However, the sensitizing efficiency did not change much. Other
synthetic porphyrin-based photosensitizers available are meso-tetraphenylporphyrin
(TPP), which was synthesized and modified by

13

Figure 1.7: Optical spectra of porphyrins, chlorins, bateriochlorins and their metal
complexes.19

14

several groups such as those of Hagan, Czuchajowski and Lozynski29,30 to introduce
hydrophilic groups and hydrophobic groups including hydrogen, hydroxyl and sulfonate,
and reduced the porphyrin to the dihydroporphyrin (chlorin) level The investigation of
biological properties of these porphyrins showed that the o, m, and p-isomers of
tetra(hydroxyphenyl)chlorins have very potent activity and tissue selectivity in photonecrosis. Especially, tetra(m-hydroxy)phenylchlorin was 25-30 times potent than HpD,
and this is now marketed as Foscan.
Porphyrins usually can satisfy most of the requirements for effective photosensitizers.
However porphyrins only have a small Q band with low molar extinction coefficient
compared with their Soret band. The longest wavelength band of porphyrins can reach
to around 650 nm. They can not be used to treat deep-seated tumors. Some reduced
porphyrins were developed, such as chlorins and bacteriochlorins, to solve the problems
associated

with

first

generation

porphyrin-based

photosensitizers.

These

photosensitizers are chemically pure and have longer wavelength absorption and less
side effects after treatment is completed. Since they absorb at long wavelengths, they
can be used to treat large tumors because long wavelength light travels further through
tissues. Figure 1.9 lists several chlorin-based photosensitizers.
Temoporfin31 is bactieriochlorin-based photosensitizer approved in 2001 in Europe to
treat neck, and head cancers and was the first sensitizer to be used to treat prostate
cancer in 2002. Compared with Photofrin, this compound has a pronounced Q band at
652 nm with a higher molar extinction coefficient, therefore a smaller drug dose is
needed in clinic trials and it has mild to moderate skin photosensitivity. Tumor cell death
was caused through necrosis and vascular damage. Padoporfin 32,33 (palladiumbacteriopheophorbide) (figure 1.9) is a lipophilic photosensitizer which has a maximum
absorption wavelength in the near-infra red region at 763 nm and could be active at a
15

Figure 1.8: Structure of HP, Photofrin, and other porphyrins used in PDT
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penetration depth of 4 mm using appropriate light, compared with Photofrin (630 nm, 1.6
mm). Padoporfin is a vascular-acting photosensitizer and was used to treat prostate
cancer in clinic studies, which showed that Padoporfin-mediated PDT has a very short
drug exposure–light interval and minimal local damage.34,35 NPe6 (talaporfin, LS II) is a
second generation photosensitizer approved for the treatment of lung cancer by the in
Japan. NPe6 is a hydrophilic chlorin derivative due to the aspartyl residue and has
UV/Visible absorption at 664 nm with a molar extinction coefficient of 4 x 10 4 M-1cm-1.
The clinical study36,37 showed that NPe6 is mainly localized in plasma instead of
organelles and the mechanism of tumor cell death was shown to be vascular stasis
resulting from direct tumor necrosis. The possibility of using NPe6 to treat other cancers
is also under investigation too in clinical trials. Only minimal skin photosensitivity was
caused after the treatment. A synthetic chlorin-based photosensitizer Verteporfin was
invented by Dolphin and Levy and modified by Callot et al and Pandey et al.38,39 This
compound has a pronounced Q band at 689 nm and has a very efficient generation of
singlet oxygen.40 Verteporfin is a lipophilic photosensitizer used for ocular PDT and
approved for age-related macular degeneration since 2000. In vivo studies showed that
it prefers to localize in neovascular endotherlium and the localization determined that
tumor cell death is through vascular damage and it is 10 times more cytotoxic than
hematoporphyrin in human adherent cell lines.41 Biodistribution studies proved that
Verteporfin can accumulate in the vasculature rapidly and clear from a patient’s body
rapidly after treatment. It is metabolized in a less reactive form and in this way reduced
the photosensitivity period.42
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Figure 1.9: Chlorin-based photosensitizers.
Another two porphyrin-type derivatives are phthalocyanine and porphycene (Figure 1.10).
Phthalocyanine (Pc) was discovered by Braun and Tcherniac in 1907 43,44 and has been
recognized as a PDT agent since 1985. From the structure, Pc can be regarded as tetraazaporphyrin and it has very strong absorption at 670-770 nm with a molar extinction
coefficient around 2.5 x 105 M-1cm-1; this makes Pc a very good photosensitizer
candidate. When chelated with diamagnetic metals such as zinc, aluminum or silicon, Pc
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gives excellent singlet oxygen yields even close to 100%.45,46 Coordination with metals
which have valency higher than two, such as silicon, also prevents aggregation by way
of axial coordination. Silicon phthalocynies in vitro and in vivo studies have shown that
this hydrophobic photosensitizer exclusively localizes in mitochondria, and tumor cell
death is mainly caused by the formation of reactive oxygen species. Phthalocyanine is a
hydrophobic photosensitizer. However, its structural flexibility allows one to introduce
hydrophilic groups to the molecule to modify its amphiphilicity so that the delivery of the
drug can be more convenient.
Porphycene is an isomer of porphyrin. Although the structure of porphycene is strained
compared with porphyrin, the stability of porphycene is still comparable to that of
porphyrin due to hydrogen bonding between the NH and N sites. Porphycene was first
synthesized by Vogel et al.,47,48 and the molecule has absorption around 600 nm with a

Figure1.10: The structures of phthalocyanine (left) and porphycene (right).
molar extinction coefficient around 5 x 10 4 M-1 cm-1. Depending on the structure,
porphycenes localize in different compartments of tumor cells such as mitochondria or
lysosome,49,50 Tumor cell death is mediated by apoptotic and necrotic responses.
1.8. Non-porphyrin Based Photosensitizers
There are some non-porphyrin based photosensitizers that have been developed. Most
of them are various dyes such as hypericin, methylene blue, and toluidine blue (Figure
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11). All these dyes have not succeeded in clinical trials due to drug delivery issues or
their low activity against tumor cells. Hypericin51 has absorption at 590 nm with a molar
extinction coefficient around 4.5 x 104 M-1 cm-1 and can generate singlet oxygen very
efficiently. This compound attracted attention because it is an inhibitor of protein kinase,
which is a key enzyme in the proliferation of tumor cells. Hypericin was found to kill
tumor cells through direct tumor cytotoxicity and vascular damage.52 Methylene blue53
has been known as an imaging reagent in the clinic for diagnosis of many diseases. It
has absorption around 666 nm and a molar extinction coefficient of 8.2 x 104 M-1cm-1.
Methylene blue is not widely used as a PDT agent due to its high reduction potential in
tumors cell to give its leuco methylene blue scompound, which is colorless. Therefore
the activity is lost. In spite of this, in vitro studies showed that methylene blue can reduce
tumor size significantly against human T-cell and B-cell lymphoma.54 Other dyes used in
PDT are aza-BODIPYs, which have absorption at 679 nm with a molar extinction
coefficient of 7.5 x 104M-1cm-1. This molecule is improved as a photosensitizer when a
halogen is introduced into the structure. The halogen increases the population of triplet
states while also reducing the fluorescence due to the heavy atom effect. An in vivo
study of ADMPM06 (Figure 1.11) showed this molecule has no discernable selectivity to
particular cell compartments. Tumor cell death was induced through direct apoptotic and
necrotic pathways. A similar strategy was used in BODIPY by introducing halogen to
molecules. The first BODIPY investigated as a PDT agent is diiodoBODIPY.55 This
compound has an absorption at 534 nm with a molar coefficient value of 1.1 x 105 M-1cm1

. The generation of singlet oxygen was observed under IR irradiation when this

molecule was excited. The localization of BODIPY depends on the structure. Some
localize in mitochondria, ER and some localize in cell membranes.
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Figure 1.11: Non-porphyrin based photosensitizers.

To achieve better localization in tumor cells over normal cells, researchers have
developed various strategies to modify photosensitizers by introducing biomolecules
such as amino acids, antibodies, and polyethylene glycols (PEGs). This strategy is
based on the fact that malignant tumor cells have cell surface antigens different from
normal cells. For example, there is much work focusing on the use of antibodies56 to
direct the photosensitizers to tumor cell over normal cells. A monoclonal antibody
(mAB)-PS conjugate is found to specifically bind to the tumor tissue due to its affinity to
tumor-associated antigen, which can accumulate up to 10 8 photosensitizers on a tumor.
The photosensitizer-biomolecule conjugates are the most promising molecules for
photodynamic

therapy

since

enhanced

photosensitizer delivery to target tissues.
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biological

specificity

provides

better

Photodynamic therapy is not only used to treat cancers. This treatment can also be used
for many other diseases. For example, many skin diseases can be treated using
photodynamic therapy. The photosensitizer Photofrin is used to treat cancers and also
was investigated against the HIV virus an in vitro study. Verteporfin is used to treat agerelated macular degeneration. Scientists including chemists, biologists, physicists and
clinicians are collaborating to explore more possibilities for expanding the applications of
this treatment.
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Chapter 2: Total Syntheses and Characterization of Isoporphyrins from b-Bilene
Salts
2.1 Introduction
Isoporphyrins 11,2 are tautomeric structures of porphyrins 2 with interrupted macrocyclic
conjugation owing to the presence of a saturated meso-carbon atom (Figure 2.1). This
interruption of conjugation causes an intense bathochromic shift of the Q-band
absorption to around 800 nm, thus making isoporphrins promising potential candidates
as photosensitizers in photodynamic therapy (PDT).

Figure 2.1: Structure of porphyrin and isoporphyrin
Previous work from our group 3 has shown that zinc isoporphyrins have favorable
properties for a photosensitizer, such as relative low dark toxicity, high phototoxicity, and
they display multiple localization sites within a cell, especially within mitochiondria.
Earlier syntheses of others particularly focused on generating transient isoporphyrins
from tetraphenylporphyrin, including electrochemical oxidation,2 photo-oxidation,4 and
chemical oxidation.5 However, these isoporphyrins were unstable and easily reverted to
their corresponding stable porphyrins. The first thermodynamically stable isoporphyrin
was achieved in our laboratory in 1992. 6 The oxidative re-aromatization of isoporphyrins
to porphyrins was suppressed by the introduction of suitable geminal substituents at the
isoporphyrin sp3 meso carbon. Yet another alternative synthesis of isoporphyrins was
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developed by Smith3 through cyclization of b-bilene salts by using an α-keto ester for the
interpyrrolic carbon, which makes it possible to approach unsymmetrical isoporphyrins.
Based on the previous work from our laboratory,3 the objectives of this project are to
synthesize various zinc(II) isoporphyrins (Figure 2.2) and conjugate them with amino
acids and study their biological properties as potential photosentizers. Zinc ions were
inserted into isoporphyrins because metalloisoporphyrins are more stable than metal
free isoporphyrins and have a significantly more red shifted Q-band (Figure 2.3)
compared with metal free analogs, usually have a low toxicity, and the potential of
selective uptake in tumors or necrosis. In addition, we hoped to conjugate
metalloisoporphyrin with peptides, proteins, PEGs or antibodies to improve the delivery
of zinc(II) isoporphyrins to cellular targets for photodynamic therapy.

Figure 2.2: Target zinc(II) isoporphyrin molecules.
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Figure 2.3: UV/Visible spectrum of zinc porphyrin and zinc isoporphyrin in CH2Cl2.
2.2 Previous Syntheses
Based on the observed stability of phlorins, which are dihydroporphyrins with a structure
similar to isoporphyrins, Woodward postulated the existence of isoporphyrins in 1961.1
This prediction was confirmed by Dolphin et al.2 when they reported synthesis of the first
metalloisoporphyrin in 1970. This discovery encouraged more efforts on synthesis of
isoporphyrins. Generally, the isoporphyrin was obtained by electrochemical oxidation,2
chemical oxidation4 or photo-oxidation5 of tetraphenylporphyrin. However, all these
isoporphyrins are unstable and are easily converted into the corresponding fully
conjugated porphyrins. The first thermodynamically stable isoporphyrin was obtained by
Xie and Smith6 by use of a variation of the MacDonald method from dipyrromethanes.
The introduction of suitable geminal substituents prevented their zinc(II) isoporphyrin
from isomerization into zinc(II) porphyrin.
a) Electrochemical oxidation method2
Dolphin et. al2. reported the first zinc tetraphenylmethoxyisoporphrin 6 as a dark green
solid obtained through controlled-potential oxidation of the corresponding zinc mesotetraphenylporphyrin 4 followed by nucleophilic attack of methanol (Scheme 2.1). The
optical absorption spectrum exhibited a maximum absorption at 860 nm. This
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isoporphyrin could be reduced back to porphyrin 7 with demetalation by addition of KI in
glacial acetic acid.

Scheme 2.1: Synthesis of tetraphenylisoporphyrin by electrochemical oxidation.2
.
b) Chemical oxidation method5
Gold6a discovered that isoporphyrins could also be generated by peroxide oxidation of
metalloporphyrins (Scheme 2.2). For example, ferric isoporphyrin 8 was obtained as a
microcrystalline solid through oxidation of (tetraphenylporphinato) iron(III) complex 9 by
t-butyl hydroperoxide. Takeda et al.5b also reported synthesis of isoporphyrins by similar
methods. Zinc tetraphenylbenzoyloxyisoporphyrin benzoate 10 was obtained by
oxidation of the corresponding porphyrin 4 with benzoyl peroxide.
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Scheme 2.2: Synthesis of tetraphenylisoporphyrin by chemical oxidation.5b,6a
c) Variation of MacDonald method6
Xie and Smith6 successfully achieved the total synthesis of the first thermodynamically
stable zinc(II) isoporphyrin 13 by using a variation of the MacDonald ‘2+2’ method
through

condensation

of

dipyrromethane

dicarboxylic

acid

11

and

diformydipyrromethane 12 using zinc acetate as a reaction template (Scheme 2.3). The
5,5-dimethyl groups prevent the isoporphyrin core from going back to the corresponding
porphyrin.
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Scheme 2.3: Synthesis of zinc(II) isoporphyrin by the MacDonald approach.6
d) Cyclization of b-bilene salts3
Smith and coworkers developed another more efficient synthesis of zinc(II) isoporphyrins
15 through cyclization of b-bilene salts 14 using an active α-keto ester reagent (Scheme
2.4). The cyclization mechanism involves a b-bilene to a,c-biladiene transformation. This
method provided an alternative pathway to synthesize unsymmetrical zinc(II)
isoporphyrins.

Scheme 2.4: Synthesis of tetraphenylisoporphyrin by cyclization of a b-bilene salt.3
Results and Discussion
Isoporphyrins possess special physical and chemical properties, such as unique optical
characteristics and redox behavior. However, in the past twenty years, efforts to
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synthesize isoporphyrins were hampered in the sense that they are very unstable and
are easily converted to more thermodynamically stable porphyrins. Oxidation of
porphyrin to isoporphyrin has been known since the 1980s, but this method was only
applied to several meso-aryl substituted porphyrins and the resultant isoporphyrins were
very unstable. Smith’s work6 provided the first stable zinc(II) isoporphyrin and made it
possible to characterize and investigate the chemistry of isoporphyrins.
b-Bilene-1,19-dicarboxylate salts are known intermediates in the synthesis of porphyrins7
and have also been used to synthesize the isoporphyrin by Smith. The route utilizes
crystalline intermediates at all stages, and the method has no inherent symmetry
limitations. It could provide an alternative way to synthesize unsymmetrical zinc(II)
isoporphyrins.

We

therefore

planned

to

use

this

method

to

approach

metalloisoporphyrins, which we would then conjugate with amino acids and evaluate
their biological properties as photosensitizers.
2.3 Retrosynthesis
The

target

molecule

can

be

achieved

by

cyclization

of

a

1,19-di-tert-

butoxycarbonylctamethy-b-bilene hydrochloride, and the b-bilene could be obtained by
condensation between a dipyrromethane carboxylic acid and a formyldipyrromethane.
Dipyrromethane carboxylic acids and diformyldipyrromethanes are both derived from the
corresponding
carboxylate

t-butyl
by

9-(benzyloxycarbonyl)-3,4,7,8-tetramethyldipyrromethane-1-

hydrogenation

and

then

a

Vilsmeier

formylation

reaction.

Dipyrromethanes can be synthesized by condensation of a 5-unsubstituted pyrrole with
a 5-acetoxymethylpyrrole (Scheme 2.5).
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Scheme 2.5: Retrosynthesis of target isoporphyrin molecule.
2.4 Synthesis
The whole synthesis started with only two pyrroles; the 5-acetoxymethylpyrrole 18 was
synthesized by using the Johnson7a method (Scheme 2.6). Addition of a sodium nitrite
solution to tert-butyl acetoacetate in acetic acid provided tert-butyl oximinoacetoacetate
20. Condensation between the oximinoacetate and 3-methyl-2,4-pentanedione in acetic
acid with portion-wise addition of a mixture of sodium acetate and zinc dust at 70 °C
furnished t-butyl 3,4,5-trimethylpyrrole-2-carboxylate 21 in about 35% yield. Then,
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radical oxidation of the α-methyl group by lead tetra-acetate at room temperature led to
the 5-acetoxymethylpyrrole 18.

Scheme 2.6: Johnson-type synthesis of pyrrole 18.
The Barton-Zard8 reaction was used to synthesize the 5-unsubsituted pyrrole 19
(Scheme 2.7). This reaction utilizes a [3+2] cycloaddition of a nitroalkene with an
alkylisocyanoacetate. Central to this method is the ability of the nitro group to depart as
nitrite under certain conditions and result in formation of an alkyl 2-unsubstituted pyrrole
carboxylate.

This

method

is

widely

used

to

synthesize

the

precursors

of

dipyrromethanes and has even been extended to the synthesis of β-nitroporphyrins.
Henry addition of nitroethane to an aldehyde catalyzed by base, followed by acetylation
of the hydroxyl group provided 2-acetoxy-3-nitrobutane 23, which was condensed with
ethyl isocyanoacetate to furnish ethyl ester pyrrole 24 in 80% yield. Here, the acetoxyl
group in 23 is a very good leaving group, which is easily eliminated under basic
conditions to generate nitroalkene in situ. Transformation of the ethyl ester pyrrole to the
benzyl ester pyrrole 25 was realized in greater than 90% yield by a transesterification
reaction using PhCH2ONa in benzyl alcohol. The benzyl ester group could be easily
removed to give carboxylic acid under neutral conditions through hydrogenation using
palladium on activated carbon.
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Scheme 2.7: Barton-Zard synthesis of α-free pyrroles 19 and 24.
The dipyrromethane 25 was constructed by condensation of the 5-acetoxymethylpyrrole
18 and the 5-unsubstituted pyrrole 19 using the Lewis acid Montmorillonite K-10 clay as
a catalyst9 (Scheme 2.8). Almost a 1:1 ratio of these two pyrroles and K-10 clay were
added to dry CH2Cl2 and the reaction mixture was kept stirring under argon for 24 hours
at

room

temperature.

tert-Butyl

9-(benzyloxy)carbonyl)-3,4,7,8-tetramethyl-

dipyrromethane-1-carboxylate 25 was obtained in greater than 90% yield. From the 1H
NMR spectrum the product was shown to be pure enough to go to the next step. Further
purification could be done through a flash column (3% MeOH/CH 2Cl2) or on a regular
column (CH2Cl2 + a little MeOH) or by recrystallization from CH2Cl2/petroleum ether, and
then left in the fridge overnight.

Scheme 2.8: Condensation between 5-acetoxypyrrole 18 and α-free pyrrole 19 in K-10.

Then the precursors of the b-bilene, namely the dipyrromethane carboxylic acid and
formydipyrromethane were both derived from the mixed ester dipyrromethane 25.
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Dipyrromethane carboxylic acid 26 was obtained by selectively removing the benzyl
group

through

hydrogenolysis

over

10%

Pd/C

catalyst

in

excellent

yield.

Formyldipyrromethane 27 was synthesized using a Vilsmeier-Haack formylation reaction.
Decarboxylation was achieved with two equivalents of p-toluenesulfonic acid in CH2Cl2
for 2 hours. The resultant unsubstituted dipyrromethane was then treated with the
Vilsmeier reagent prepared in situ, by mixing of DMF and benzoyl chloride, to give the
desired product formyldipyrromethane 27 upon basic hydrolysis, in good yield (Scheme
2.9).

Scheme 2.9: Synthesis of formyldipyrromethane by the Vilsmeier-Haack reaction
Here, benzoyl chloride was used to replace phosphorus oxychoride because it is more
moderate compared with the harsh conditions of POCl 3/DMF. PhCOCl/DMF generates
the same intermediate chloromethyleneiminum salt that POCl3/DMF does (Scheme 2.10).
The latter will generate hydrochloric acid because phosphorus can easily release
chloride ions in exchange of oxygen and combine with water to produce hydrochloric
acid. So, the Vilsmeier-Haack10 reagent provided an alternative way for formylation of
the dipyrromethane, which is sensitive to the action of acetic reagents.
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Scheme 2.10: Vilsmeier reagent for formylation of dipyrromethane.
The required b-bilene hydrochloride 11 was obtained by condensation of the two
dipyrromethane

halves:

formyldipyrromethane

dipyrromethane
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(Scheme2.11).

butyloxycarbonylpyrromethane-1-carboxylic
formylpyrromethane-1-carboxylate

27

acid

catalyzed

carboxylic

acid

Condensation
26
by

with
two

26

and

of

9-tert-

tert-butyl

equivalents

of

9p-

tolunesulfonic acid in CH2Cl2 furnished the corresponding b-bilene-1,19-di-tert-butyl
ester

as

its

toluenesulfonic

salt

14.

The

reaction

was

monitored

by

spectrophotometry and the b-bilene salt showed a strong absorption around 500
nm in its UV/Visible spectrum when the reaction was complete. This b-bilene salt
was converted into the hydrochloride salt by brief treatment by dry HCl gas in

Scheme 2.11: Synthesis of b-bilene hydrochloride salt by condensation of
dipyrromethane carboxylic acid 26 and formyldipyrromethane 27.
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distilled CH2Cl2 and the solution turned from orange to dark red. Purification of the
product was done by recrystallization using CH2Cl2/hexane overnight in the fridge to
give the crystalline hydrochloride in about 70% yield. The UV-visible spectrum of
the b-bilene hydrochloric salt in CH2Cl2 showed a strong absorption at 502 nm, as
shown in Figure 2.4.

Figure 2.4: UV-visible spectrum of b-bilene hydrochloride salt 14 in CH2Cl2
Ring closure of the b-bilene salt is the key step to obtain isoporphyrin. The b-bilene
has been already used to synthesize porphyrins, employing trimethyl orthoformate
as a one-carbon linking unit. 12 Here, we needed to look for a suitable linking
reagent 13 which is able to prevent the isoporphyrin product from going back to
corresponding more stable porphyrin. At same time, this reagent must be at least
as reactive as trimethyl orthoformate toward electrophilic attack by the b-bilene. So
an α-diketone or α-keto ester was selected. The strategy involved cleavage of the
tert-butyl ester group of the b-bilene hydrochloride using trifluoroacetic acid, then
the reaction mixture was diluted with dry CH2Cl2 followed by addition
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Scheme 2.12: cyclization of b-bilene salt using methyl pyruvate.
methyl pyruvate, and the whole reaction was monitored by spectrophotometry. After
one hour, the UV-visible spectrum showed absorptions at 450 and 520 nm, which
do not belong to either the starting material b-bilene salt or the product isoporphyrin.
These two absorptions actually are characteristic of an open chain and non conjugated tetrapyrrole. The reaction solution was washed with water containing
several drops of aqueous sodium bicarbonate to neutralize excess TFA. The color
of the solution changed from red to green. The spectra of UV -visible spectrum
indicated two new absorptions at 430 and 790 nm which are very similar to those of
isoporphyrins. This may be due to the neutral nature of the solution compared with
acidic conditions. Then zinc acetate was added as a reaction template because of
its good coordination ability and its partial solubility in organic co -solvents. Zinc
acetate changed the greenish color of the solution to red and showed absorptions
at 470 and 540 nm as found under acidic conditions. DDQ was added to oxidize the
zinc chelated open system to zinc(II) isoporphyrin 28 within ten minutes;
characteristic absorptions at 430 and 825 nm appeared in the UV-visible spectrum
in CH2Cl2. Alternatively, the reaction could be left in the air for several days; the
intermediate was oxidized into zinc(II) isoporphyrin 28 (Scheme 2.12). Purification
of the product was performed using an alumina column followed by a silica g el
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column. Recrystallization of the product was performed using CH2Cl2/petroleum
ether. The identity of the product was confirmed by mass spectrometry (Figure 2.5)
and the UV-visible spectrum of the product is shown in Figure 2.6.

Figure 2.5: The mass spectrum of zinc isoporphyrin 28.
With the zinc isoporphyrin in hand, it was hoped that saponification of the 5-methyl
ester group of the isoporphyrin could provide the corresponding carboxylic acid,
which could then be conjugated with organelle-directing peptides so that we can
further evaluate its biological properties. The reaction was attempted under basic,
acidic and neutral condition. When the reaction was performed using 5% NaOH 14 in
dry methanol, the UV-visible spectrum gave a sharp absorption around 400 nm
after workup. This is obviously the result of decarboxylation of corresponding
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carboxylic acid to give porphyrin. The rearrangement of isoporphyrin led to the
more thermodynamically stable porphyrin. Then, ethylenediamine was used as 1.0,

Figure 2.6: UV-visible spectrum of zinc(II) isoporphyrin 28 in CH2Cl2.
1.5 and 4.0 equivalents vs. isoporphyrin at room temperature in CH2Cl2; the UVvisible spectra showed peaks around 430 and 670 nm which appear to belong to
metal-free isoporphyrin. However, these peaks disappeared upon work-up with
water or dilute HCl. There is a possibility that ethylenediamine removed the zinc
metal from the isoporphyrin through chelation to form a five membered ring and
gave metal-free isoporphyrin, which is relatively unstable and decomposed
immediately (Scheme 2.13). Lithium iodide 15 was next used for the cleavage of the
ester under neutral conditions. The reaction mixture was refluxed in ethyl acetate,
DMF and pyridine for 24-48 hours, but the UV-visible and 1H NMR spectra of the
zinc(II) isoporphyrin showed no change. This is perhaps due to the sterically
hindered isoporphyrin ring system. Therefore, the more active reagent trimethylsilyl
iodide 16 was employed instead of LiI. However, UV-visible spectra did not show any
peaks above 400 nm. Thus, It appears that the zinc(II) isoporphyrin decomposed
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during the reaction. A substitute method to produce TMSI in situ by refluxing LiI and
TMSCl in CH 3 CN solvent did not work either for the hydrolysis step (Scheme 2.14).
Lewis acid boron halogens can also be used to cleave relatively simple hindered
esters. When the reaction was performed at low temperature (around -25 oC), the
UV-visible absorptions at 430 and 830 nm of the

Scheme 2.13: Hydrolysis of methyl ester under basic conditions.

isoporphyrin were present, but these absorptions disappeared after work-up with
water, and a strong new absorption at 400 nm belonging to the corresponding
porphyrin Soret absorption appeared.
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Scheme 2.14: Attempted hydrolyses of zinc(II) isoporphyrin methyl ester under neutral
and acidic conditions.
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Acidic conditions such as BBr3 17 were also tried on the zinc(II) isoporphyrin but did
not work. Based on the above work, we surmised that zinc(II) isoporphyr ins are not
stable under harsh acidic or basic condition and even to strong nucleophiles due to
the fact that the porphyrin is a good leaving group. Once the ester on isoporphyrin
is hydrolyzed, the carboxylic acid group tends to decarboxylate immediately and
form the corresponding porphyrin or ring opened system.
To avoid this problem, the following strategies were planned. One choice was to
introduce the benzyl ester group during the cyclization so that the ester group can
be removed by hydrogenolysis under neutral conditions. Similarly, the b-bilene salt
might also be cyclized by using 2,3-butanedione and the resultant acetyl group
could possibly be converted into an amine group by an amination reaction (Scheme
2.15). The b-bilene salt was successfully cyclized with benzyl pyruvate or 2,3butanedione under the same conditions as described above in three steps. The
obtained zinc(II) isoporphyrins 31 and 32 have UV-visible absorptions at 431 and
807 nm (Figure 2.7) and 407 and 807 nm (Figure 2.8), respectively.
The benzyl ester substituted zinc(II) isoporphyrin was subjected to hydrogenolysis
with Pd/C under hydrogen gas in THF overnight at room temperature; the UV
spectrum showed typical peaks around 400, 532 and 668 nm which belong to
porphyrin. This assumption is still consistent with a hydrolysis reaction. The
carboxylic acid left as a result of decarboxylation and formed the corresponding
porphyrin. For the acetyl substituted zinc(II) isoporphyrin, attempts to convert the
ketone group into an amine group through reductive amination 18 using BOCprotected ethylenediamine as nucleophile and sodium triacetoxylborohydride as
reducing agent failed, probably for similar reasons (Scheme 2.16). The UV/visible
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spectrum showed a large peak at 406 nm and no peak around 800 nm, which
indicated the zinc(II) isoporphyrin decomposed or was isomerized to porphyrin.

Scheme 2.15: Cyclization of b-bilene salt using benzyl pyruvate or 2,3-butanedione.
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Figure 2.7: UV/visible spectrum in CH 2Cl2 of zinc(II) isoporphyrin 31 from
cyclization of b-bilene salt with benzyl pyruvate.

Figure 2.8: UV/visible spectrum in CH 2Cl2 of zinc(II) isoporphyrin 32 from cyclization
of b-bilene salt with 2,3-butanedione.
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Scheme 2.16: Attempted reductive amination of zinc(II) isoporphyrin 32.
Another choice was to cyclize the b-bilene salt by using benzyl or ethyl
acetoacetate; in the product the resultant carboxylic acid group is separated from
the α-position upon hydrolysis to avoid isomerization of isoporphyrin to porphyrin by
simple decarboxylation (Scheme 2.17). Both benzyl acetoacetate and ethyl
acetoacetate were used to cyclize the b-bilene hbydrochloride, and the reactions
were monitored by UV-visible absorption spectroscopy. All the absorption spectra
of intermediates are consistent with those intermediates seen during cyclization of
the b-bilene salt using methyl pyruvate except for the oxidation step (Figure 2.9).
There was no peak around 800 nm after adding DDQ or leaving it in air for a week,
which indicated that zinc(II) isoporphyrin was not formed. The possible reason
could be that the α-H from benzyl acetoacetate is not acidic enough to facilitate
transformation into the intermediate required for cyclization to take place.
From the above attempts to functionalize zinc(II) isoporphyrin such as hydrolysis,
amination and aminolysis, it seems that isoporphyrins are sensitive to strong acid, strong
base and even nucleophiles such as lithium iodide. Therefore, introducing a functional
group such as amine during cyclization would be a good choice for modification of zinc(II)
isoporphyrins. In this way functionalization of the isoporphyrin under harsh conditions
can be avoided. Pyruvate amide was chosen as a cyclizing reagent with the b-bilene salt,
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Scheme 2.17: Cyclization of b-bilene hydrochloride using acetoacetate esters.
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Figure 2.9: UV-Visible spectral changes in CH2Cl2 during cyclization of b-bilene
hydrochloride 14 with benzyl acetoacetate.
with the intention that the amine group would be employed later to conjugate with
biomolecules. Two methods were attempted to make the α-keto amides. One involves a
peptidic coupling reaction 19 between α-keto acids and amines in the presence of
coupling reagents such as DCC with DMAP，BOP-Cl, PyBOP-PF6 with TEA and EDC
with HOBt (Figure 2.10). The other method involves chlorination of α-keto acids followed
by aminolysis with amines. A test reaction between pyruvic acid and hexylamine was
examined with different coupling agents and the results are presented in Table 2.1. From
this table it can be seen that coupling agents DCC with DMAP, BOPCl or PyBOP with
TEA or DIEA only gave trace amount or very low yields of product. In contrast, HOBt
with EDC led to an improved yield at 47% with DMF as the solvent. However for similar
synthesis of β,γ-unsaturated α-keto amides reported by Rodriguez,20 both BOPCl/TEA
and PyBOP/DIEA gave them quantitive yields.
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Figure 2.10: The coupling reagents used in reactions.
Table 2.1: The Coupling Reaction Using Different Reagents.

entry

Coupling reagents

Solvent system

yield

1

DCC/DMAP

DCM

trace

2

BOPCl/TEA

DCM

10%

3

PyBOP/TEA

DCM

12%

4

BOPCl or PyBOP/DIEA

DCM

15% and 19%

5

HOBt/EDC

DMF

47%

Meantime, a parallel alternative method was tried that involved chlorination of pyruvic
acid with oxalyl chloride in CH2Cl2 followed by aminolysis21 with hexylamine using TEA
as base. A catalytic amount of DMF was added to speed up the reaction (Scheme 2.18).
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The tedious part of this method is that oxalyl chloride is hard to remove from the reaction
after chlorination; the remaining oxalyl chloride reacted with hexylamine to give a
symmetrical diamide 39 which was inseparable from the product on a chromatography
column. The purification was done by recrystallization using CH 2Cl2/diethyl ether as the
solvent system, to give 52% yield of product 38.

Scheme 2.18: Synthesis of pyruvate amide 38 by aminolysis reaction.
Therefore, the hexyl pyruvatamide was used as a test reagent to see if it was possible to
cyclize b-bilene salts using an α-ketoamide. Under the same conditions as previously, a
peak around 821 nm in the UV/visible spectrum appeared with time and indicated the
formation of zinc(II) isoporphyrin 40 (Scheme 2.19). The hexylpyruvate amide proved
that α-keto amides can cyclize with a b-bilene salt, so it was decided to synthesize a Nprotected α-keto amine so that it can be deprotected later and used as a group to
conjugate with amino acids. The similar conjugation reaction between pyruvic acid and
mono-BOC protected ethylenediamine was performed with HOBt/EDC as coupling
reagents. The product 41 was generated with a slightly lower yield of 41%. Similarly, the
BOC-protected lysine was also conjugated with pyruvic acid under the same conditions
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with a 32% yield of the product 42 (Scheme 2.20). Both of these two pyruvate amides
were used to cyclize b-bilene salts in three steps. For mono-BOC-protected
ethylenediamine pyruvate amide, a peak appeared around 826 nm (Figure 2.11) after
zinc acetate was added and

Scheme 2.19: Cyclization of b-bilene salt with hexyamine pyruvate amide.
it was left in air for five minutes, which proved that the macrocycle was formed. However,
the peak disappeared with time unexpectedly since it should be increased in size
through oxidation by oxygen in air. The assumption is that the cyclization of b-bilene salt
into zinc(II) isoporphyrin and cyclization to give porphyrin compete with each other; with
a long chain on the meso-carbon of the isoporphyrin, the ring opening is more favored
than cyclization, and the open chain compound is cyclized into porphyrin with time. In
the case of the BOC-protected lysine pyruvate, the cyclization did not succeed,
UV/visible spectrophotometry gave no proof of formation of zinc(II) isoporphyrin. This is
probably due to the steric effect from the lysine chain compared with BOC-protected
enthylenediamine pyruvate (Scheme 2.21).
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Scheme 2.20: Synthesis of BOC-ethylenediamine and BOC-lysine pyruvate amide
41 and 42.

Figure 2.11: The UV/visible spectrum in CH2Cl2 of the cyclization of b-bilene salt
with BOC-ethylenediame pyruvate amide 42. The peak at 400 nm indicates
porphyrin formation.
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Scheme 2.21: Cyclization of b-bilene salt using BOC-lysine and BOCethylenediamine pyruvate amides 41 and 42.
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2.5. Conclusion
Zinc isoporphyrins were synthesized by cyclization of b-bilene salts with active α-keto
esters in good yield. The product was characterized using NMR spectroscopy, mass
spectroscopy

and

UV-visible

spectroscopy.

The

resultant

zinc(II)

decamethylisoporphyrin chloride is stable at room temperature in daylight without
decomposition or transformation into porphyrin. Attempts to hydrolyze the 5-methyl ester
was so far unsuccessful due to facile decarboxylative conversion into porphyrin during
the hydrolysis step. Efforts to introduce functional groups or biomolecules onto the zinc(II)
isoporphyrin during cyclization did not solve the problem of isoporphyrin conjugation with
biomolecules.

2.6. Experiment Part
tert-Butyl 3,4,5-trimethylpyrrole-2-carboxylate 21
Sodium nitrite (11.5 g, 0.16 mol) in water (40 ml) was added drop-wise with stirring and
cooling to t-butyl acetoacetate（26 g, 0.16 mol）in glacial acetic acid (54 ml) at 0 ºC.
Stirring was continued for a further 3 h; then the mixture was kept overnight at room
temperature. The resultant t-butyl oximinoacetate solution was added drop-wise to a
solution of 3-methyl-2,4-pentanedione (25 g, 0.22 mol) in acetic acid (88 ml) during
portion-wise addition of an intimate mixture of zinc dust (25 g) and sodium acetate (25 g).
The addition rate was controlled so that the solution temperature was maintained around
70 ºC. The addition continued for about 1.5 h and the reaction mixture was refluxed for 2
h. The reaction was monitored by TLC. After reaction was complete, the reaction
solution was poured into ice/water and a yellow precipitate was filtered and washed with
water until neutral. The solid was dissolved in CH2Cl2 and dried over anhydrous Na 2SO4
overnight. The solvent was evaporated and the solid was recrystallized from
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CH2Cl2/ethanol in the fridge to yield yellow needle crystals. 1H NMR (CDCl3, 400 MHz) δ
8.45 (s, br, 1H), 2.22 (s, 3H), 2.17 (s, 3H), 1.90 (s, 3H), 1.55 (s, 9H).

t-Butyl 5-acetoxymethyl-3,4-dimethylpyrrole-2-carboxylate 18
tert-Butyl 3,4,5-trimethylpyrrole-2-carboxylate (1.74 g, 8.3 mmol) was dissolved in acetic
acid (39 ml) and acetic anhydride (1.0 ml). Then excess lead tetra-acetate (4.05 g, 9.1
mmol) was added to the solution portion-wise under argon. After addition was complete,
the mixture was stirred overnight. The reaction was monitored using TLC. When the
reaction was complete, the brown solution was treated drop-wise with 40 ml of ice/water
and a yellow precipitate was formed. The solid was filtered and washed with distilled
water to remove acetic acid and lead acetate. The solid was dried over anhydrous
Na2SO4 in CH2Cl2 and recrystallization from CH2Cl2/hexane in the fridge gave a yellow
solid 1.40g (60%). 1H NMR (CDCl3, 400 MHz) δ 8.88 (s, br, 1H), 5.01 (s, 2H, -CH2-O),
2.23 (s, 3H, COCH3), 2.07 (s, 3H), 2.00 (s, 3H), 1.56 (s, 9H).

Ethyl 3,4-dimethylpyrrole-2-carboxylate 24
Acetaldehyde (13.0 ml, 0.465 mol) was stirred into isopropanol (8.5 ml) containing
potassium fluoride (0.67 g, 0.023 mol, 0.05 mol eq), and the stirring was continued until
the aldehyde had completely dissolved. To the stirred alcoholic solution was then added,
drop by drop, nitroethane (16.5 ml, 0.46 mol)in an ice bath during 1 h; after this addition,
stirring was continued overnight at room temperature under argon. Then the catalyst
was removed by filtration. The residue, upon the removal of solvent, was poured into
water and the residual oily matter was extracted with ether. Then the extract was dried
over anhydrous Na2SO4 and the solvent was removed to give yellow oily product 2-nitrobutanol-3 (21.35 g, 40%).
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To a flask was added acetic anhydride (19.2 g, 188 mmol, 1.5 eq), 4dimethylaminopyridine (DMAP, 0.2 g) and CH 2Cl2 (10 ml). 2-Nitro-3-butanol (15 g, 126
mmol) was added to the mixture over 20 min. The mixture was allowed to stir for 4 h at
room temperature under argon. After reaction was complete, methanol (60 ml) was
added to the solution which was stirred for 30 min to destroy excess acetic anhydride.
Then, the solution was poured into dilute aqueous NaHCO 3 (18 g in 100 ml water) and
extracted with CH2Cl2 (3 x 40 ml), the organic layer was dried over anhydrous Na2SO4
and filtered through a short column of silica gel. Removal of solvent gave the product as
yellowish liquid (20.30 g, 49.5%).

To a solution of ethyl isocyanoacetate (2.51 g, 19 mmol, 1.05 eq), and
tetramethylguanidine (4.41g, 38 mmol) in 6 ml of THF/Isopropanol (1:1) was added a
solution of β-acetoxy-3-nitrobutane (3.0 g, 18.6 mmol) in 18 ml THF/isopropanol (1:1)
drop-wise in an ice bath. After addition was complete, the solution was stirred at room
temperature overnight under argon. When TLC showed reaction was complete, the
resultant solution was concentrated to remove solvent. The oily residue was taken up in
CH2Cl2 and washed successively with water (6 ml x 3), 5% aqueous HCl (6 ml x 3),
water (6 ml x 3), aqueous saturated NaHCO 3 (6 ml) and brine (6 ml); then the product
was dried over anhydrous Na 2SO4 and the solvent was removed under vacuum to give
the crude product. Recrystallization from CH 2Cl2/hexane gave the product as a yellowish
solid. 1H NMR (CDCl3, 400 MHz) δ 8.65 (s, br,1H), 6.65 (d, 1H), 4.32 (q, 2H, O-CH2-CH3),
2.27 (s, 3H), 2.01 (s, 3H), 1.35 (t, 3H, CH2-CH3).

Benzyl 3,4-dimethylpyrrole-2-carboxylate 19
Sodium metal (0.168 g, 7.3 mmol) was added to benzyl alcohol (60 ml) under argon.
Once all the sodium had reacted, the ethyl ester pyrrole 24 (2.32 g, 14 mmol) was added
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and the resultant mixture was heated in an oil bath at 90 ºC for 10 h. The mixture was
allowed to stand at room temperature overnight and 1 equiv of acetic acid (0.438 g, 7.3
mmol) was added to neutralize the sodium benzoate. Benzyl alcohol was evaporated to
dryness under reduced pressure and the residue was dissolved in CH 2Cl2, washed with
water and treated with decolorizing carbon. After filtration through a Celite cake, the
solution was dried over anhydrous MgSO 4 and the solvent was evaporated under
vacuum to yield a brown solid (1.5 g, 90% yield). 1H NMR (CDCl3, 400 MHz) δ 8.70 (s, br,
1H), 7.26-7.41 (m, 5H), 6.65 (d, 1H), 5.30 (s, 2H), 2.28 (s, 3H), 2.01 (s, 3H).

tert-Butyl 9-(benzyloxycarbonyl)-3,4,7,8-tetramethyldipyrromethane-1-carboxylate
25
Montmorillonite clay (K10; 9 g) was added to a solution of 5-acetoxymethylpyrrole 18
(2.72 g, 10 mmol) and 5-unsubstituted pyrrole 19 (2.52 g, 10.1 mmol) under argon in
CH2Cl2 (100 ml) in a round-bottomed flask. The resultant mixture was stirred vigorously
overnight and the reaction was monitored by TLC. After reaction was complete, the clay
catalyst was filtered off and washed with CH 2Cl2 and the solvent was removed on a
rotary evaporator. From 1H NMR analysis, the crude product was already pure enough to
be used in the next step. Further purification was done on a silica gel column using
CH2Cl2 containing a little methanol as elution solvent. Alternatively the product could be
recrystallized from CH2Cl2/petroleum ether in the fridge. 1H NMR (CDCl3, 400 MHz) δ
8.93, 8.68 (s, br,1H each), 7.26-7.35 (m, 5H), 5.27 (s, 2H, CH2-Ph), 3.81 (s, 2H), 2.26 (s,
3H), 2.22 (s,3H), 1.94 (s, 3H), 1.93 (s, 3H), 1.53 (s, 9H).

1-(tert-Butyloxycarbonyl)-2,3,7,8-tetramethyldipyrromethane-9-carboxylic acid 26
A solution of mixed ester dipyrromethane 25 (2.0 g, 46 mmol) in approximately 80 ml of
freshly distilled THF was degassed with argon for approximately 15 min. Then to the
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solution was added 10% Pd/C (0.13 g) and the suspension was stirred under pressure of
hydrogen gas at room temperature for 16 h; when the TLC showed the reaction was
complete, the catalyst was removed by filtering through a bed of Celite and washed with
THF. The collected filtrate was evaporated and a yellowish foamy solid formed. The
product was further dried to give 1.50 g of product 26 (95% yield). δ 1H NMR (CDCl3, 400
MHz) 3.85 (s, 2H), 2.28, 2.18, 2.08, 2.01 (s, 3H each), 1.55 (s, 9H).

tert-Butyl 9-formyl-2,3,7,8-tetramethyldipyrromethane-1-carboxylate 27
To a 100 ml round bottom flask were added dipyrromethane monocarboxylic acid 26
(300 mg, 0.86 mmol) and 40 ml of distilled CH2Cl2 under argon. p-Toluenesulfonic acid
(328 mg, 1.7 mmol) was added portion-wise. Stirring was continued for 1.5 h until TLC
showed completion of reaction. Saturated NaHCO3 was added to neutralize the solution,
followed brine, and the organic phase was dried over anhydrous MgSO 4. Evaporation of
the solvent yielded a brown-reddish semi-solid which was dried under high vacuum to
remove any solvents. Dry DMF (1.0 ml) was added to the crude material and the solution
was cooled to 0 ºC. Meanwhile, Vilsmeier complex was prepared by adding benzoyl
chloride (0.6 ml, 5.1 mmol) drop-wise to dry DMF (0.8 ml, 10.3 mmol) at 0 ºC, with
stirring for 30 min. The Vilsmeier complex was added drop-wise to the decarboxylated
mixture with stirring and after 15 min, stirring was continued at room temperature for a
further 50 min. TLC showed formation of the imine salt. Toluene (10 ml) was added and
small grains of precipitate were formed. The toluene was evaporated and the residue
was dissolved in ethanol (25 ml), before 1.5 g of NaHCO 3 in 25 ml water was added.
Stirring was continued overnight at room temperature; the yellowish precipitate was
collected, the solid was dissolved in CH2Cl2 and washed with water and dried over
anhydrous Na2SO4. Then the solvent was removed by evaporation and the yellowish
solid was chromatographed on a silica gel column eluting with 3% methanol/ CH 2Cl2 to
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afford 171 mg (60%) of the title product. 1H NMR (CDCl3, 400 MHz) δ 10.05(s, br,1H),
9.50 (s, 1H), 9.22 (s, br, 1H), 3.88 (s, 2H), 2.26, 2.24, 1.99, 1.96 (s, CH 3 each), 1.52
(s,9H).

Di-tert-butyl

2,3,7,8,12,13,17,18-octamethyl-b-bilene-1,19-dicarboxylate

hydrochloride 14
Dipyrromethane monocarboxylic acid 26 (0.14 mmol, 50 mg) and formyldipyrromethane
27 (0.12 mmol, 40 mg) were dissolved in 10 ml of dry CH2Cl2 and stirred under argon. pToluenesulfonic acid (53.0 mg, 2 equiv) was added portion-wise to the solution and the
mixture was kept stirring for 2 h; the reaction was monitored using UV/visible
spectroscopy. When a strong absorption at 502 nm was evident, the dark red solution
was washed with 5% NaHCO3 solution and water and then dried over anhydrous MgSO 4.
The solvent was evaporated under reduced pressure to provide the b-bilene
intermediate salt, which was dissolved in 5 ml of dry CH2Cl2 and hydrogen chloride was
bubbled for 30 sec and whereupon the color changed to dark red as the hydrochloride
salt formed. The solvent was evaporated and the residue was taken up twice in dry
toluene and evaporated to remove any traces of water and HCl. The resultant residue
was recrystallized from CH2Cl2/hexane and kept in the fridge overnight to give red
product (45 mg, 63%). 1H NMR (CDCl3, 400 MHz) 7.07 (1H), 4.22 (CH2, 4H), 2.22, 2.21,
2.04, 2.02, (each CH3, 6H), 1.55 (t-butyl, 18H).

Zinc(II)

2,3,5,7,8,12,13,17,18-nonamethyl-5-(methoxycarbonyl)isoporphyrin

chloride 28
b-Bilene hydrochloride 14(50 mg, 0.08 ml) was added to a flask and cold TFA (0.3 ml)
was added under argon and the reaction was kept stirring for 10 min. The solution was
diluted with 20 ml of CH2Cl2 and this is followed by addition of methyl pyruvate (8.2 mg,
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0.08 mmol). The mixture was stirred another 2 h. whereupon the UV/visible spectrum
showed the disappearance of the absorption around 500 nm and new absorptions
around 450 and 520 nm. The reaction was stopped and the excess TFA was removed
by washing with water and the reddish solution changed to green after work-up, which
had absorption maximum around 430 and 790 nm. The green intermediate was
dissolved in dry CH2Cl2 (30 ml) followed by addition of Zn(OAc)2 (20 mg) in 1 ml of dry
methanol under argon. The solution immediately changed back to reddish and new
absorptions around 470 and 540 nm were apparent. After about 10 min, DDQ (50 mg,
0.22 mmol) was added to oxidize the product for 30 min, the UV-visible spectrum of the
solution then showed absorptions around 430 and 830 nm, these being characteristic
absorptions of the zinc(II) isoporphyrin 28. Then the reaction was kept for about 1 h and
washed with water and brine. The product was dried over anhydrous Na 2SO4. The
purification was performed by chromatography on an alumina column eluting with
CH2Cl2 and the fraction with the absorption of zinc(II) isoporphyrin was collected. Further
purification was performed on a silica gel column eluted with CH2Cl2/ethyl acetate (7:3)
and the product was recrystallized from CH2Cl2/petroleum ether. 1H NMR (CDCl3,
400MHz) δ, ppm 7.66 (s, meso-H, 1H), 7.58 (s, meso-H, 2H), 3.63 (s, 5-OCH3, 3H), 2.43,
2.41, 2.38, 2.18 (s, β-CH3, 24H), 1.97 (s, 5-CH3, 3H).

Zinc(II) 2,3,5,7,8,12,13,17,18-Nonamethyl-5-benzylcarbonylisoporphyrin chloride 31
This compound was prepared as described above, in 5% yield. 1H NMR (CDCl3, 400
MHz) δ ppm 7.63 (s, 2H), 7.59 (s, 1H), 7.01-6.99 (5H), 5.0 (s, 2H), 2.45, 2.41, 2.37, 1.99
(s, β-CH3, 24H), 1.94 (s, 3H).

Zinc(II) 2, 3, 5,8,12,13,17,18-nonamethyl-5-acetylisoporphyrin chloride 32
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This compound was prepared as described above, in 20% yield. 1H NMR (CDCl3, 400
MHz) δ ppm 8.11-8.04 (m, 3H), 2.60, 2.57, 2.29, 2.27 (s, β-CH3, 24H), 1.92 (s, 3H), 1.89
(s, 5-CH3, 3H).

Hexylpyruvate amide 38
Method I: Pyruvic acid (0.20 g, 2.27 mmol) was dissolved in CH2Cl2 (30 ml) and then
Et3N (0.34 g, 0.47 ml) was added under argon. The mixture was cooled down to 0 oC,
and BOPCl (0.70 g, 2.7 mmol) was added in one portion. The mixture was stirred at 0 oC
for 30 min and then hexylamine (0.34 g, 3.40 mmol) was added. The mixture was
allowed to warm to room temperature and was then stirred overnight. The solution was
diluted with CH2Cl2 and washed with aqueous 1N HCl, water and then brine. The organic
layer was dried over Na 2SO4 and the product was purified by silica gel column
chromatography eluting with 2% MeOH in CH2Cl2 to give the product 38.8 mg (10%).
Method 2: Pyruvic acid (0.20 g, 2.27 mmol) was dissolved in CH2Cl2 (30ml) and then
oxalyl chloride (1.5 ml) was added followed by a drop of DMF; when the mixture stopped
bubbling, it was left stirring for 1 h. Then the solvent was removed in vacuo. The residue
was dissolved in CH2Cl2 (20 ml) and then hexylamine (0.34 g) was added at 0 oC,
followed by TEA (0.34 g, 0.47 ml). The mixture was stirred overnight at room
temperature. Then the solution was washed with 1 N HCl, water, brine and dried over
anhydrous Na2SO4. The product was purified by crystallization from CH2Cl2/ether to give
required product (0.20 g, 52%). 1H NMR (CDCl3, 400 MHz) δ ppm 6.94 (s, 1H), 3.30 (t,
2H) 2.47 (s, 3H), 1.53 (m, 2H), 1.29 (m, 6H), 0.89 (t, 3H). HRMS (ESI): m/z Calcd for
C9H17NNaO2: 194.1157; found: 194.1152.

BOC-ethylenediamine pyruvate amide 41: This synthesis followed procedure used for
compound 38.
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Yield: 37%, 1H NMR (CDCl3, 400MHz): δ ppm 7.49 (s. 1H), 5.0 (s, 1H), 3.40 (t, 2H), 3.28
(t, 2H), 2.43 (s, 3H), 1.39 (s, 9H). HRMS (ESI): m/z Calcd for C10H18N2NaO4: 254.1164;
found: 254.1151.

BOC-lysine pyruvate amide 42: The preparation of lysine pyruvate amide followed the
procedure used for compound 38. Yield: 40% 1H NMR (CDCl3, 400MHz): δ, ppm 7.38 (s,
1H), 7.36 (s, 1H) 4.52 (m, 1H), 3.74 (s, 3H), 3.09 (t, 2H) 2.46 (s, 3H), 1.91-1.69 (m, 4H),
1.41(s, 9H), 1.32(m, 2H). HRMS (ESI): m/z Calcd for C15H25N2O6: 329.1713; found:
329.1723.
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2.7 Supporting Information

1

H NMR spectra of pyrrole 21 and 18 in CDCl3 at 400 MHz.
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1

H NMR spectra of pyrrole 24 and 19 in CDCl3 at 400 MHz.
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1

H NMR spectra of dipyrromethanes 25 and 27 in CDCl3 at 400 MHz.
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1

H NMR spectra of b-bilene salt 14 and isoporphyrin 28 in CDCl3 at 400 MHz.
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1

H NMR spectra of isoporphyrin 32 and pyruvate amide 38 in CDCl3 at 400 MHz.
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1

H NMR spectra of pyruvate amide 41 and 42 in CDCl3 at 400 MHz.
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Chapter 3: Syntheses of Zinc(II) Isoporphyrins through MacDonald Condensation
3.1. Background
Dipyrrolic intermediates including dipyrromethenes 1,2 and dipyrromethanes3-6 have been
used to synthesize porphyrins. Usually the synthesis of the macrocycle involves
condensation between one half bearing electrophilic groups such as formyl7,8 or
bromomethyl9 and the other half which acts as a nucleophile, such as an α-free

Scheme 3.1: Synthesis of porphyrin by [2+2] dipyrromethene (Fischer, 3+4 to 1) and
dipyrromethane (MacDonald, 5+6 to 2) condensation.
or

bromo

substituted

dipyrromethenes

(Scheme

3.1).

This

method

using

dipyrromethenes was developed by Hans Fischer and is an example of a [2+2]10-12
approach, usually only applied to synthesize symmetrical porphyrins 13,14 since this
methodology has no selectivity between both ends of the two dipyrrole halves. On the
other hand, use of dipyrromethanes (MacDonald approach) also yields porphyrins with
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the same limitations as the Fischer approach, but under milder conditions. For
asymmetric porphyrins, this method will result a mixture of products due to the selectivity
limitation unless one or other of the two dipyrromethenes or two dipyrromethanes is
symmetrically substituted about its central methane carbon atom.. The MacDonald
dipyrromethane method was expanded successfully to synthesis of symmetrical
isoporphyrins by Smith’s group,15-17 and became a fairly universal method to synthesize
symmetrical isoporphyrins. The synthesis of zinc(II) isoporphyrin by the [2+2] approach
usually involves a condensation reaction between a 1,9-diformyldipyrromethane and 1,9unsubstituted dipyrromethane, catalyzed by acid (Scheme 3.2). According to the

Scheme 3.2: Synthesis of zinc(II) isoporphyrin 7 by MacDonald 2 + 2 condensation.
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structure of the target isoporphyrin, one of the dipyrromethane halves should be mesodisubstituted by alkyl or other groups. Metal is necessarily needed to serve as a
template and to stabilize the isoporphyrin compounds once formed. In Chapter 2,
attempts to introduce functional group such as carboxylate or acetyl group to a mesocarbon during cyclization of a b-bilene were discussed;18 however, the transformation of
these groups into carboxylic acid or amine groups failed when attempts were made to
further functionalize the corresponding zinc(II) isoporphyrins after cyclization. The most
plausible reason could be due to the fact that porphyrin is a very good and stable leaving
group, and once the ester or amide bond on the meso-carbon of the zinc(II) isoporphyrin
is cleaved, the decarboxylation takes place leaving a fully aromatic porphyrin as the
leaving group. Therefore, to avoid this problem, the isoporphyrin 12 bearing two PMe
(CH2CH2CO2CH3) groups on pyrrole subunits was chosen as the target. From the
structure we can see the fully conjugated macrocycle is interrupted by one meso-carbon
which is saturated by geminal methyl groups.
3.2. Retrosynthesis
According to the MacDonald 2 + 2 condensation, the target molecule can be cyclized by
reaction between a 5,5-dimethyldipyrromethane-1,9-dicarboxylate 13 and a 1,9diformyldipyrromethane 16 in three steps. These two dipyrromethanes can be obtained
by debenzylation and and debenzylation and diformylation of the corresponding
dipyrromethanes, which were obtained through condensation of pyrrole 15 with acetone
(for 13) and self-condensation of pyrrole 18 (for 16) (Scheme 3.3). The pyrrole starting
materials were synthesized by conventional methods including synthesis of α-free
pyrrole 15 by Baton Zard method and Johnson synthesis of pyrrole 18.
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Scheme 3.3: Retrosynthesis of zinc(II) isoporphyrin 12 by the 2+2 MacDonald
condensation approach.
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3.3. Synthesis of Isoporporphyrins
The synthesis started with pyrroles 18 and 20. Pyrrole 20 was synthesized, as follows,
by Johnson’s method.19,20 Benzyl acetoacetate was treated with sodium nitrite in acetic
acid to generate benzyl oximinoacetoacetate 19, which was condensed with 3-methyl2,4-pentanedione in glacial acetic acid in the presence of zinc dust and sodium acetate.
The mixture was refluxed for one hour and the yellow precipitate was separated and
recrystallized from CH2Cl2/hexane to give the product in around 65% yield. Pyrrole 18
was synthesized using a similar strategy; the precursor 21 was made by Michael
addition of methyl acrylate to 2,4-pentanedione under basic conditions, and this was
then condensed with benzyl oximinoacetoacetate, under the same conditions as
previously, to afford the pyrrole 18 in around 50% yield. Pyrrole 18 was then treated with
bromine in dry ether to give the intermediate 2-bromomethylpyrrole, which was
converted into the corresponding symmetrical dipyrromethane 17 through selfcondensation by refluxing in methanol.21 The product was purified by crystallization from
cold methanol (Scheme 3.4).
Dipyrromethane 17 was converted into the dicarboxylic acid 22 by catalytic
hydrogenation using palladium on activated carbon as catalyst. This dicarboxylic acid
was further converted into the 1,9-diformyldipyrromthane 16 by a Vilsmeier-Haack
reaction in two steps. Decarboxylation of the dipyrromethane dicarboxylic acid was
performed at 160 oC in DMF for one hour and resulted in the 1,9-di-unsubstituted
dipyrromethane, which was treated with a mixture of DMF and benzoyl chloride
(Vilsmeier reagent) followed by basic hydrolysis to give the product 16 in 70% yield. The
other half, 5,5-dimethyldipyrromethane 14,22 was synthesized by condensation between
the α-free pyrrole 15 (2 equivalents) and acetone with BF3.OEt2 as catalyst. Another
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Scheme 3.4: Synthesis of pyrroles 18 and 20 and dipyrromethanes 17 and 28.
major fraction was separated from chromatography column (running faster than the
designed product), which was identified as compound 23 according to 1H NMR (Scheme
3.5). Cyclization to give the zinc(II) isoporphyrin was finished in three steps 15 (Scheme
3.6): (1) The dipyrromethane dicarboxylic acid 13 was treated with toluenesulfonic acid
to

decarboxylate

the

two

α-positions

of

the

dipyrromethane;

(2)

The

diformydipyrromethane 16 was added, followed by zinc acetate as a template, and the
reaction mixture was kept in the dark for 12 hours; (3) The reaction mixture was opened
to air to oxidize the cyclized intermediate. The reaction was monitored by UV/visible
absorption spectroscopy (Figure 3.1), with the characteristic peak around 800 nm
becoming more pronounced with time, usually reaching a maximum after seven days.
The product was purified by chromatography on silica gel, eluted with CH2Cl2/MeOH to
give a yellowish solid in 20% yield. For zinc(II) isoporphyrin 12, the Soret band and Qband showed up at 414 and 799 nm, respectively. The identity of the product was also
confirmed by mass spectrometry (m/z at 657.2643).
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Scheme 3.5: Synthesis of dipyrromethane dicarboxylic acid 13 and
diformydipyrromethane 16.

Scheme 3.6: Synthesis of zinc isoporphyrin 12 by 2+2 MacDonald cyclization.
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Figure 3.1: Absorption spectrum of zinc(II) isoporphyrin 12 in CH2Cl2.
After the success in the synthesis of zinc(II) isoporphyrin 12, we expanded this method
to the synthesis of other zinc(II) isoporphyrins. Molecules 24 and 29 were therefore
designed, which have one, two or three ester groups; these isoporphyrins could be
converted into the corresponding carboxylic acid substituted isoporphyrins so that they
could be conjugated with biomolecules. In this way one can compare the differences of
the biological properties of isoporphyrins mono-, di- and tri-conjugated with biomolecules.
The retrosyntheses of these two molecules are similar to that for zinc(II) isoporphyrin 12;
these involve two dipyrromethanes with two carboxylic acid groups on both ends of one
dipyrromethane 25 or 30 and two formyl groups on both ends of the other
dipyrromethane 26 or 31. Of course, the functional groups can be switched between
these two dipyrromethanes 27 and 28 or between 32 and 17. Theoretically, there should
be no differences when these two halves approach each other to form macrocycles
(Scheme 3.7).
Dipyrromethane 25 was synthesized by condensation of α-free pyrrole with ethyl
acetoacetate, catalyzed by BF3.OEt2 in ethanol; the solution was refluxed overnight and
the product was separated by chromatography to give 7-15% yields. Meanwhile, another
major fraction was separated and identified to be 5,5-dimethydipyrromethane 14. A
possible mechanism for formation of 14 supposes that the ethyl acetoacetate was
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hydrolyzed to carboxylic acid under acidic conditions, which was converted to acetone
by acid catalyzed decarboxylation through a six membered ring; the α-free pyrrole then
reacted with the generated acetone to form 5,5-dimethyldipyrromethane 14 (Scheme
3.8). The other dipyrromethane half 28 was synthesized with the same strategy as
previously used, by bromination of the α-methylpyrrole 20 followed by self-condensation
by refluxing it in methanol. The product 28 was crystallized from methanol to give a white
solid in 70% yield. Then dipyrromethane 28 was catalytically debenzylated to give the
dicarboxylic acid, which was treated with TFA/trimethylorthoformate23 and then
recrystallized from ethanol to give the diformydipyrromethane 26 (Scheme 3.9) in 35%
yield. The dipyrrolmethane 25 was debenzylated by hydrogenation catalyzed by Pd/C
and the resultant dicarboxylic acid was used as the precursor of the bis-α-free
dipyrromethane. The cyclization the corresponding dipyrromethane dicarboxylic acid
from 25 with the diformyldipyrromethane 26 was performed under the same conditions
as previously reported in three steps (Scheme 3.10). Unfortunately, the desired product
was not obtained according to UV/visible absorption spectroscopy, the characteristic
peak of zinc(II) isoporphyrin around 800 nm being absent. According to Lash’s
synthesis24 of extended indene-fused porphyrins 39 (Scheme 3.11), when the diformyl
groups were located on the more strained dipyrromethane 36 instead of 35, the reaction
gave better yields than the other way around. We therefore took the same strategy with
the synthesis of our zinc(II) isoporphyrin in this case. Before we switched the carboxylic
acid and formyl groups between the two dipyrromethanes; we

synthesized

dipyrromethane 30 by reacting the α-free pyrrole 15 with ethyl levulinate, catalyzed by
BF3.OEt2 in EtOH, to give a 30% yield compared with dipyrromethane 25 (Scheme 3.12),
which had a lower yield of around 10% because of the competition from production of
the side product dipyrromethane 23. The cyclization of dipyrromethane 30 with the same
diformydipyrromethane 26 failed to give the corresponding isoporphyrin, the UV/visible
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Scheme 3.7: Retrosynthesis of zinc(II) isoporphyrins 24，29 and 33 by MacDonald 2+2
condensation.
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Scheme 3.8: Synthesis of dipyrromethanes and the proposed route for formation of side
product 15.

Scheme 3.9: Sythesis of dipyrromethanes 28 and 26.
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absorption around 500 nm indicating only one side was joined together to give an openchain b-bilene. Therefore, the formyl groups were introduced onto dipyrromethane 30
instead of dipyrromethane 26, which remained as the dipyrromethane dicarboxylic acid
prior to cyclization. These two dipyrromethanes 32 and 28 were used for the cyclization
using the identical previous conditions, and finally gave the desired zinc(II) Isoporphyrin
product 33. The reaction was mainly monitored by UV/visible absorption spectroscopy,
and the product possessed a Soret band at 423 nm and a Q-band at 813 nm (Scheme
3.13).

Scheme 3.10: Attempt to synthesize Isoporphyrin 24 and 33 by MacDonald 2+2
condensation.
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Scheme 3.11: Lash’s synthesis of indene-fused porphyrins.24

Scheme 3.12: Synthesis of diformydipyrromethane 30 and diformydipyrromethane 32.
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Scheme 3.13: Synthesis of zinc(II) isoporphyrin 34 by MacDonald 2+2 condensation
between diformyldipyrromethane 32 and dipyrromethane carboxylate 28, and UV-visible
spectrum of 33 in CH2Cl2.
Based on the route used for synthesis of zinc(II) isoporphyrins 12 and 33, the
isoporphyrin 40 was produced by cyclization between the dicarboxylic acid of
dipyrromethane 30 and diformydipyrromethane 16 in around 4% yield. This zinc(II)
isoporphyrin has a Soret band at 423 nm and a Q-band at 804 nm (Scheme 3.14).
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Scheme 3.14: Synthesis of zinc(II) isoporphyrin 40 by 2+2 MacDonald condensation,
and the UV/visible spectrum of 40 in CH2Cl2.

3.4 Attempts to Hydrolyze Ester Groups on Zinc(II) Isoporphyrins
After success in the synthesis of the zinc(II) isoporphyrins, various methods to convert
the meso-methyl ester group into the corresponding carboxylic acid were attempted so
that they could subsequently be conjugated with biomolecules. As discussed in Chapter
2, when the ester is directly attached to the 5-position of the zinc(II) isoporphyrin, the
isoporphyrin will leave as a zinc(II) porphyrin after hydrolysis and spontaneous
decarboxylation. However, with an ester group on the pyrrole unit of zinc(II) isoporphyrin
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12, there should be no such problem with the hydrolysis. For the zinc(II) isoporphyrins
33 and 40, since the ester groups are either distant from the meso-position of the
isoporphyrin or attached to the -positions of the pyrrole subunits of isoporphyrins, there
should also be no problem. Therefore, the hydrolysis of zinc(II) isoporphyrins was
explored mainly using zinc(II) isoporphyrin 12 since it had the best yield during its
synthesis (Table 3.1). Zinc(II) isoporphyrin 12 was therefore subjected to strong basic
conditions using NaOH25 in MeOH at room temperature; the reaction was monitored by
UV/visible spectroscopy. With time the peak around 800 nm disappeared and there was
a new peak that appeared at 629 nm, which unfortunately belongs to the ring-cleaved
open chain system. This was unexpected since it seemed unlikely that this can take
place for zinc(II) isoporphyrin 12. Therefore several neutral hydrolytic conditions were
tried on zinc(II) isoporphyrin 12 in the hope that the macrocycle of this isoporphyrin
might be preserved under these mild conditions (Scheme 3.15). With iodide-based
reagents including LiI,26 TMSI and TMSCl/LiI,27 and CH3CH2CH2SLi,28 the macro-ring
opened during hydrolysis although ester hydrolysis did take place, especially when LiI
was used. A fraction separated by using Sephadex 20, had its major mass peak at m/z
629.3317, an ion that belongs to the corresponding zinc(II) isoporphyrin carboxylic acid,
was observed from both the ESI and Maldi mass spectra (Figure 3.2). However, the
UV/visible absorption of this compound showed no peak around 800 nm; the spectrum
showed this compound to be an open-ring system, which proved that the LiI hydrolyzed
methyl ester, but also opened the the isoporphyrin ring. With trimethyltin hydroxide29 and
bis(trimethyltin) oxide, the zinc(II) isoporphyrin also decomposed; the UV/visible
absorption was similar to that seen when LiI was used. Enzymatic hydrolysis using
lipase30 showed no reactivity in phosphate buffer solution even after one week; the mass
spectrum showed the starting material still remained as the only peak. Some acidic
conditions such as BCl331 and BBr3 were also tried on the zinc(II) isoporphyrin but they
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did not work either; the spectrophotometry peak around 800 nm became smaller and
was completely gone after aqueous work up.

Scheme 3.15: Attempted hydrolysis of zinc(II) isoporphyrin 12 by LiI and the UV/visible
spectrum in CH2Cl2 of the ring-opened product.
Table 3.1:The Hydrolysis of Zinc(II) Isoporphyrins Under Different Conditions.
Tries
1
2
3
4
5
6
7
8

reagents
LiI
TMSI
TMSCl/LiI
Li-S-propane
(CH3)3SnOH
(CH3)3SnOSn(CH3)3
Lipase enzyme
BCl3 or BBr3

solvents
Ethyl acetate
CHCl3
Acetonitrile
CH3CH2CH2SH
1,2-DCE
1,2-DCE
Phosphate buffer
CHCl3
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temperature
reflux
reflux
reflux
R. T
reflux
reflux
R. T.
R. T

result
ring-opened
ring-opened
ring-opened
ring-opened
ring-opened
ring-opened
no reaction
ring-opened

Figure 3.2: Mass spectrum of product of hydrolysis of zinc(II) isoporphyrin 12 by using LiI.
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3.5 Functionalization of Dipyrromethanes Before Cyclization to Give Zinc(II)
Isoporphyrin
From all the hydrolyses attempted using the above conditions, it seemed that zinc(II)
isoporphyrins are not very stable to strong acids, bases, or nucleophiles. Under acidic
conditions, the zinc ion could be removed from the isoporphyrin, but the metal free
isoporphyrins are not very stable and decomposed rapidly. Trimethyltin hydroxide and
iodide-based reagents are all strong nucleophiles, which are reactive enough to
hydrolyze the ester group but they also open the isoporphyrin ring at the same time.
Enzymatic hydrolysis depends on how the molecule fits into the lipase core, and for this
case there was no reactivity using zinc(II) isoporphyrins. Since we had no success using
methyl esters, we changed our synthetic strategy for isoporphyrins conjugation with
biomolecules.
Strategy I: A t-butyl ester was introduced into the zinc(II) isoporphyrin since it is easy to
remove compared with a methyl ester. Therefore, the zinc(II) isoporphyrin 42 was
designed. The retrosynthetic analysis of this molecule is similar to the previous cases
(Scheme 3.16). The dipyrromethane dicarboxylate half remained the same, and it was
necessary to convert the methyl esters of the other half into tert-butyl esters. We tried
several conditions which could possibly hydrolyze a methyl ester over a benzyl ester on
the dipyrromethane 17 (Scheme 3.17). But no selectivity under basic conditions between
these two ester groups was observed, so we moved to acidic conditions with H2SO4 in
DMSO overnight; the solution turned black and the mass spectrum of the product
showed only the starting material peak. Then LiI was used in ethyl acetate and THF;
both solvents gave a low yield of product after purification. Trimethyltin hydroxide 29 is a
very good reagent to hydrolyze methyl esters compared with other esters including ethyl,
tert-butyl and other more complicated esters, according to the literature. A solution of
dipyrromethane 17 was refluxed in 1,2-DCE with the presence of trimethyltin hydroxide;
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with time a white pinkish solid precipitated from the solution and more precipitate came
out when the solution was cooled down to room temperature. The precipitate was
collected without further purification. 1H NMR spectroscopy showed it to be pure enough
to go to next step, and the benzyl esters remained intact. After dipyrromethane
dicarboxylic acid 44 was obtained, several attempts at tert-butyl esterification of this
dipyrromethane were made (Scheme 3.18). The dipyrromethane dicarboxylic acid 44
was treated with oxalyl chloride in THF with a little DMF as a catalyst, followed by
addition of tert-butyl alcohol and TEA (base) in CH2Cl2. The mixture was heated to 40 oC
and kept for ten hours under argon. Unfortunately, the tert-butyl ester was not obtained
after column chromatography and the mass spectrum did not give any hint of the
required product. Then, a typical coupling reaction for making an ester group using
EDCI/DMAP in DMF was tried, but unfortunately the reaction did not take place under
these conditions. Then ButOAc32 was used as an esterification reagent and solvent
under acidic conditions, but the product was not detected once again. When neat oxalyl
chloride was used as chlorinating reagent and solvent, the acyl chloride was formed.
The dipyrromethane dicarboxylic acid 44 is not very soluble in oxalyl chloride; however,
when the reaction mixture was heated to 40 oC, the solid disappeared with time, which
indicated that the carboxylic acid was converted into the acyl chloride. The excess oxalyl
chloride was removed and the residue was dissolved in CH2Cl2 and treated with tertbutyl alcohol in presence of TEA, and then the mixture was kept at 40 oC for ten hours.
As a result, the product was obtained in about 40% yield and its identity was confirmed
by mass spectrometry, with a peak at m/z 721.3455 (MW+Na).
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Scheme 3.16: Retrosynthetic analysis of tert-butyl ester substituted zinc(II) isoporphyrin
42.
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Scheme 3.17: Attempts to preferentially hydrolyze the methyl esters over the benzyl
esters of dipyrromethane 17, to synthesize dipyrromethane 44.

Scheme 3.18: Attempts to transform the carboxylic acid to tert-butyl ester of
dipyrromethane 45.
Then the tert-butyl substituted dipyrromethane 44 was subjected to Pd-catalyzed
hydrogenation in THF to remove the benzyl protecting groups, and the resulting
dicarboxylic acid was refluxed in DMF at 160 oC for one hour and treated the α-free
dipyrromethane along with PhCOCl at 0 oC; this was followed by hydrolysis using
aqueous NaHCO3 in EtOH. A yellow solid was collected and recrystallized from ethanol,

93

giving the diformyldipyrromethane 43 in about 60% yield (Scheme 3.19). Cyclization of
tert-butyl ester-substituted diformyldipyrromethane 43 with 5,5-dimethyldipyrromethane
dicarboxylic acid 13 gave the zinc(II) isoporphyrin product 42 smoothly, which has a
Soret band and Q-band at 409 and 801 nm, respectively (Scheme 3.20). Then the zinc(II)
isoporphyrin 42 was dissolved in CHCl3 and treated with TFA (several drops) under
argon; the reaction was again monitored by UV/visible absorption spectroscopy, and the
peak at 801 nm disappeared with time, possibly indicating that the TFA had removed the
zinc(II) ion from the isoporphyrin. The TFA was removed using a stream of N2 gas, and
then zinc acetate in MeOH was added to the solution of the residue in CH2Cl2 [to reinsert the zinc(II) to stabilize the isoporphyrin]. Unfortunately, the UV/visible spectrum did
not change at all, (Scheme 3.21). Once the demetalation took place, the isoporphyrin
must have decomposed very quickly. An attempt was also made to cleave the tert-butyl
ester by using zinc bromide but this was also unsuccessful.

Scheme 3.19: Synthesis of tert-butyl ester-substituted diformydipyrromethane 43.
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Scheme 3.20: Synthesis of zinc(II) isoporphyrin 42 by MacDonald 2+2 condensation,
and UV-visible spectrum of 42 in CH2Cl2.
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Scheme 3.21: Attempt to hydrolyze tert-butyl ester of zinc(II) isoporphyrin 42 and UVvisible spectrum in CH2Cl2 of the reaction product.
Strategy II: Since the transformation of the tert-butyl esters to the corresponding
carboxylic acids did not succeed, the strategy was again changed. The new plan was to
introduce an imine group into the molecule before cyclization. The mono BOC-protected
ethylenediamine was chosen to be introduced into the molecule so that it could be
deprotected later. Two methods were tried on dipyrromethane 44; the first involved
chlorination of the dipyrromethane dicarboxylic acid 44 by using oxalyl chloride followed
by amination with mono-BOC protected ethylenediamine under basic conditions. This
reaction gave about 25% yield. Another method was to use TBTU/HOBt33 promoted
conjugation with DIEA as a base, and this gave a better yield (around 40%); purification
was also easier than in the first method. However, the attempt to convert the
dipyrromethane 46 in to diformyldipyrromethane 48 failed (Scheme 3.22). The
assumption is that in the decarboxylation step, N-BOC could be cleaved under high
temperature conditions, and the free amine will hinder formylation of α-free
dipyrromethane.
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Scheme 3.22: Attempted transformation of dipyrromethane 44 into
diformydipyrromethane 48.
Then we switched the formyl groups and carboxylic acid groups between these two
dipyrromethanes in an attempt to avoid the abovementioned problem. Therefore, several
attempts were made to synthesize the 5,5-dimethyldipyrromethane 49 (Scheme 3.23).
The first attempt was by Vilsmeier-Haack formylation. Dipyrromethane dicarboxylic acid
13 was obtained by debenzylation of the diester and then the dicarboxylic acid was
heated to 160 oC in DMF for one hour before the solution was cooled down to room
temperature and the PhCOCl/DMF complex was added. The mixture was stirred for
another hour followed finally by hydrolysis with NaHCO3 in ethanol. However the
reaction did not give the desired product. Some yellow solid was obtained by filtration
after hydrolysis, but it was hard to dissolve it in CHCl3 and it did not move on a TLC plate.
The problem is probably because of

oxidation or decomposition of

α-free

dipyrromethane under the high temperature conditions, or the failure of hydrolysis of the
Vilsmeier imine intermediate. Then we turned to acidic conditions for decarboxylation,
using TFA, followed by addition
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Scheme 3.23: Efforts to synthesize diformydipyrromethane 49 under various conditions.
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triethyl orthoformate for the formylation step. The reaction still failed to give the required
product. Yet another another formylation complex, 4-nitro-PhCOCl/DMF, was employed
since it could generate a better leaving group than PhCOCl/DMF during hydrolysis.
However, the reaction still failed.
Since one of the problems was possibly due to incomplete decarboxylation, then we
tried to look for a method that can give α-free dipyrromethane 52 directly. According to
the literature,34,35 3,4-dimethylpyrrole can react with acetone, catalyzed by perchloric
acid, to give 52 directly. Therefore, we tried to synthesize 3,4-dimethylpyrrole by
hydrolysis of the ethyl pyrrole-2-carboxylate, followed by decarboxylation catalyzed by
KOH in ethylene glycol. Unfortunately, this reaction only gave a 15% yield of product 51.
Therefore this route was abandoned. Instead of using the benzyl ester pyrrole, the ethyl
ester pyrrole was used to synthesize the corresponding dipyrromethane 53,36 which was
hydrolyzed to give the corresponding carboxylic acid by using KOH/THF/H2O, followed
TFA/TMOF formylation to give a 20% yield of the product 49. Another route for
formylation was tried by converting the dipyrromethane

53

into the α-free

dipyrromethane in one pot by refluxing in ethylene glycol with aqueous KOH. The -free
dipyrromethane 52 was precipitated by adding water and this was used in the next step
immediately to make diformydipyrromethane37 using PhCOCl/DMF at 0 oC. To avoid the
failure of hydrolysis of the imine intermediate, the complex was dissolved in a mixture of
EtOH/NaHCO3 and refluxed for about ten minutes; the product diformydipyrromethane
49 was generated in a satisfying 65% yield.
Then the two halves, diformylpyrromethane 49 and dipyrromethane dicarboxylic acid 47
(Scheme 3.24) were subjected to the cyclization conditions once again to see if the
macrocycle could be formed; the reaction failed to give the corresponding zinc(II)
isoporphyrin , and after one week, there was no peak around 800 nm in the UV/visible
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spectrum. The assumption is that the N-BOC group was cleaved by p-toluenesulfonic
acid, especially when the solution of zinc acetate in methanol was added. The N-BOC is
easily displaced in polar solvents.38 Once the N-BOC was cleaved, the free amine could
react with the formyl group in competition with the α-free dipyrromethane. Based on this
assumption, we changed our strategy once again.
The purpose of adding p-TSA was to cleave the carboxylic acid groups and
protonate/activate the aldehyde group during cyclization. Therefore, the new plan was to
remove the carboxylic acid group (to give free α-positions) before cyclization, and then
an acid weaker than p-TSA can be added to protonate the aldehyde during cyclization to
avoid the cleavage of the N-BOC group. Therefore, the dipyrromethane was obtained by
an iodination/de-iodonation procedure. The corresponding dipyrromethane dicarboxylic
acid of 47 was treated with I2/Na2CO3 to introduce iodine at both α-positions to give
diiododipyrromethane 55, followed by hydrogenation catalyzed using PtO 2,39 to give the
α-free dipyrromethane 56 for the next step (Scheme 3.25). Then cyclization of
dipyrromethanes 49 and 56 was attempted, under the same conditions as earlier, except
that acetic acid was used instead of p-TSA. The reaction was kept in air for a week but
no product was formed. The UV/visible spectrum was very similar to the previous one. A
possible reason could be that acetic acid is not strong enough to promote the reaction
(Scheme 3.26). Meanwhile we tried other protecting groups, using mono-FMOC
protected ethylenediamine because it is very stable to acid, which is mandatory during
cyclization; therefore mono-FMOC protected ethylenediamine was introduced onto
dipyrromethane dicarboxylic acid 44 by using two methods. The mono-BOC protected
dipyrromethane 46 was cleaved by TFA, and the resultant dipyrromethane was reprotected using FMOC-Cl/NaHCO3 in dioxane/H2O. The identity of the product was
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confirmed by mass spectrometry (m/z at 1137.4724), but only a trace amount was
separated. Another

Scheme 3.24: Attempt to synthesize zinc(II) isoporphyrin 54 by MacDonald 2+2
condensation, and the UV-visible spectrum of the product in CH2Cl2.
method attempted is the conjugation reaction between dipyrromethane dicarboxylic acid
44 and mono-FMOC protected ethylenediamine using HATU/DIEA. The product 57 was
obtained as a redish solid in 30% yield after column chromatography (Scheme 3.27).
Then the dipyrromethane 57 needed to be converted into its corresponding carboxylic
acid to achieve cyclization later. Usually, the FMOC group is more easily removed than a
benzyl ester group under hydrogenolysis conditions. However it has been found that the
benzyl group can be cleaved in preference to an FMOC group by using TES/Pd
mediated hydrogenation in MeOH. Therefore the solution of dipyrromethane 57 in MeOH
was treated with TES/Pd; unfortunately, the benzyl and FMOC were both cleaved. The
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assumption is the N-FMOC group lessened the difference between benzyl ester
compared with C-FMOC.

Scheme 3.25: Synthesis of α-free dipyrromethane 56 by iodination to give 55 and deiodination reactions.

Scheme 3.26: Attempt to synthesize zinc(II) isoporphyrin 54 by condensation of
dipyrromethanes 49 and 56, and UV-visible spectrum in CH2Cl2 of the product.
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Scheme 3.27: Synthesis of dipyrromethane 59.
Another way to avoid the deprotection of the benzyl ester in preference to the N-FMOC
is to introduce a formyl group and then protect the ester groups. Based on this,
diformydipyrromethane 16 was hydrolyzed first and protected with benzyl ester groups
so that it could be finally cleaved by hydrogenation (Scheme 3.28). Before protection of
the carboxylic acids, we used the zinc(II) isoporphyrin 12 as a sample to test the reaction
to see if the zinc(II) isoporphyrin is stable to Pd-catalyzed hydrogenation. However, the
test showed that the zinc(II) isoporphyrin was reduced to porphyrin according to the
UV/visible absorption changes during the reaction. The peak around 800 nm
disappeared and a new sharp (Soret) peak appeared at 400 nm along with typical zinc(II)
porphyrin Q bands from 531 to 568 nm (Scheme 3.29).
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Scheme 3.28: Synthesis of dipyrromethane 60.

Scheme 3.29: Instability of zinc(II) isoporphyrin under hydrogenation conditions, and the
UV-visible spectrum of the zinc(II) porphyrin product in CH 2Cl2.
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3.6 Experiment Part
Compound 19: Sodium nitrite (15.57 g, 0.225 mol) was dissolved in 30 ml of water, and
the resulting solution was added to a solution of benzyl acetoacetate (42.05 g, 0.218
mmol) in 60 ml acetic acid in an ice bath; the mixture was well stirred overnight. The
solution turned orange and was kept in a refrigerator for use in the next step.
Benzyl 3,4,5-trimethlpyrrole-2-carboxylate 20: To a solution of 2,4-pentanedione (25
g, 0.25 mmol) in acetic acid (100 ml) was added a solution of compound 19 dropwise
over 2 h with vigorous magnetic stirring. Simultaneously, a well-mixed powder of 37 g of
zinc dust and 37 g of anhydrous sodium acetate was added portion-wise at room
temperature. Then the solution was heated to 80 oC overnight, and the mixture was
cooled down to room temperature and poured into ice water with slow stirring. The
yellow precipitate was collected by filtration, and the pyrrole was redissolved in CH2Cl2
and filtered again to remove residual zinc. The product was recrystallized from ethanol
as pale yellow crystals (31.70 g, 60%). Mp 115 oC, (Lit19 mp 119-120 oC). 1H NMR (400
MHz; CDCl3): δ 8.57 (s, 1H), 7.38-7.30 (m, 5H), 5.28 (s, 2H), 2.28 (s, 3H), 2.17 (s, 3H),
1.90 (s, 3H).
Methyl 4-acetyl-5-oxohexanoate 21: 2,4-Pentanedione (100.4 g, 1 mol) and
potassium carbonate (3.3 g) were dissolved in 2-butanone (50 ml), and then the
temperature was brought to refluxing and a solution of methyl acrylate (83 g, 0.93 mol) in
15 ml of 2-butanone was added slowly to avoid over boiling. After the addition was
complete, the mixture was refluxed for 5 h. It was then cooled down to room temperature
and filtered to remove potassium carbonate. The filtrate was evaporated under vacuum
and further purified by distillation to give a yellow oily liquid (121 g, 70%). 1H NMR (400
MHz; CDCl3): δ 3.72(t, 1H), 3.66(s, 3H), 2.18(s, 6H), 2.1-2.6(m, 4H).

105

Benzyl

4-(2-methoxycarbonylethyl)-3,5-dimethylpyrrole-2-carboxylate

18:

The

same amount as above of solution of compound 19 (prepared from the same ratio of
chemicals) was added dropwise to a solution of compound 21 (46.56 g, 0.25 mol) in 70
ml glacial acetic acid; at the same time, a mixed powder of 43 g of zinc dust and 43 g of
sodium acetate was added portion-wise. After the addition was over, the solution was
heated to 80 oC with stirring for 2-3 h. The mixture was then cooled to room temperature
and poured into ice/water with stirring. The pale yellow precipitate was collected by
filtration and then the precipitate was dissolved in CH2Cl2 (200 ml) and filtered again to
remove residual zinc. The residue was crystallized from methanol to give the product as
a yellowish solid, (34 g, 50%) M.p 99 oC, (Lit19 mp 99-100 oC). 1H NMR (400 MHz;
CDCl3): 8.54 (s, 2H), 7.43-7.32 (m, 5H), 5.28 (s, 2H), 3.66 (s, 6H), 2.70 (t, 2H), 2.42 (t,
2H), 2.29 (s, 3H), 2.20 (s, 3H).
2,2-Bis(5-benzyloxycarbonyl-3,4-dimethylpyrrol-2-yl)propane 14: Pyrrole 15 (2.29 g,
0.01 mol) was dissolved in 30 ml of ethanol and 6 ml of acetone, and the solution was
warmed until all the solid was dissolved. Then 0.94 ml (8.55 mmol) BF3.OEt2 was added
and the mixture was refluxed for 1 d, before the solvent was removed and the residue
was dissolved in CH2Cl2 and washed with Na2CO3, brine and then dried over anhydrous
Na2SO4. After removing the solvent, the product was purified by chromatography using
1:5 ethyl acetate/cyclohexane to give the product (1.5 g, 60% yield). Mp 143 oC, (Lit15
Mp 135-136 oC). 1H NMR (400 MHz; CDCl3): δ 8.79(s, 2H), 746-7.32(m,10H), 5.34(s,
4H), 2.26(s,6H), 1.66(s, 6H), 1.50(s, 6H).
Dibenzy

3,7-bis(2-methoxycarbonylethyl)-2,8-dimethyldipyrromethane-1,9-

dicarboxylate 17: Pyrrole 18 (15.7 g, 0.05 mol) was dissolved in 500 ml of anhydrous
diethyl ether, and bromine (2.56 ml, 0.05 mol) was added dropwise. The solution turned
brown during addition, and the mixture was kept stirring at room temperature overnight,
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whereupon a thick precipitate was apparent. Then the diethyl ether was removed to give
a pink solid which was dissolved in 100 ml methanol and refluxed overnight. When the
solution was cooled down to room temperature, a precipitate appeared, which was
filtered and washed with cold methanol to give a white solid (10.70 g, 70%). Mp 102-104
o

C, (Lit40 mp 96-97 oC). 1H NMR (400 MHz; CDCl3): δ 9.00(s, 2H), 7.38-7.31(m, 10H),

5.25(s, 4H), 3.97(s, 2H), 3,56 (s, 6H), 2.75(t, 4H), 2.51(t, 4H), 2.28(s, 6H).
1,9-Diformyl-3,7-bis(2-methoxycarbonylethyl)-2,8-dimethyldipyrromethane

16:

Dipyrromethane 17 (6.14 g, 0.01 mol) was dissolved in 300 ml THF, and then 5% Pd/C
(350 mg) catalyst was added. The suspension was stirred under a H2 atmosphere
overnight. After TLC showed reaction was complete, the reaction was stopped and the
solution was passed through a Celite cake to remove the catalyst. A sticky solid on the
top of the Celite cake was redissolved in THF and neutralized in water by ammonia and
then passed again through the Celite cake. The filtrate was acidified with acetic acid and
the product precipitated from aqueous solution. The solid was collected by filtration. The
THF part was evaporated and combined with the solid to give a total of 4.0 g (92%) of
dpyrromethane dicarboxylic acid. This dipyrromethane dicarboxylic acid (4.00 g, 0.092
mol) was dissolved in 12 ml of DMF and heated to 160 oC for about 1 h under the
protection of an argon atmosphere and then the solution was cooled down to room
temperature and the Vilsmeier complex comprising DMF (4.34 ml) and benzoyl chloride
(3.25 ml), which had been prepared in advance, was added dropwise at 0 oC. After the
addition was complete, the reaction continued for another 2 h. Some precipitate
appeared, so 20 ml of benzene was added and solid was filtered, washed with
petroleum ether and then dried in the air. Then the solid was dissolved in ethanol and 3
g of NaHCO3 was added and the mixture was stirred overnight. A yellow precipitate
appeared, which was collected and air dried to give product (2.6 g, 70%). Mp 174 oC
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(Lit41 Mp 180-181oC). 1H NMR (400 MHz; CDCl3): δ 10.03(s, 2H), 9.45(s, 2H), 4.05(s,
2H), 3.71(s, 6H), 2.79(t, 4H), 2.55(t, 4H), 2.29(s, 6H).
Zinc 13,17-bis(2-methoxylcarbonylethyl)-2,3,4,5,7,8,12,18-octamethylisoporphyrin
chloride 12: Dipyrromethane 14 (0.249 g, 0.5 mmol) was dissolved in 50 ml THF and
then 30 mg 10% Pd/C catalyst was added and the mixture was stirred under a H2
atmosphere for about 2 h, until TLC showed the reaction was complete. Then the
solution was passed thought a Celite cake to remove catalyst, and the filtrate was
evaporated to give a yellowish solid. This solid was dissolved in 200 ml of CH2Cl2 and ptoluenesulfonic acid (0.375 g,1.97 mmol) in 16 ml MeOH was added and the solution
was heated to 40 oC for about 10 min to remove the carboxylic acid groups. After TLC
showed the reaction was complete, a solution of diformyldipyrromethane 16 (0.201 mg,
0.005 mmol) in CH2Cl2 (30 ml) was added, followed by addition of excess zinc acetate
(0.18 g, 0.82 mmol) in MeOH (5 ml). The mixture was stirred at 38 °C for 3 d and then
another 4 d at room temperature under air. The solution turned dark with time and finally
gave a dark brown mixture. Then the solution was washed with water, sodium
bicarbonate solution, and brine, and dried over anhydrous Na2SO4. The solvent was
removed and the residue was purified by chromatography eluting with 2-4% MeOH/
CH2Cl2 and further recrystallized from hexane/ CH2Cl2 to give a greenish solid. Mp >260
o

C (Lit43 mp > 250oC). 1H NMR (400 MHz; CDCl3): 7.75 (s, 1H), 7.55 (s, 2H), 3.65 (s, 6H),

3.20 (t, 4H), 2.69 (t, 3H), 2.42 (s, 12H) 2.38 (s, 6H), 1.91 (s, 6H). UV/Vis (CH 2Cl2): λmax (ε,
M-1 cm-1): 414 nm (3.0 x 104), 729 (1.6 x 104), 799 (4.7 x 104).
Ethyl 4,4-bis(5-benzyloxycarbonyl-3,4-dimethylpyrrol-2-yl)butanoate 25: α-Free
pyrrole 17 (2.29 g, 0.01 mol) and ethyl acetoacetate (0.651 g, 5.0 mmol) were dissolved
in 15 ml absolute ethanol and 0.5 ml (4 mmol) of boron trifluoride etherate was added
and the mixture was refluxed overnight. Another 2.5 mmol (0.22g, 0.25 ml) of ethyl
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acetoacetate was added and the mixture was refluxed for another 1 d. Then the solvent
was removed and the residue was taken up in CH2Cl2, washed with water, NaHCO3,
brine, and dried over anhydrous Na2SO4. The solvent was evaporated and the residue
was purified by silica gel column chromatography, eluting \with (ethyl acetate/hexane 1:5)
to give the product (0.40 g, 7%). 1H NMR (400 MHz; CDCl3): δ 9.34 (s, 2H), 7.46-7.31 (m,
10H), 5.33 (s, 4H), 4.09 (q, 2H), 3.02 (s, 2H), 2.30 (s, 6H), 1.56 (s, 6H), 1.16 (t, 3H).
Dibenzyl 2,3,7,8-tetramethyldipyrromethane-1,9-dicarboxylate 28: Compound 28
was synthesized following the procedure for compound 17 to afford the product
(3.20g,70 %). Mp 180 oC. (Lit42 mp 178-180 oC). 1H NMR (400 MHz; CDCl3): δ 8.79 (s,
2H), 7.34-7.30 (m, 10H), 5.25 (s, 4H), 3.79 (s, 2H), 2.25 (s, 6H), 1.93 (s, 6H).
2,2-Bis(5-formyl-3,4-dimethylpyrrol-2-y-l)propane 26: Benzyl 3,4,5-trimethylpyrrole-2carboxylate (2.35 g, 0.005 mol) was dissolved in THF (100 ml) and 150 mg of 5% Pd/C
catalyst was added. The solution was stirred under a H2 atmosphere overnight,
whereupon the TLC showed the reaction was complete. The solution was passed
through a Celite cake to remove the catalyst and the sticky part on top of the Celite cake
was dissolved in water and neutralized by aqueous ammonia and passed through the
Celite cake again. Then the aqueous solution was acidified with acetic acid to afford a
white precipitate which was filtered and dried in a vacuum oven. The THF part was
evaporated and the solids were combined together to give the product dicarboxylic acid
(1.3 g, 90%). Then the acid was added to cold TFA (20 ml) for 10 min and 4 ml of TEOF
was added slowly. After addition was complete, the mixture was stirred for about 1 h and
then poured into 100 ml of ice/water, and ammonium hydroxide was added to
neutralized the solution to pH=7. Then the solution was extracted with CH2Cl2 (100 ml x
3). The organic phase was washed with water, brine and then dried over anhydrous
Na2SO4. The solvent was removed and the brown solid was recrystallized from EtOH to
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give the pure product (0.23 g, 20% yield).

1

H NMR (400 MHz; CDCl3): δ 9.47(s, 2H),

3.87(s, 2H), 2.24(s, 6H), 1.98(s, 6H).
Ethyl

4,4-bis(5-benzyloxylcarbonyl-3,4-dimethylpyrrol-2-yl)pentanoate

30:

The

synthesis of compound 30 followed the procedure for compound 25 to afford the product
as a transparent oil, (1.7 g, 30% yield). 1H NMR (400 MHz; CDCl3): δ 8.71(s, 2H), 7.457.33 (m, 10H), 5.32 (s, 4H), 4.07 (q, 2H), 2.41 (t, 2H), 2.22 (s, 6H), 2.11 (t, 2H), 1.59 (s,
6H).
Ethyl 4,4-bis(5-formyl-3,4-dimethyl-1H-pyrrol-2-yl)pentanoate 32: The synthesis of
compound 32 followed the procedure for compound 16 to afford the product (0.29 g,
37%) starting with (1.2 g, 2.0 mmol) of 30 1H NMR (400 MHz; CDCl3): 9.54 (s, 2H), 9.20
(s, 2H), 4.08 (t, 2H), 2.21 (s, 6H), 2.12 (t, 2H), 1,63 (t, 2H), 1.23 (t, 4H).
3,3'-(2,2'-methylenebis(5-((benzyloxy)carbonyl)-4-methyl-1H-pyrrole-3,2
diyl))dipropanoic acid 44: Dipyrromethane 17 (0.1 g, 0.159 mmol) was dissolved in
1,2-DCE (15 ml) and trimethyltin hydroxide(143 mg, 0.796 mmol) was added. The
mixture was refluxed until a large amount of solid was precipitated and the mixture was
then refluxed for another 24 h. The mixture was cooled down to room temperature. All of
the solid was filtered off and dissolved in ethyl acetate and then neutralized using
aqueous HCl. The organic layer was washed with water, brine, and then dried over
anhydrous Na2SO4. The solvent was removed and a pink solid was obtained (56 mg,
60%). 1H NMR (400 MHz; CDCl3): 11.99 (s, 2H), 11.18 (s, 2H), 7.41-7.28 (m, 10H), 5.25
(s, 4H), 3.85(s, 2H), 2.48 (t, 4H), 2.12 (s, 6H), 2.05 (t, 4H).
Dibenzyl

5,5'-methylenebis[4-(3-(tert-butoxy)-3-oxopropyl]-3-methyl-1H-pyrrole-2-

carboxylate) 45: Compound 44 (200 mg, 0.34 mmol) was added to oxalyl chloride (20
ml), and the mixture was warmed to 40 oC under protection of argon for about 30 min to
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1 h, depending on the reaction scale, but in any case until the solid disappeared. The
mixture was kept at 40 oC for another 30 min before the oxalyl chloride was removed
and the residue was dissolved in Bu tOH/CHCl3 (10 ml/2 ml) at room temperature and
TEA (1 ml) was added The solution was heated to 45-50 oC and stirred overnight under
argon. Then the solvent was removed and the solid was taken up in CHCl3, and washed
with water, 3% aqueous HCl, and then NaHCO3, brine and finally dried over anhydrous
Na2SO4. The solvent was removed and the residue was purified using silica gel column
chromatography eluted with 2% MeOH/ CH2Cl2 to give the product as a brown sticky oil
(95 mg, 40%). 1H NMR (400 MHz; CDCl3): 8.95 (s, 2H), 7.35-7.25) (m, 10H), 5.25 (s,
4H), 3.92 (s, 2H), 2.68 (t, 4H), 2.34 (t, 4H), 2.28 (s, 6H), 1.38 (s, 18H). (
Di-tert-butyl

3,3'-(2,2'-Methylenebis(5-formyl-4-methyl-1H-pyrrole-3,2-

diyl))dipropanoate 43: Compound 45 (410 mg, 0.587 mmol) was dissolved in 80 ml
THF and 50 mg (10%) Pd/C was added and the solution was stirred under a H2
atmosphere overnight. After TLC showed the starting material had disappeared, the
solution was passed through a Celite cake to remove catalyst, and the resulting
carboxylic acid was dissolved in DMF (5 ml) and the solution was heated to 160 oC with
stirring for about I h. The solution was then was cooled down to room temperature and
the Vilsmeier complex of PhCOCl/DMF (0.30/0.40 ml) was added dropwise at 0 oC. The
mixture was stirred for about 1 h and then the DMF was removed and the residue was
dissolved in EtOH. Aqueous NaHCO3 was added to hydrolyze the intermediate and a
yellow precipitate was collected and washed with water, and then air dried. The solid
was recrystallized from EtOH to give the product (75 mg, 45%).1H NMR (400 MHz;
CDCl3): 10.62 (s, 2H), 9.36 (s, 2H), 3.96 (s, 2H), 2.64 (t, 4H), 2.30 (t, 4H), 2.22 (s, 6H),
1.36 (s, 18H).
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Dibenzyl

5,5'-methylenebis{4-[3-(2-(tert-butoxycarbonyl)amino)ethyl)amino)-3-

oxopropyl]-3-methyl-1H-pyrrole-2-carboxylate} 46: Method I: Dipyrromethane 44 (0.1
g, 0.159 mmol) was dissolved in 15 ml oxalyl chloride and heated at 40 oC with stirring
until all the solid disappeared. The mixture was kept at 40 oC for another 1 h and then
the oxalyl chloride was removed and the residue was dissolved in CHCl3 and a solution
of BOC-NHCH2CH2NH2 (50 mg, 0.32 mmol) and TEA (32 mg, 0.32 mmol) in CHCl3 (20
ml) was added. The solution was stirred at room temperature overnight before being
washed with water, 3% aqueous HCl, aqueous NaHCO3 and brine, and then dried over
anhydrous Na2SO4. The residue was purified by silica gel column chromatography
eluting with 4% MeOH/ CH2Cl2 to give the product (27 mg, 20%).
Method II: To a solution of 44 (0.1 g, 0.159 mmol) in DMF (1.5 ml) was sequentially
added HATU (110 mg, 0.29 mmol) and DIEA (0.10 ml) and the solution was stirred at
room temperature for 1 h before NH2CH2CH2NHBOC (50 mg, 0.32 mmol) was added.
The solution was stirred for 1 d, and the solution was then diluted with ethyl acetate (50
ml) and washed with 10% citric acid, saturated NaHCO 3 and then brine. The organic
phase was dried over anhydrous Na2SO4 and the solvent was removed in vacuo and the
residue was purified by silica gel column chromatography eluting with 4% MeOH/ CH2Cl2
to give the product (55 mg, 41%). 1H NMR (400 MHz; CDCl3): 9.84 (s, 2H), 7.39-7.28 (m,
10H), 6.26 (s, 2H), 5.26 (s, 4H), 3.92 (s, 2H), 3.27 (t, 4H), 3.09 (t, 4H), 2.78 (t, 3H), 2.38
(t, 4H), 2.27 (s, 6H), 1.39 (s, 18H).
1,9-Diformyl-2,3,5,5,7,8-hexamethyldipyrromethane 49: Method I: Dipyrromethane 14
(1.245 g, 2.5 mmol) was dissolved in THF (80 ml), and 50 mg (5%) Pd/C catalyst was
added. The mixture was stirred under an H2 atmosphere overnight before the solution
was passed through a Celite cake to remove the catalyst. The THF was removed and
the solid was dissolved and left in TFA (15 ml) for 5 min, before excess TEOF (2 ml) was
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added to the TFA solution and the mixture was stirred at room temperature for 1 h. The
solution was poured into ice/water and the aqueous solution was neutralized by aqueous
ammonia to pH=7. Then the solution was extracted with CHCl3 three times and washed
with water, brine and finally dried over anhydrous Na2SO4. The solvent was removed
and the solid was recrystallized from EtOH to give the product (140 mg, 20% yield);
Method II: Dipyrromethane 53 (1.87 g, 5.0 mmol) and KOH (2.0 g) were dissolved in
ethylene glycol (15 ml) and a little water was added before the solution was refluxed at
180-200 oC for 1 h. After the solution was cooled down to room temperature, it was
diluted with water and the mixture was extracted with hexane three times. The organic
layer was washed with water, brine and dried over anhydrous Na2SO4. The yellowish oily
residue was dissolved in DMF (5 ml) and the complex PhCOCl/DMF (2.6/4.2 ml) was
added at 0 oC dropwise to the solution. After 2 h, 20 ml of toluene was added and the
mixture was kept in ice/water for a while until most of the precipitate came out. The imine
salt was filtered and washed with toluene and the solid was taken up in 2 g of NaHCO3
in 50/50 ml EtOH/H2O. The solution was heated at reflux for 15 min and after the
solution was cooled down to room temperature, 40 ml of water was added and the
mixture was allowed to stand overnight. The solid was filtered off, dried and
recrystallized from chloroform/petroleum ether to give the desired product aldehyde as
pale yellow crystals (0.92 g, 65% yield). 1H NMR (400 MHz; CDCl3): δ 9.54 (s, 2H), 8.86
(s, 2H), 2.21 (s, 6H), 1.67 (s, 6H), 1.51 (s, 6H).
3,4-Dimethylpyrrole 51: Pyrrole 50 (1.67 g, 0.01 mol) and KOH (1.0 g) were added to
10 ml of ethylene glycol and the solution was refluxed for about 1 h. The solution was
cooled down to room temperature and diluted with water to 50 ml and the solution was
then extracted with hexane three times. The organic layer was washed with water, brine,
and then dried over anhydrous Na2SO4. The solvent was removed and the residue was
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purified by silica gel column chromatography eluting with hexane/ CH2Cl2 (2:1) to give
3,4-dimethylpyrrole as a brown liquid (95 mg, 10% yield). 1H NMR (400 MHz; CDCl3):
7.40 (s, 2H), 6.51 (s, 2H), 2.00 (s, 3H), 1.99 (s, 3H).
Diethyl 5,5'-(propane-2,2-diyl)bis(3,4-dimethyl-1H-pyrrole-2-carboxylate) 53: The
synthesis of compound 53 followed the procedure for dipyrromethane 15, starting with
(3.34 g, 0.02 mol) to obtain product (4.8 g, 70%). Mp 131-133oC, (Lit22 Mp 125126oC) .1H NMR (400 MHz; CDCl3): δ 8.69 (s, 2H), 4.30 (q, 4H), 2.22 (s, 6H), 1.66 (s,
6H), 1.55 (s, 6H), 1.37 (t, 6H).
Bis(5-iodo-4-(3-((2-((tert-butoxycarbonyl)amino)ethyl)amino)-3-oxopropyl)-3methylpyrrole)methane 55: Dipyrromethane 46 (1.08 g, 1.25 mmol) was dissolved in
THF (80 ml) and 80 mg of (5%) Pd/C catalyst was added before the mixture was stirred
under a H2 atmosphere overnight. Then the solution was passed through a Celite cake
and the solvent was removed to give a solid which was added to 90/30 ml (H2O/MeOH)
and then NaHCO3 (0.6 g) was added and the solution was sonicated until a clear pink
solution was formed. Then a solution of I2 (0.5 g) in 60 ml of MeOH was added at room
temperature slowly. The mixture was stirred for 2 h before the reaction was stopped. The
precipitate was filtered and washed with water, hexane and air dried to give 0.62 g (60%)
1

H NMR (400 MHz; CDCl3): 3.20 (t, 4H), 3.18 (t, 4H), 2.93 (t, 4H), 2.35 (t, 4H), 2.0 (t, 6H),

1.42 (t, 9H).
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3.7. Supporting information

1

H NMR spectra of pyrrole 18 and 20 in CDCl3 at 400 MHz
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1

H NMR spectra of dipyrromethane 17 and 28 in CDCl3 at 400 MHz
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1

H NMR spectra of dipyrromethane 14 and 16 in CDCl3 at 400 MHz
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1

H NMR spectra of isoporphyrin 12 and dipyrromethane 25 in CDCl3 at 400 MHz
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1

H NMR spectra of dipyrromehane 26 and 30 in CDCl3 at 400 MHz

119

1

H NMR spectra of dipyrromehane 32 and 44 in CDCl3 at 400 MHz
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1

H NMR spectra of dipyrromehane 43 and 45 in CDCl3 at 400 MHz
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1

H NMR spectra of dipyrromehane 46 and 49 in CDCl3 at 400 MHz
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Chapter 4: Synthesis of BODIPY Dyes from Dipyrrolyketones and Their
Transformations
4.1. Introduction
4,4-Difluoro-4-bora-3a,4a-diaza-s-indacene1,2(Figure 4.1), known well as BODIPY have
been recognized as one of the most versatile fluorophore dyes in last three decades
since their potential use as photo labels was discovered.

Because of their sharp

fluorescence emissions, high quantum yields, large molar absorption coefficients and
relative chemical and thermal stabilities, 3,4 BODIPY dyes have been intensively
employed as biological labeling reagents 5,6 in protein and DNA research. Moreover, the
electrochemical activity of BODIPYs makes these dyes promising candidates as dopants
in light emitting devices and polymer-based electroactive films.7

Figure 4.1: The structure of BODIPY.
Synthetic approaches to BODIPY dyes have not changed much since they were
discovered. The first synthesis of BODIPY was reported by Treibs and Kreuzer in 1968; 1
however, this molecule was ignored until the potential uses of this this dye in biological
labeling was discovered at the end of the 1980s. Since then numerous syntheses of
these molecules were documented. All kinds of functionalization of these molecules
have also been well-explored. After 30 years, achieving long wavelength absorbing and
emitting BODIPYs with amphiphilic properties is still the target of chemists.
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There are several strategies used to synthesize BODIPY dyes. The first synthetic
method involved condensation of two identical pyrrole and a carbonyl source such as
an aldehyde,8 acyl chloride9 or anhydride10 catalyzed by acid; then oxidation of the
resulting dipyrromethane into a dipyrromethene followed by complexation with BF 3.OEt2
will lead to BODIPYs (Scheme 4.1A). This method was usually employed to build
symmetrical BODIPYs. Another method involves acid catalyzed condensation of two
different pyrrolic units where one of them bears a carbonyl group and the other one is an
α-free pyrrole11 (Scheme 4.1B). This method can directly give dipyrrins, which can be
converted into BODIPYs by complexation with BF 3.OEt2 in one step. This method is
generally used to construct unsymmetrical BODIPYs. The third approach is derived from
method one, which involves condensation of two identical α-formylpyrroles catalyzed by
POCl312 (Scheme 4.1C). The mechanism is believed to be analogous to the VilsmeyerHaack reaction to form a vinylogous intermediate between one α-formylpyrrole and
POCl3, followed by attack of another α-formylpyrrole. This method is only suitable to
(A)
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(B)

(C)

Scheme 4.1: Various routes to synthesize BODIPYs.
synthesize meso-unsubstituted BODIPYs. So far, the meso-aryl BODIPYs account for
most synthesis of these molecules in the literatures and in patents.
Depending on which substitutuents are required to be introduced on the meso-carbon,
the methods in Scheme 4.1 can be applied accordingly. For example, for method A,
para-iodobenzaldehyde or a para-esterified benzaldehyde were used during BODIPY
synthesis so that BODIPYs could be functionalized later by coupling reactions or by
conjugation. Carboxylic acids can be introduced into BODIPYs directly when a cyclic
anhydride was used as the carbonyl source, which can be further conjugated with
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proteins and used for protein labeling. Method B allows more versatile functionalization
of BODIPYs since it is easier to modulate the photophysical properties and hydrophobic
and hydrophilic properties by various functionalizations of different position on BODIPYs.
Many BODIPY-based labeling dyes are made using this particular method. Method C is
useful to make highly symmetrical BODIPYs; this reaction gives excellent yields
compared with method A.

Scheme 4.2: Some resonance structures of BODIPY.
According to the resonance structure of BODIPYs (Scheme 4.2), carbons 1, 3, 5, and 7
are electrophilic positions on BODIPYs, and carbons 2 and 6 are nucleophilic positions.
So the functionalization of BODIPYs actually follows these fundamental principles.
Knoevenagel condensation can be performed on the active methyl groups on all
electrophilic carbons at 1, 3, 5, and 7 with benzaldehyde to extend the π-electron
conjugation, thereby increasing the wavelength of absorption of BODIPYs since these
methyl groups are very nucleophilic, 13-17(Scheme 4.3A). Another electrophilic point is
carbon 8, for the meso-free BODIPYs. Nucleophilic attack on carbon 8 usually needs to
be accomplished with oxidation to remove a hydrogen. So far, there is only one example
of this case, which is use of NaCN as a nucleophile. 1,18,19 Meso-cyanoBODIPYs have a
significant red shift compared with meso-free BODIPYs.

Introduction of sulfur20 and

halogens21 at the meso-position allows more versatility for modification of carbon 8..
Replacement and coupling reactions can introduce many groups at the meso-carbon.
Even some natural products have been introduced. Substitution reactions were also well
explored at the boron to introduce aryl, 22 alkynyl23, alkyl,24 alkyloxy,25 etc. From the
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resonance structure of BODIPYs we can see that the 2, 6 positions are the most
electron rich sites and therefore most susceptible to nucleophiles. Formylation,26
nitration,27 sulfonation,28 and halogenation29 were already reported. Palladium catalyzed
oxidative coupling reactions30 to extend the π-conjugation was also reported (Scheme
4.3B).
(A)
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(B)

Scheme 4.3: Functionalization of BODIPYs by various methods.
Dipyrrolyketone (pyrroketones) have not been used much in polypyrrole chemistry. From
their structure (Scheme 4.4), pyrroketones are actually bis-vinylogous amides and
therefore do not react as normal ketones. For instance, pyrroketones can not be reduced
by borohydride31 to dipyrromethane or dipyrromethene. 32 Various syntheses of
dipyrroketones are well documented.

The symmetrical dipyrromethanes can be

synthesized by treatment of pyrrole Grignard reagents with phosgene in one step
(Scheme 4.5).
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Scheme 4.4: Keto-enol tautomers of pyrroketone.

Scheme 4.5: Syntheses of symmetrical pyrroketones.
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Scheme 4.6: Synthesis of unsymmetrical pyrroketones.
with phosgene in one step, or treatment α-free pyrroles with thiophosgene followed by
oxidative hydrolysis of the corresponding symmetrical thioketone products. 20 An
alternative approach for synthesis of symmetrical pyrroketones is to oxidize the
corresponding symmetrical dipyrromethane with PbO 2/Pb(OAc)4 or Br2/SOCl233 (Scheme
4.5). For the unsymmetrical pyrroketones, the most efficient method involves a modified
Vilsmeier-Haack reaction between a pyrrole N,N-dimethylcarboxamide complex with
another different α-free pyrrole using phosphoryl chloride. 32
Some of the methods used to synthesize symmetrical pyrroketone can also be applied to
unsymmetrical pyrroketone. For example, treatment of a pyrrole acyl chloride with
another pyrrole Grignard derivative or oxidation of unsymmetrical dipyrromethane with
PbO2/Pb(OAc)4 or Br2/SOCl2 gives the corresponding unsymmetrical pyrroketones
(Scheme 4.6). A very important related analogue is a reaction of dipyrromethane N,N-
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dimethylcarboxamide with phosphoryl chloride and another α-free dipyrromethane
followed by hydrolysis of corresponding tetrapyrrole to give

Scheme 4.7: Synthesis of meso-acetoxyporphyrin from oxophlorin.
b-oxobilanes, which are stable to acid catalyzed distribution of pyrrole rings because of
the oxo-function, and therefore can be cyclized into oxophlorin and eventually
transformed into porphyrin. Acetylation of the oxophlorin with acetic anhydride gives
meso-acetoxyporphyrin31,34,35 (Scheme 4.7).
From the above brief introduction to BODIPYs and pyrroketones and to their chemical
transformation into porphyrins, one can see that BODIPYs and pyrrokeotnes are
structurally related. Based on the reactivity of pyrroktones in the synthesis of porphyrins,
it is possible that pyrroketones can be converted into their fully conjugated
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dipyrromethene by use of reagents such as acetic anhydride, which can lead to
BODIPYs directly after complexation with BF 3.OEt2. The objective of this project is to
expore a new synthetic method to BODIPYs from pyrroketones and to further
functionalization of the new BODIPYs such as nucleophilic addition/elimination and
coupling reactions. We also wanted to look at various pyrroketones to investigate the
substituent applicability of any new methods.
4.2. Synthesis of Pyrroketones and Their Trasformation
Pyrroketones are actually bis-vinylogous amides; therefore the proposed transformations
of pyrroketone are shown in Scheme 4.8. Protonation takes place on the oxygen atom,
and depending on the electrophiles, substituents can be introduced either on nitrogen or
on oxygen atoms. Pyrroketones can also be converted into their imidoyl halides through
substitution of the oxygen atom. It was also planned to examine reactions including
protonation,36 O-alkylation,37 and halogenation38 (highlighted by green arrows) to convert

Scheme 4.8: Transformations of pyrroketones.
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pyrroketones into their dipyrrins (dipyrromethenes) which can then be used later in
BODIPY synthesis.
Firstly, some pyrroketones were synthesized by the methods mentioned above. Two
major dipyrromethanes bearing ester groups on the α-positions were synthesized
according to the procedure in Chapter 3. These two dipyrromethane 34 and 35 were
then oxidized into the corresponding pyrroketones 36 and 3733 with PbO2/Pb(OAc)4 in
acetic acid in about 50% yield (Scheme 4.9). From the 1H NMR spectrum, protons at
3.97 and 3.79 ppm, which belong to meso carbon of dipyrromethane 34 and 35
disappeared, and the identity of these two product 36 and 37 was confirmed by mass
spectroscopy, with m/z at 651.231(MW + Na) and 484.21, respectively.
Attempts were made to protonate these two pyrroketones with all kinds of acids such as
HCl, TFA and BF3.OEt2; all acids partially converted pyrroketones into their dipyrrins
salts; according to UV-visible absorptions around 430 nm, the most pronounced peak
still belonged to starting material pyrroketones at 360 nm. Protonated pyrroketones are
deprotonated during aqueous workup or treatment with bases. Then activation of the
pyrroketones with acetic anhydride to convert them into their fully conjugated molecules
was tried. Acetic anhydride and triflic anhydride 39 (Scheme 4.10) were therefore tried on
the pyrroketones 36 and 37. The pyrroketones did not react upon treatment with acetic
anhydride according their UV-visible absorption. However, the stronger triflic
anhydride/pyridine mixture formed a red solution and peaks at 432 and 534 nm in the
UV-visible spectrs indicated the formation of a fully conjugated dipyrrin-type system.
However, this intermediate can not withstand an aqueous workup and the peak around
430 nm disappeared. DIEA/BF3.OEt2 was added to if the intermediate could be
converted into a BODIPY and characterized. However, the intermediate could not
withstand organic bases either. Another strategy tried was to introduce a bromine atom
136

at the meso carbon by adding LiBr to a solution of activated pyrroketone after
Tf2O/pyridine treatment;37,40 this did not work either.

Scheme 4.9: Synthesis of pyrroketone through oxidation.

Scheme 4.10: Activation of pyrroketones by acids and anhydrides.
Eletrophiles such as methyl trifluoromethansulfonate41 and Meerwein’s salts42 (Et3OBF4
and Me3OBF4) were reacted with pyrroketones 36 and 37 (Scheme 4.11). Methyl
trifluoromethanesulfonate slightly changed the reaction solution from colorless to red.
With Meerwein’s reagents, the pyrroketones were converted completely into their

137

dipyrrin analogues based on the orange red color of the reaction solution and their UVvisible absorption at 446 nm. Unfortunately, upon aqueous workup, this intermediate
reversed to the starting material according to the UV-visible spectral change (Figure 4.2),
DIEA/ BF3.OEt2 was added to make corresponding the BODIPY but this did not work.
However, from 1H NMR spectra (Figure 4.3), extra peaks at 4.20 (q, 2H) and 1.22 (t, 3H)

Scheme 4.11: Alkylation of pyrroketone using Et3OBF4 in CHCl3.

138

Figure 4.2: UV/Vis absorption spectrum of Alkylation of pyrroketone using Et3OBF4 in
CH2Cl2

Figure 4.3: 1H NMR spectra of pyrroketone 36 and product 39 in CDCl3
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attributed to ethyl group on the heteroatom nitrogen proved the ethyl group actually went
to the nitrogen of the pyrrole instead of the oxygen on the meso carbon, and this result
was further confirmed by the mass spectrum with m/z at 656.27
From all the protonation and nucleophilic substitution reactions tried on the pyrroketones,
one can see that even strong acids do not react with pyrroketones, and strong
nucleophiles can convert pyrroketones partially or completely into their fully conjugated
dipyrrin intermediates. The problem is that these intermediates are not stable enough to
withstand water or nucleophiles during work-up. Halogenation reactions were also
attempted on the two pyrroketones. Typical chlorinating reagents such as POCl 3,43
PCl5,37 oxalyl chloridel44 and phosgene45 were tried under different conditions at room
temperature or at reflux. All these reagents gave a red solution which indicated the
formation of the fully conjugated dipyrrin system, and UV-visible absorption
spectroscopy showed a sharp peak around 500-530 nm. However, the stability of these
compounds or intermediates was was a serious problem which made them hard to
separate and they easily decomposed upon aqueous work-up or interaction with
nucleophiles. Specifically, when POCl3/DMF was used to chlorinate the pyrroketone, the
fully conjugated system was formed according to UV-visible absorptions at 528
(pyrroketone 36) and 534 nm (pyrroketone 37), which are most likely the intermediates
or products (Scheme 4.12). Especially for pyrroketone 36, a peak at m/z 645.17 in the
mass spectrum showed that the product 40 was actually formed (Figure 4.4), along with
some other side products, such as a dimer or trimer. However, it was not possible to
separate the product by chromatography or by crystallization. When POCl 3/PCl546 was
used as the chlorinating reagent ， the UV-visible absorptions at 505 and 529 nm
(pyrroketone 37) indicated the fully conjugated dipyrrin system had been formed and
aqueous workup did not destroy it since the UV-visible absorptions almost had no
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change. Mass spectrometry showed m/z peaks at 1279.4662 (MW+K) for pyrroketone
36, which indicated the formation of dimer of dipyrromethene (Scheme 4.13).

Scheme 4.12: Chlorination of pyrroketone 36 using POCl3 and the UV-Visible absorption
spectrum in CH2Cl2.
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Scheme 4.13: Chlorination of pyrroketone 36 using POCl/PCl5 and the UV-visible
absorption spectrum in CH2Cl2.
Profile of chlorodipyrromethene

Figure 4.4: Mass spectrum of the product from chlorination of pyrroketone 36 with
POCl3/PCl5.
The reactivity of various activiting reagents such acids, anhydrides and halogenating
reagents on pyrroketones were investigated. Specifically, triflic anhydride can only
partially convert pyrroketones into their dipyrryl system; soft halogenating reagents such
as SOCl2 have no reactivity. For strong chloronating reagents such as POCl3 or PCl5, the
pyrroketones are completely converted into the fully conjugated dipyrrin intermediates or
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products. However, these intermediates or products are not stable enough to survive
aqueous workup, base treatment, or other nucleophiles. The combination of POCl 3 and
PCl5 transformed the pyrroketones into their dipyrrin, but this deduction is based only on
its mass spectrum. From the chemistry of pyrroketones used in porphyrin synthesis, it is
assumed that the electron-withdrawing benzyl ester groups on the pyrroketone
destablize the conjugated intermediates which revert to starting material very easily
upon attack of water or other nucleophiles (Scheme 4.14). Therefore, It was planned to
eliminate the electron withdrawing group from pyrroles on the pyrroketones and use alkyl
substituted pyrroketone to explore all these reactions. Extremely successful reactions
with the dipyrroketone dibenzyl esters 36 and 37 are reported in Chapter 5 of this
Dissertation.

Scheme 4.14: The reversible process of pyrroketone and its dipyrromethene.
Before synthesis of the new alkylpyrroketones, several α-free pyrroles were made by the
following methods depending on the structure of pyrroles (Scheme 4.15). (1) The 2ethoxyl carbonyl pyrroles were converted into corresponding α-free pyrroles 44, 45 and
46 by de-esterification under basic conditions. 47 (2) The 5-tert-butoxylcarbonylpyrrole 47
was transformed into α-free pyrrole 48 by de-esterification under acetic conditions.48 (3)
5-Benzyl ester pyrroles 50 and 51 were debenzylated, followed by decarboxylation of all
resultant carboxylic acids to make α-free pyrroles 48 and 52. (4) 2-Ethoxylpyrrole 49 was
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reduced to give the α-free pyrrole 48 using LiAlH4 directly.49 Specifically, α-free pyrroles
44, 45 and 46 were made by refluxing pyrroles 41, 42 and 43 using NaOH as base in
ethylene glycol solvent at 180 oC, all with a yield around 30%. Pyrrole 48 was made by
treatment of pyrrole 47 with TFA in 10% yield. Pyrroles 48 and 52 were made by
debenzylation of pyrroles 50 and 51, respectively, followed by decarboxylation with TFA.
These reacxtions gave a yield around 30%. α-Free pyrrole 48 can also be obtained
directly by reducing the ester group of α-free pyrrole to alkyl using LiAlH4 in THF. Some
α-free pyrroles were made in 2 or 3 steps by a combination of these methods. For
example, pyrrole 44 was also made by de-esterification of pyrrole 53 followed by
reduction of the acetyl group at the 3-position of pyrrole 54. This two-step reaction
actually gave a higher yield than the one step reaction using Method (1). Overall, deesterification under basic conditions gave better yields than under acidic conditions, and
reduction gave the best yield among all these condtions. All these compounds were
characterized by 1H NMR,

13

C NMR and HRMS (ESI). Usually the de-esterification

causes the peaks of the ester to disappear from the 1HNMR spectrum and the resultant
α-free pyrrole shows a new 2-H peak around 6.30-6.50 ppm. These α-free pyrroles are
not very stable in light or air; therefore, once synthesized, they were stored in the freezer
or immediately used in the next step for syntheses of thioketones.
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Scheme 4.15: Syntheses of α-free pyrroles from their precursors under various
conditions.
Some of the α-free pyrroles 44-46 and 48 were used to synthesize dipyrrothiones
(Scheme 4.16). Pyrroles 44, 45, 46 and 48 were treated with thiophosgene 20,50,51 in THF
or ether at 0

o

C; the reaction was monitored by TLC until starting material had

disappeared. Then methanol was added to destroy excess thiophosgene. The residue
was purified by silica gel column chromatography, eluting with toluene/chloroform (4/1)
or hexane/ethyl acetate (4/1) to give an organge solid in about 40% yield. From 1H NMR,
the pyrrole α-H around 6.40 ppm disappeared, and the NH group of the product
pyrrothiones exibited a huge downshift from 7.4 to 9.0 ppm compared with the α-free
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pyrroles. The structures of the pyrrothiones 55 and 58 were comfired by their mass
spectra, with peaks at m/z 289.1739 (MW+H) and 233.1106 (MW+H), respectively.

Scheme 4.16: Synthesis of pyrrothiones and pyrroketones.
During chlorination of thioketones with various chlorinating reagent such as POCl 3,
oxalyl chloridfe or phosgene at room temperature, the solutions of these intermediates
turned red upon addition of the chlorinating reagent but turned brown with time. Then the
reaction was tried at 0 oC this also happened; low temperature can not prevent the color
change. The reaction was monitored by UV-visible spectroscopy; the thiokeone 55 has
an absorption at 421 nm, and the fully conjugated intermediate shifted to 500 nm after
chlorination with phosgene in CH2Cl2. Similarly, thioketone 58 has an absorption at 437
nm and the intermediate shifted to 518 nm after chlorination with oxalyl chloride in
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CH2Cl2. All these peaks disappeared with time, probably because the strong chlorinating
reagents decomposed the thioketones. Since chlorination of thioketones failed to give
chlorodipyrromethene, the thioketones were transformed into pyrroketones by using
hydrogen peroxide under basic conditions. Analytically pure samples were purified by
sublimition using a strong vaccum pump. The product sublimed around 220

o

C.

Compared with thioketones, the NH group is slightly shifted from about 9.00 to 8.50 ppm;
the alkyl groups on thioketones have nearly same shift as do those of pyrroketones.
These structures of the two pyrroketones were confirmed by mass spectra, with peaks at
m/z 233.1334 and 273.2013, respectively.
From the previous experiments and discussion, pyrroketone with electron withdrawing
group do not have significant reactivity toward acid and eletrophiles; therefore, It was
dedided to try the same reactions on electron rich alky substituted pyrroketones.
Therefore pyrroketone 59 was protonated by HCl gas in CH2Cl2. The solution turned
yellow from colorless, and UV-visible spectroscopy showed a sharp peak at 428 nm
compared with pyrroketone 59 which has an absorption around 341 nm (Figure 4.5). An
attempt was made to convert the meso-hydroxydipyrromethene system into a BODIPY
using DIEA/BF3.OEt2 (Scheme 4.17). Unfortunately, the intermediates were not stable
upon treatment with the organic base, DIEA, and they reverted to the starting material
pyrroketone by deprotanation. Then pyrroketones 59 and 60 were subjected to
treatrment with DIEA/BF3.OEt2 directly, and sharp peaks at 466 and 476 nm (Figure 4.6),
respectively,were observed in the UV-visible spectra (Figure 4.5). Purification was still
problematic using a chromatography column. But isolation of product 62 was confirmed
by its mass spectrum with m/z at 338.3426. Since pyrroketones can be protonated into
their meso-hydroxydipyrromethene salt, it is very likely they can also be converted into
similar intermediates by electrophiles.
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Scheme 4.17: Attempts to synthesize meso-hydroxy BODIPY.
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Figure 4.5: Optical spectra in CH2Cl2 of dipyrrylketone (A) and salt (B) after treatment
with HCl(g).
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Figure 4.6: The Abosorption spectra of pyrroketone 59 and its corresponding BODIPY
61 in CH2Cl2.

Therefore reactions with Meerwein’s reagent Et 3OBF4 were attempted (Scheme 4.18).
Pyrroketones 59 and 60 were treated with Et3OBF452 in CHCl3. and a red solution
resulted, indicating the presence of fully conjugated dipyrrin system; this was confirmed
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by UV-visible spectroscopy, showing peaks at 438 and 451 nm, repectively. The solution
was washed with water and saturated NaHCO 3 and the intermediates were not
destroyed or decolorized according to their UV-visible spectra.

Scheme 4.18: Reaction of pyrroketones with Meerwein’s salt in CHCl3.

64

63

Figure 4.7: Crystal structures of BODIPY 63 and 64.
These new intermediates were treated with DIEA/BF 3OEt2 in CHCl3 to give the
corresponding BODIPYs. BODIPY 63 has an absorption maximum at 487 nm and
BODIPY 64 has its absorption at 508 nm. Characteristic resonances for the ethoxy
group in their 1H NMR spectra appeared at 4.12 (q) and and 1.52 (t) ppm The X-ray
structures for both BODIPYs 63 and 64 were also obtained (Figure 4.7). The molecule
63 has very nearly Cs symmetry, with the BF2 plane and dipyrryl plane forming a dihedral
angle of 89.37(4)o, with the atoms of the OEt group lying a mean of 0.012 Ả from the BF2
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Figure 4.8: Normalized aborption and fluorescence spectra of BODIPYs 63 and 64 in
CH2Cl2.
plane; BODIPY 64 has a similar structure, with dihedral angle 88.68(1)o, but the dipyrryl
ethyl groups are anti related to each other. Their nomalized absorption and fluorescence
were also studied and showed in Figure 4.8. The spectra of these two BODIPYs are of
comparable shape to those already described in the literature with a narrow absorption
band around 500 nm (which belongs to S 0-S1 transition) plus a weak broad absorption
around 460 nm. The two BODIPYs also have a slightly shifted sharp emission bands at
493 and 518 nm, respectively, with a mirror image shape compared to the absorption
spectra.
Next, chlorination of pyrroketones 59 and 60 was attempted using phosgene in CH2Cl2
(Scheme 4.19). Pyrroketone 59 and 60 were dissolved in CHCl3 and treated with
phosgene solution in toluene. The solution turned red with time and the UV-visible
spectra showed peaks at 485 and 505 nm (Figure 4.9). Then nitrogen gas was passed
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Scheme 4.19: Chlorination of pyrroketone using phosgene.
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Figure 4.9: Absorption spectra of pyrroketones and their meso-chlorodipyrrins in CH2Cl2.

through solution to purge excess phosgene into a NaHCO 3 solution. The products 65
and 66 were crystallized from CH2Cl2/petroleum ether system as red solids in about 90%
yield. The most noticeable change in the 1H NMR spectrs is the downfield shift of the NH
group, which is shifted from around 8.60 ppm to 12.50 and 12.93 ppm for
dipyrromethenes 65 and 66. The identity of the products was also comfirmed by mass
spectroscopy, with m/z at 235.0992 and 291.1623, respectively. Figure 4.8 shows the
UV-visible changes during chlorination.
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The chlorination of pyrroketone was explored first by Fisher 53 in 1933. However, very
little work has been done with chlorodipyrromethene. Therefore, we explored several
electrophilic substitution reactions and some coupling reactions using chlorodipyrromethene to investigate their reactivities.
Chlorodipyrromethene 65 was used as the substrate and several replacement (additionelimination) reactions were explored (Scheme 4.20). The first one attempted was with
the Grignard reagent EtMgBr. From the resulting mass spectra, both meso-ethyl
dipyromethene 67 and meso-free dipyrromethene 68 were obtained when 65 was
treated with EtMgBr. However, It was difficult to separate these two products using silica
gel column chromatography. Therefore, they were converted into the corresponding
BODIPYs by complexation with BF3.OEt2

using DIEA as base. The two resulting

BODIPYs 69 and 70 were easily separated with CH2Cl2/hexane as eluting system on a
silica gel column. Meso-free BODIPY was found to be the major product in 47% yield,
and the expected ethyl-substituted product was obtained as the minor product in only 17%
yield. From the 1H NMR spectra, the meso-ethyl group of BODIPY 69 appeared at 3.02
ppm (q) and the meso-H of BODIPY 70 appeared at 7.02 ppm. The structures of these
two BODIPYs were also comfirmed by mass spectroscopy with m/z at 276.1713 and
248.1404, respectively.
Addition/elimination

reactions

using

sodium

methoxide

were

also

tried

on

chlorodipyrromethene 65; instead of giving the meso-methoxy dipyrromethene 71, the
product was found to be α-methyl ester pyrrole 72. Sodium ethoxide was also used to
test if the reaction was reproducible, and once again α-ethyl ester pyrrole 73 was the
product; the structures of these two unexpected pyrroles were also confirmed by their
crystal structures. A possible mechanism for their formation is proposed in Scheme 4.21.
This involves the addition of the the meso-chloro of the meso-dipyrromethene to give a
methoxy intermediate, which re-aromatized into meso-alkoxy dipyrromethene through
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elimination of chloride (the better leaving group), followed by attack of alkoxide to form
5,5-dimethoxydipyrromehtane intermediate. This then undergoes a base-catalyzed
version of the already known pyrrole and very facile deacylation reaction to give the
unexpected pyrroles 72 or 73; the overall mechanism involves a dipyrrole cleavage
reaction.
Replacement reactions by weak nucleophiles such TBAF and KCN were attempted but
did not work. For coupling reactions, Suzuki and stille coupling reactions were attempted
on chlorodipyrromethene but they failed to give the expected products.
Since chlorodipyrromethenes seemed unstable and products from them were difficult to
separate, they were converted into their BODIPYs which are more stable and more easy
to isolate. Chlorodipyrromethene 74 and 75 were treated with DIEA/BF3.OEt2 and their
BODIPYs (Scheme 4.22) showed about a 20 nm red-shifted UV-visible absorption at
503 and 527 nm (Figure 4.10) compared with the starting materials at 485 and 505 nm,
respectively. Both showed a small shoulder at 460 nm in their UV/visible absorption
spectra. The structures of the products were confirmed by mass spectroscopy, with
peaks at m/z 282.1010 and 319.1550 (MW – F) for BODIPYs 74 and 75, respectively.
Single crystals suitable for X-ray structure analysis were obtained for both 8-chloroBODIPYs 74 and 75 (Figure 4.11). The non-hydrogen atoms. except for fluorine in 74,
are fairly coplanar, with mean deviation 0.052 Ả, and the BF2 plane is nearly orthogonal
to it, with dihedral angle 89.88(2)o. Compound 75 has three molecules in the asymmetric
unit, two of which have the ethyl groups related syn, and one with anti ethyls, Analogous
dihedral angles in the three molecules are in the range 88.45(2)-89.37(2)°.
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Scheme 4.20: Investigation of reactivity of meso-chloro dipyrromethene and X-ray
Crystal structure of unexpected pyrroles 72 and 73.
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Scheme 4.21: Proposed mechanism for cleavage of meso-chlorodipyrromethene by
alkoxide.

Scheme 4.22: Synthesis of meso-chloro BODIPYs.
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Figure 4.10: Normalized absorption and relative fluorescence spectra, in CH 2Cl2 of
chloro-BODIPYs.
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Figure 4.11: Chrystal structures of meso-chloro BODIPYs 74 and 75.

The same addition/elimination reactions were tried on BODIPY 74 (Scheme 4.23). A
solution of EtMgBr24 in THF was added at -78 oC and also at room temperature and the
two reactions gave different products. The replacement reaction only took place at the
meso-position without effecting the fluorides on the boron to give product 69 in a 75%
yield at low temperature. However, at room temperature, 7,22 all the halogens, including
the two B-F groups were replaced by EtMgBr to give the fully substituted product 76 in
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83% yield. Both BODIPYs 69 and 76 have characteristic UV-visible absorptions at 499
nm and m/z at 276.1713 and 296.2507, respectively. The 1H NMR spectra of BODIPYs
69 and 76 showed the characteristic 8-ethyl protons at 3.02 (q) and 1.32 (t) ppm,
respectively; the B-ethyl protons of BODIPY 76 appeared at 0.79 and 0.30 ppm.
The replacement reaction with the oxygen-centered nucleophile25 sodium methoxide
was performed both at room temperature and under reflux at 80 oC (Scheme 4.23); both
conditions gave mixtures of meso-substituted and boron-substituted products but in
different percentages. At room temperature, displacement of meso-chlorine ocurred
rapidly to give the major product 77, and one of the boron florines was also displaced
with extended reaction times to give the minor product 78. If the same reaction was
performed at reflux with exess sodium methoxide, the fully substituted product 79 was
obtained as the major product. The B-monomethoxy product 78 was found to be the
minor product. The 1H NMR spectra of BODIPYs 77, 78 and 79 showed the 8-OMe
protons as a singlet around 3.97 ppm, while the B-OMe protons of 78 and 79 appeared
at around 2.89 ppm. All three methoxy substituted products were structurally confirmed
by mass spectroscopy with m/z at 278.1504 for 77, 259.1392(MW-F) for 78, and
324.1719 (MW-OMe) for BODIPY 79.
The same reaction was carried out with sodium ethoxide to compare with the yield of
alkylation of pyrroketones with Meerweit’s reagents. The replacement reaction gave a
slightly lower yield (46-52%) compared with when Meerwein’s reagent was used.
Another oxygen-centered nucleophile, sodium phenoxide, was also tried using BODIPY
74, and the reaction gave the expected product 80 in 81% yield. The aromatic phenoxy
group has resonances around 6.99-7.33 ppm in the 1HNMR spectrum, and mass
spectroscopy showed a m/z at 340.1662. The normalized absorption and fluorescence
spectra are shown in Figure 12. All these BODIPYs absorption/emission spectra have a
similar shape to the BODIPYs described in the literature with a sharp absorption peak
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Scheme 4.23: Replacement reactions of meso-chloroBODIPY by various nucleophiles.
around 500 nm and a small shoulder around 460 nm, (Figure 4.12). Compared with the
starting material, meso-chloroBODIPY, substitution by an alkoxy group caused a blue
shift of 12-16 nm, and alkyl substitution gave the BODIPY a mirror blue shift of 4 nm.
Their emission bands are slightly shifted to long wavelength as a mirror image with
around a 10 nm Stokes shift.
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Figure 4.12: Normalized absorption and relative fluorescence spectra of BODIPYs 63,
69, 76, 77, 79 and 80 in CH2Cl2.
Three sulfur nucleophiles54 (Scheme 4.24) were also reacted with BODIPY 74. Typically
a solution of chloroBODIPY 74 and sulfur nucleophile in THF was stirred in the presence
of K2CO3 as base at room temperature and gave a very good yield of products. With 2mercaptobenzothiozole, the reaction gave BODIPY 81 in 56% yield, while 1mercaptomethyl-p-carborane gave 82 in 92% yield and SH-1,2-carborane gave BODIPY
83 in 90% yield. One nitrogen-centered nucleophile, propargyl amine, was investigated
using chloroBODIPY 74. The reaction gave BODIPY 83 in 92% yield with excess
propargyl amine as base.
BODIPYs 81, 82 and 83 showed red-shifted UV-visible absorptions at 539 and 529 and
554 nm, respectively, (Figure 4.13). Amine-substituted BODIPY 83 showed a blue shift
from 503 to 458 nm compared with the starting material 74. In the 1H NMR spectrum of
BODIPY 81, the aromatic protons appear at 7.28-7.98 ppm and BODIPY 82 has the
SCH2 protons at 2.95 ppm; BODIPY 84 has chemical shift at 5.25 for the amine group
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and 2.47 for the ethynyl group. Mass spectroscopy confirmed the structure of BODIPYs
81, 82 and 83 with m/z at 394.1019 (MW-F), 437.3033 and 423.2571, respectively.
BODIPYs 81, 82 and 83 were characterized by X-ray crystallography (Figure 4.14). In
BODIPY 81, the dipyrryl and BF2 planes form a dihedral angle of 88.03(7) o, while the
mercaptobenzothiazole plane forms a dihedral angle of 77.03(2) o with the dipyrryl unit. In
BODIPY 82, the dipyrryl and BF2 planes form a dihedral angle of 88.8 (1)°, the linkage
between dipyrryl and p-carborane is extended, with a C-S-CH2-C torsion angle of

Scheme 4.24: The replacement reactons of meso-chloroBODIPY by sulfur and nitrogen
centered nucleophiles.
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Figure 4.14: The crystal structures of BODIPYs 81-83.
175.3(6)o. The best plane of the CSCC linkage forms a dihedral angle of 83.8(2)o with
the dipyrryl plane.
Replacement reactions with Grignard reagents 7,55 such as phenyl magnesium bromide,
vinyl magnesium bromide and phenyethynyl magnesium bromide were attempted in
order to introduce meso-phenyl, vinyl or phenylenthynyl substitutents into the BODIPYs.
However, all these reagents were unreactive toward meso-chloroBODIPY with used with
only one equivalent. Excess of these reagents quenched the fluorescence of
chloroBODIPY. Once heated, the BODIPY would precipitate immediately and there were
some TLC spots appearing under short wavelength UV light. Some weak nucleophiles
such as TBAF and KCN were also investigated using chloroBODIPY, but they did not
react either.
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Pd(0)-catalyzed cross-coupling procedures with BODIPYs have been well explored,
including use of the Suzuki, 56 Stille,57 Heck58 and Sonogoshira59 reactions. These
transformations have been performed either directly on the BODIPY core 30,60,61 or on a
substituent,26 and have largely facilitated the functionalization of BODIPYs. In particular
coupling reactions of 3,5-dichloro-BODIPYs afforded many sophisticated products. 60
Compared with the 3,5-positions, the meso-carbon is more electrophilic based on their
vibration structures and Mulliken-charge analysis on the core carbon atoms of
tetramethyl-BODIPY.13 Recently, various Pd(0)-catalyzed cross-coupling reactions were
performed on 8-halo-BODIPYs.21 We also attempted numerous coupling reactions of
BODIPYs with intention to provide more a versatile functionalization access to new
BODIPYs.
The Suzuki coupling reaction 56,62-65 was attempted first. ChloroBODIPY 74 was coupled
with phenylboronic acid using Pd(PPh 3)4 as catalyst and K2CO3 as base (Scheme 4.25).
The mixture was heated under refux in DME or THF for 24 hours and monitored using
UV-visible spectroscopy and TLC. The starting material disappeared with time and
several new peaks appeared in the UV-visible spectra around 500 nm in CH2Cl2,
indicating a mixture of products. The expected product, meso-phenyl BODIPY 85 was
separated as the major fraction in 46% yield.

1

H NMR spectroscopy showed the

expected aromatic area at 7.27-7.49 nm, which is consistent with literature reports and
the structure of the product was also confirmed by its mass spectrum with m/z at
324.1717. Another two fractions were also separated upon chromatography, which were
found to be meso-phenoxy-BODIPY 80 and the meso-free BODIPY 70. The mechanism
of formation of the meso-phenoxy BODIPY is still under investigation, and all data are
identical with those from the replacement reaction with sodium phenoxide. The 1H NMR
spectrum of meso-free BODIPY is also identical with that from the replacement reaction
when a Grignard reagent is used. Some alkyl boronic acids such as methyl, ethyl,
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isopropyl, and vinyl boronic acid were also used. However, only meso-free BODIPY was
separated and the starting material was still the major fraction. The reaction was also
tried under microwave conditions but again did not work. This is probably due to the fact
that these boronic acids have a small organic part compared with phenyl boronic acid.

Scheme 4.25: Suzuki coupling reactions of BODIPY 74 with boronic acids.
The Sonogashira coupling reacton 66-68 of ethylnyltrimethylsilane with chloroBODIPY 74
catalyzed by PdCl2(PPh3)2 was performed under standard conditions with TEA as base
(Scheme 4.26). The mixture was refluxed in THF for about 24 hours and the reaction
was monitored by TLC and UV-visible spectroscopy. The reaction resulted a very
obvious color change caused by the product which has about a 40 nm red shift
compared with the starting material. The separation of product was problematic using
silica gel column chromatography. Separation was achieved later using a peptic TLC
plate to give about a 35% yield of product 86 with UV/visible absorption at 544 nm in
CH2Cl2. A similar compound was also recently synthesized by conventional methods
using an alkynyl aldehyde as electrophile. 69 In the replacement reaction, Grignard
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reagents did not work on chloroBODIPYs, so a coupling reaction of Grignard reagent
with BODIPYs was attempted. The chloroBODIPY was treated with phenylethynyl
magnesium bromide in the presence of the catalyst Pd(PPh 3)4 in THF and the mixture
was refluxed for five minutes. The reaction resulted in a red solution and the UV/visible
absorption spectrum showed a sharp peak at 554 nm. The structure of the product was
confirmed by

1

H NMR spectroscopy to be the fully substituted BODIPY 87. The

assumption is that the strong Grignard reagents diminished the difference between
chloride and fluoride under palladium catalysis.
Finally, Stille coupling reactions57,70,71 were performed on chloroBODIPY with
tributylphenylstannane catalyzed by Pd(PPh 3)4 without any base. The mixture was
refluxed in toluene and TLC showed the reaction was not only completed within five
hours, but also the product was the only spot on a TLC plate. The product 85 was
separated with a flash column on silica gel to remove very minor reaction impurities to
give the product in 93% yield. This yield is far better than those from the Suzuki reaction.
Heck coupling reactions were attempted with styrene using Pd(II)(PPh3)2Cl2 as catalyst
and TEA as base, but the reaction did not yield any useful product. There was no
UV/visible absorption change during this reaction.
From the above coupling reactions performed on cloroBODIPY 74, one can see that
Suzuki, Stille and Sonogashira coupling reactions all worked, but the Heck coupling
reaction did not. The products from these reactions were obtained in 36-93% yields, with
the lowest yield obtained for the 8-chloro-BODIPY under Suzuki conditions and highest
yield with organotin reagent.
Since we observed the Stille coupling reaction to be the most efficient and economic
reaction among all these coupling reactions, we therefore further investigated the Stille
coupling reaction with other reagents to see if we could expand this method to more
substrates and make it a more versatile approach for functionalization of BODIPYs.
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Various organotin reagents bearing alkyl, alkenyl, alkynyl and heterocyclic aromatic
groups were used in coupling reactions to investigate the sp 2-sp3, sp2-sp2 and sp2-sp
coupling reactions with BODIPYs (Table 4.1). All the coupling reactions produced the
corresponding 8-functionalized BODIPYs in nearly quantitative yields, except for the
reaction with tributylethynyltin, which gave BODIPY 91 in only 31% yield. When TMSprotected ethynyl organotin was used, the yield improved to 71% yield for product 86,
presumably because the TMS-protected ethynyl product is more stable. Aromatic Stille
reagents

such

as

2-(tributylstannyl)pyrrole,

2-(tributylstannyl)thiophene

and

2-

(tributylstannyl)pyridine were also employed since these compounds can also be
synthesized by traditional methods. For the first two electron-rich stannane reagents, the
products 92 and 93 were obtained in excellent yields around 95-99%, However, for the
electron deficient pyridyl tin reagent, only meso-free BODIPY was generated. The
structures of the BODIPY products were confirmed by 1H and

13

C NMR, HRMS (ESI-

TOF) mass spectrometry and UV-visible spectroscopy. The 1H NMR spectrum of 8phenyl-BODIPY 85 showed aromatic protons between 7.49-7.27 ppm, consistent with
literature reports,40,41 and the structure of the product was confirmed by mass
spectroscopy (m/z 324.1717). The meso-methyl group of BODIPY 88 appeared at 2.40
ppm in its 1H NMR spectrum and the product showed m/z at 262.1556. For BODIPYs 89
and 90, the 1H NMR spectra showed the alkene group as two doublets at 6.74 (dd),5.69
(dd) and 5.56 (dd) ppm for BODIPY 89 and 4.46 (dd), 4.37 (dd) ppm for BODIPY 90.
The ethoxy group of 90 absorbed at 3.90 (q) and 1.38 (t) ppm. The mass spectra
confirmed the identity of the two product with m/z at 274.1557 and 318.1817,
respectively. BODIPY 91 has a typical peak at 3.92 ppm for the alkynyl group in its 1H
NMR spectrum, and m/z at 272.1380. BODIPY 86 showed the TMS protecting group at
0.29 ppm in its 1H NMR spectrum and m/z 325.1708 (MW-F) in its mass spectrum; the
aromatic ring of BODIPYs 92 and 93 showed peaks between 6.77-6.06 ppm and 7.51167

6.98 ppm, and the N-CH3 of BODIPY 92 showed a peak at 3.40 ppm in its 1H NMR
spectrum. These two BODIPYs were also characterized by m/z at 327.1799 and
352.1094, respectively. The X-ray crystal structures of BODIPYs 85, 88, 89, 92 and 93
were also obtained by slow diffusion of hexane into a CH 2Cl2 solution of each, and they
are shown in Figure 4.15.
In the X-ray structures, BODIPY 85 deviates from its potential Cs symmetry by the BF2
and phenyl planes being twisted in opposite directions from orthogonality with the
dipyrryl plane, the BF2 forming a dihedral angle of 88.13(5)° and the phenyl a dihedral
angle of 82.40(3)° with it. BODIPY 88 is unusual in that its dipyrryl group lies in a
crystallographic mirror and its BF2 across it; thus they are exactly orthogonal.The X-ray
structure for BODIPY 89 was also obtained. Its dipyrryl and BF2 planes form a dihedral
angle of 88.82(2)o. The ethene substitutent is not quite orthogonal to the dipyrryl nor
coplanar with the BF2, a C-C-C=C tortion angle about the bond to it being 65(10)°.
BODIPY 92 deviates only slightly form Cs symmetry, with the BF2 plane forming a
dihedral angle of 89.51(9)o with the dipyrryl plane and the methylpyrrole plane forming
an angle of 85.77(4)o with it, only one of the major orientations of the disordered
thiophene is shown for BODIPY 93; it forms a dihedral angle of 84.31(8)°with dipyrryl,
and the BF2 plane forms a dihedral angle of 88.56(4)°with the dipyrryl plane.
The spectroscopic properties of these compounds were studied and their UV/visible
absorption and steady-state fluorescence emission spectra in CH2Cl2 were recorded. As
an example, Figures 4.10, 4.12, 4.13 and 4.16 show the normalized absorption and
fluorescence spectra of some BODIPYs. Specifically, literature compounds 85 and 88
have absorption and emission values similar to those previously reported.42 The newly
synthesized BODIPYs 74, 63 75 and 64 show spectra of comparable shape to those
BODIPYs described in the literature, with a narrow absorption band (λ max ca. 500 nm),
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Scheme 4.26: Coupling reactions of BODIPY 74 with different reagents.
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Table 4.1: Stille coupling reactions of 8-chloro-BODIPY 74

BODIPYS

Organotin

85

Bu3SnPh

R

Yield (% )

93

86

71

88

Me4Sn

97

89

Bu3Sn(CH=CH2)

97

90

Bu3Sn(EtOC=CH2)

93

91

Bu3Sn(C

CH)

31

92

95

93

99

Note: The reaction was performed using 0.2 mmol for all the organotin reagents except
for 86 which started with (25 mg, 0.088 mmol).
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88

85

89

93

92

Figure 4.15: X-Ray structures of BODIPYs synthesized from Stille coupling reactions.
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Figure 4.16: Normalized absorption and relative fluorescence intensity spectra, in CH2Cl2,
of BODIPYs 85, 86, 90, 91, 92 and 93.
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which belongs to the s0-s1 transition, plus a weak broad absorption around 460 nm
assigned to s0-s2 transition. All the BODIPYs have a slightly shifted sharp emission band
with a mirror image shape. Table 4.1 presents the photophysical data of these BODIPYs,
including the maximum absorption and fluorescence wavelengths, molar extinction
coefficients and fluorescence quantum yields in CH 2Cl2. Meso-chloro-BODIPY 74 has an
absorption at 503 nm and a 9 nm Stokes-shifted fluorescence. The replacement of the
chloro- by methoxy- (BODIPY 77), ethoxy- (BODIPYs 63 and 64), or phenoxy- (BODIPY
80) causes a 12-16 nm blue-shift of the BODIPYs. On the other hand, substitution with
alkenyl- (BODIPYs 89 and 90), ethynyl- (BODIPYs 86 and 91), thio- (BODIPYs 81, 82
and 83) or an aromatic heterocyclic ring (BODIPYs 92 and 93) causes a red-shift (within
40 nm) in the corresponding BODIPYs. Carbon nucleophiles induce a very small blue
shift The fluorescence quantum yields of 74 and 75

are around 0.51 and 0.33;

replacement of the meso-chloro by an oxygen-centered nucleophile causes the quantum
yields to increase significantly. In particular, for 63 and 64, they increased about 0.30
compared with their meso-chloro-BODIPY counterparts 74 and 75; in particular, the
quantum yield of BODIPY 63 is close to 1.00. Substitution of the chloro- by alkyl- (e.g.
methyl and ethyl as in BODIPY 69 and 88) or aromatic (phenyl) groups (BODIPY 85)
also causes the quantum yields to increase significantly compared with the precursor
chloro-BODIPY. However, sulfur-centered nucleophiles (BODIPY 81-83) caused the
quantum yield to decrease; for example, the corresponding compounds 81 and 82 have
very low quantum yields (0.04 and 0.09, respectively). Meso-alkenyl-, ethynyl- and
heteroaromatic ring-substituted BODIPYs 89-93 have relatively low quantum yields,
especially so for BODIPY 89 which is almost non-fluorescent. Substitution on the boron
has no significant impact on absorption, but does have a large effect on the quantum
yield. For example, the substitution by a methoxy group on boron causes the quantum
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yield to increase by 0.42 (BODIPY 79). However, alkyl substitution on the boron reduces
the quantum yield of BODIPY 69 from 0.83 to the 0.32 value of BODIPY 76 .
Steady-state Absorption and Fluorescence Spectroscopy
The absorption measurements were carried out on an Agilent 8453 spectrophotometer
and the steady-state fluorescence spectroscopic studies were performed in CH 2Cl2 on a
PTI QuantaMaster4 / 2006SE spectrofluorometer. The slit width was 3 nm for both the
excitation and emission measurements. The fluorescence quantum yields of BODIPYs
was obtained by comparing the area under the corrected emission spectrum of the test
sample with that of Rhodamine 6G in ethanol.
The fluorescent quantum yields (Фexp) were calculated using the following equation

Фref is the standard fluorescent quantum yield, F x is the area under the sample
emission peak, Fstd is the area under the standard’s emission peak, Astd is the optical
density at which the standard was excited, A x is the optical density at which the sample
was excited, n represents the refractive index of the solvent of sample solution, and nstd
is the refractive index of the standard’s solvent.

Table 4.2. Spectral properties of BODIPYS in CH2Cl2 at room temperature. The
fluorescence quantum yields (λexc = 490 nm) were calculated using, rhodamine 6G (0.80
in ethanol) as the reference 32 and a PTI Quantum Master4/2006SE spectrofluorimeter
was used
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Abs

Emission

λmax (nm)

λmax (nm)

63

487

493

0.99

4.77

64

508

518

0.67

4.44

69

499

505

0.83

4.75

74

503

512

0.51

4.79

75

527

542

0.33

4.50

76

499

507

0.32

4.20

77

487

493

0.57

4.95

79

487

496

1.00

4.67

80

491

499

0.99

4.71

81

539

553

0.04

4.69

82

529

542

0.09

4.23

85

501

511

0.62

4.76

86

545

556

0.13

4.63

88

497

508

0.77

4.82

89

505

511

0.00

4.67

90

513

522

0.14

4.61

91

544

556

0.29

4.57

92

513

521

0.10

4.73

93

514

521

0.05

4.87

BODIPY

Log ε
φf
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(M-1.cm-1)

4.3 Conclusion
Symmetrical pyrroketones were made via thioketones by treatment with PbO2/Pb(OAc)2
The chemistry of pyrroketones was investigated by electrophilic alkylation with
Meerwein’s salt, chlorination by phosgene and protonation by acids. Reactivity of their
derivatives, 8-chloro-dipyrromethenes and 8-chloroBODIPYs, were compared using
nucleophilic substitution (addition/elimination) with, for example, oxygen-centered
nucleophiles, sulfur-centered nucleophiles and carbon-centered nucleophiles and
coupling reactions including Sonogashira, Heck, Suzuki and Stille coupling were also
investigated. The resuls show that BODIPYs are more stable than dipyrromethenes
(dipyrrins) in most of the reactions, and they are easy to handle during purification. The
advantage of dipyrrins over BODIPYs is that there are no competitive reactions involving
the B-F bonds during substutition reactions. Some BODIPYs were obtained by
substitution (addition/elimination) or coupling reactions of 8-chloroBODIPYs, which are
hard to synthesize by conventional methods. The photophysical properties of these new
BODIPYs were studied including absorption, fluorescence and determination of their
quantum yields.

4.4 Experimental Part
General information:
All the solvents and chemicals were purchased from Aldrich, Fisher and TCI. Silica gel
60 (230 x 400 mesh) and TLC plates (0.2 mm thickness) were purchased from Sorbent
Technologies. All conmertial reagents were used without further purification. Water and
air sensitive reactions were performed under argon protection and in dry solvents.
Melting points were measured on an electrothermal Mel-Temp instrument, UV/visible
absorption spectra was measured on an Agilent 8453 spectrophotometer and the steady
state

fluorescence

spectroscopic

studies
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were

performed

on

a

PTI

QuantaMaster4/2006SE spectrofluorometer with the slit width set at 3 nm. High and low
resolution mass spectra were performed on Bruker ProFlex III MALDI-TOF and Hitachi
M8000 ESI mass spectrometers. FT-IR data were obtained on a Bruker Tensor 27
system (2004), 1H NMR and 13C NMR spectra were obtained with a Bruker AV-400 MHZ
spectrometer, and chemical shifts are expressed in ppm.
Dibenzyl

5,5’-carbonylbis(4-(3-methoxy-3-oxopropyl)-3-methyl-1H-pyrrole-2-

carboxylate) 36: A solution of dipyrromethane 34 (2.0 g, 3.25 mmol) in acetic acid (80
ml) was treated with Pb(OAc)4 (3.12 g, 7.0 mmol) and stirred at room temperature for 4 d
under argon. Then PbO2 (2.4 g, 9.3 mmol) was added and the solution was stirred for
another two d. The solution was centrifuged and the supernatant was poured into ice
water. The precipitate was collected and dissolved in diethyl ether, before being washed
with water, 5% NaHCO3 and brine and then dried over anhydrous Na2SO4. Then the
solution was concentrated to a minimum volume and crystallized in a refrigerator to give
product as a yellowish white solid (1.2 g, 60%). 1H NMR (400 MHz; CDCl3): 7.38-7.31 (m,
10H), 5.00 (s, 4H), 3,67 (s, 6H), 3.01 (t, 3H), 2.71 (t, 3H), 2.27 (s, 6H). 1H-NMR (400
MHz; CDCl3): 176.73, 173.56, 161.74, 135.02, 132.23, 130.16, 128.66, 128.36, 127.73,
126.97, 121.68, 66.77, 51.58, 35.19, 20.28, 10.37.
Dibenzyl

5,5'-carbonylbis(3,4-dimethyl-1H-pyrrole-2-carboxylate)

37

was

synthesized using the same procedure as used for 36: (0.79g, 50%)1H NMR (400 MHz;
CDCl3): 7.37 (m, 10H), 5.14 (s, 4H), 2,25 (s,3H), 2.23 (s, 3H).
Benzyl 5-(5-((benzyloxy)carbonyl)-3-(3-methoxy-3-oxopropyl)-4-methyl-1H-pyrrole2-carbonyl)-1-ethyl-4-(3-methoxy-3-oxopropyl)-3-methyl-1H-pyrrole-2-carboxylate
39: 1H NMR (400 MHz, CDCl3): 9.22 (s, 2H), 7.46-7.27 (m, 10H), 5.34 (s, 2H), 5.35 (s,
2H), 4.30 (q, J = 4.29 Hz, 2H), 3.56 (s, 3H), 3.62 (s, 3H) 2.89 (t, 2H) 2.59 (t, 2H), 2.47 (t,
2H)2.35 (t, 2H) 2.31 (s, 3H), 2.25 (s, 3H), 1.22 (t, J = 4.29 Hz, 3H);

177

13

C NMR

(CDCl3):179.40, 173.06, 172.82, 161,28, 160.71, 135.99, 135.53, 133.26, 131.03,
130.87, 128.67, 128.62, 128.47, 128.42, 128.33, 128.29, 128.26, 127.82,124.37,
122.94, 122.05, 66.67, 51.56, ,42.16, 34.89, 34.26, 29..69, 19.96, 19.87, 17.35,
14.15, 14.11, 11.50, 10.07.

Preparation of α-Free Pyrroles
General procedure for hydrolysis under basic conditions: α-Ester pyrrole (5.0 mmol)
was dissolved in 10-15 ml of ethylene glycol. Then potassium hydroxide (10.0 mmol)
was added under an argon atmosphere and the mixture was refluxed for 2 h. After the
reaction had cooled down to room temperature, the mixture was diluted with water and
extracted with hexane and then washed with water, brine and finally dried over
anhydrous Na2SO4. After removal of the solvent, the residue was purified by
chromatography on a silica gel column eluted with hexane/ CH2Cl2 (2/1) to give the pure
product.
General procedure for hydrolysis under acidic conditions: tert-Butyl ester pyrrole or
pyrrole carboxylic acid (2.0 mmol) was dissolved in TFA at 0 oC, the mixture was stirred
for 1 h and then poured into ice water and neutralized with ammonia to pH = 7. The
solution was extracted with hexane or CH2Cl2 and washed with water, brine, and dried
over anhydrous Na2SO4. After removal of the solvent, the residue was purified by
chromatography on a silica gel column eluted with hexane/ CH2Cl2 (2/1) to give the pure
product
General procedure for reduction of ester pyrrole to alkyl pyrrole: 2-Unsubstituted 5ester pyrrole (2.0 mmol) was dissolved in dry THF (50 ml) and the solution was added to
a suspension of LiAlH4 (2.4 mmol). The mixture was refluxed for 5 h and then it was
cooled to room temperature and the excess LiAlH 4 was destroyed by addition of
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aqueous saturated Na2SO4. The solution was extracted with hexane or CHCl3 and then
washed with water, brine and dried over anhydrous Na2SO4 and the residue was purified
by chromatography on a silica gel column eluted with hexane/ CH2Cl2 or hexane/ethyl
acetate.

2,4-Dimethyl-3-ethylpyrrole 44: 1H NMR (400 MHz; CDCl3): 7.48 (s, 1H), 6.40 (s, 1H),
2.42 (q, 2H), 2.10 (s, 3H), 2.00 (s, 3H), 1.09 (t, 3H).
2,4-Dimethylpyrrole 45: 1H-NMR (400 MHz; CDCl3): 7.64 (s, 1H), 6.50 (s, 1H), 5.89
(s,1H), 2.34 (s, 3H), 2.22 (s, 3H).
2,4-Dimethyl-3-butylpyrrole 46: 1H NMR (400 MHz; CDCl3): 7.51 (s, 1H), 6.45 (s, 1H),
2.45 (t, 2H), 2.24 (s, 3H), 2.12 (s, 3H), 1.48 (m, 4H), 1.04 (t, 3H).
2,3,4-Trimethylpyrrole 48: 1H NMR (400 MHz; CDCl3): 7.45 (s, 1H), 6.40 (s, 1H), 2.16
(s, 3H), 2.12 (s, 3H), 1.94 (s, 3H)
2,4-Dimethyl-3-acetylpyrrole 54: 1H NMR (400 MHz; CDCl3): 8.45 (s, 1H), 6.35 (s, 1H),
2.50 (s, 3H)， 2.42 (s, 3H), 2.27 (s, 3H)
2,4,7,9-Tetramethyldipyrryl-5-thioketone 55 : A solution of thiophosgene (1.15 g, 10.0
mmol) in toluene (10 ml) was added dropwise to a solution of 2,4-dimethylpyrrole 45 (2.0
g, 21.0 mmol) in dry ether (30 ml) at 0 °C. The mixture was stirred for about 1 h (until
TLC showed the starting material had disappeared). Then methanol (30 ml) was added
and the mixture was stirred for another 30 min. The solvents were removed in vacuo and
the residue was purified on a silica gel column eluted with toluene/chloroform (4:1). The
thioketone product was obtained as an orange solid (980 mg, 40%), with Mp 180181°C.1H NMR (400 MHz; CDCl3): 8.96 (s, 2H), 5.91 (s, 2H), 2.27 (s, 6H), 2.07 (s, 6H);
13

C NMR (CDCl3): δ 175.30, 133.30, 127.98, 127.56, 111.74, 13.09, 12.65; HRMS (ESI):

Calcd m/z for C13H16N2S: 233.1107; found: 233.1106.
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The synthesis of 3,5-dibutyl-2,4,7,9-tetramethyldipyrryl-5-thioketone 56 followed the
procedure reported above for 55: (Yield: 1.23g, 34%). 1H NMR (400 MHz; CDCl3): 8.95
(s, 2H), 2.36 (t, 4H), 2.23 (s, 6H), 1.99 (s, 6H), 1,40-1.31(m, 8H), 0.92(t, 6H). HRMS
(ESI): Calcd m/z for C17H25N2S: 344.5572; found: 344.5576.
The synthesis of 3,8-diethyl-2,4,7,9-tetramethyl-5-dipyrryl-5-thioketone 58 followed
the procedure reported above for 55. Yield 1.30 g, (43%). Mp 205-207 oC 1H NMR (400
MHz; CDCl3): 8.95 (s, 2H), 2.40-2.35 (q, J = 7.5 Hz, 4H), 2.23 (s, 6H), 2.00 (s, 6H), 1.071.03 (t, J = 7.5 Hz, 6H);

13

C-NMR (CDCl3): 189.39, 136.19, 134.67, 126.67, 125.56,

17.47, 14.99, 11.73, 10.88. HRMS (ESI): Calcd m/z for C17H25N2S: 289.1733; found:
289.1739.
2,4,7,9-Tetramethyldipyrryl-5-dipyrroketone 59: To the thioketone 55 (232 mg, 1.0
mmol) in EtOH (95%, 100 ml) was added KOH (1.0 g) and to the mixture was added
aqueous H2O2 (5%, 10 ml) dropwise in an ice bath. Then the solution was heated on a
steam bath for about 5 min. The solution was cooled to room temperature and water
(300 ml) was added and it was then extracted with chloroform three times. The organic
layers were collected and washed with water, brine and then dried over anhydrous
Na2SO4. The solvent was evaporated and the residue was purified by sublimation to give
the product dipyrrylketone as a pale yellow solid. (170 mg, 78%). Mp 232-233 °C. 1H
NMR (400 MHz; CDCl3): 8.63 (s, 2H), 5.85(s, 2H), 2.28 (s, 6H), 2.19 (s, 6H);

13

C-NMR

(CDCl3): 175.30, 133.30, 127.98, 127.56, 111.74, 13.09, 12.65; HRMS (ESI): Calcd m/z
for C13H16N2O: 217.1335; found: 217.1334. UV/vis (CH2Cl2) λmax (ε) 295 nm (8600), 341
nm (14600). IR νmax (C=O) (Nujol) 1573 cm-1.
3,5-Diethyl-2,4,7,9-tetramethyl-5-dipyrroketone 60: Yield, 224 mg, (82%). Mp 205207 °C . 1H NMR (400 MHz; CDCl3): 8.61 (s, 2H), 2.43-2.37 (q, J = 7.5 Hz, 4H), 2.23 (s,
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6H), 2.14 (s, 6H), 1.07 (t, J = 7.5 Hz, 3H)

13

C-NMR (CDCl3): 175.23, 129.65, 127.24,

125.27, 124.25, 17.37, 15.20, 11.41, 10.70. HRMS (ESI): Calcd m/z for C17H25N2O:
273.1967; found: 273.2013. UV/vis λmax (CHCl3) 288 nm (11700), 357 (25000). IR ν max
(C=O) (CHCl3 or Nujol) 1575 cm-1.

BODIPY 63: Method A: Dipyrrylketone 59 (60 mg, 0.27 mmol) was dissolved in dry
CHCl3 (20 mL) and triethyloxonium tetrafluoroborate (105.1 mg, 0.54 mmol) was added.
The solution turned red with time and UV-visible spectroscopy showed a sharp peak at
438 nm. The mixture was stirred overnight and then washed with water, brine and finally
dried over anhydrous Na 2SO4. After evaporation, the residue was dissolved in CHCl 3
(30.0 ml) and DIEA (1.62 mmol, 6 equiv) was added and the solution was stirred for
about 30 min before addition of BF3.OEt2 (2.7 mmol, 10 equiv); the reaction solution was
then stirred overnight. UV-visible spectroscopy showed a sharp peak at 487 nm. Then
the mixture was washed with aqueous NaHCO 3, brine and then dried over anhydrous
Na2SO4. The residue was purified by chromatography (eluted with CH 2Cl2/hexane) to
give BODIPY 63 as an orange red solid. (64 mg, 82%).

Method B: BODIPY 74 (56.4 mg, 0.20 mmol) was dissolved in MeOH (20 ml) in an ice
bath and NaOEt (20.4 mg, 0.3 mmol) was added. The mixture was stirred for 45 min
while being monitored by TLC and UV-visible spectroscopy. The solvent was removed in
vacuo and the residue was taken up in CHCl 3 and washed with water, brine and then
dried over anhydrous Na2SO4. The product was purified by chromatography (eluted with
CH2Cl2/hexane) to give an orange solid (26.8 mg, 46%). Mp. 126-128 °C; 1H NMR (400
MHz; CDCl3): 6.02 (s, 2H), 4.12 (q, J = 7.1 Hz, 2H), 2.51 (s, 6H), 2.38 (s, 6H), 1.53 (t, J =
7.1 Hz, 3H); 13C NMR (100 MHz; CDCl3): 159.12, 154.13, 139.13, 127.94, 119.57, 74.14,
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15.31, 14.45, 13.75; HRMS (ESI): m/z Calcd for C15H19BF2N2O: 292.1668; found:
292.1654; UV/vis (CH2Cl2) λmax (ε) 487 nm (58900).

BODIPY 64: Method A: Yield: (66 mg, 71%); Method B: Yield: (36.2 mg, 52%); Mp. 135137 °C; 1H NMR (400 MHz; CDCl3): 4.09 (q, J = 7.1 Hz, 2H), 2.48 (s, 6H), 2.48 (q, J =
7.5 Hz, 4H), 2.32 (s, 6H), 1.55 (t, J = 7.1 Hz, 3H), 1.06 (t, J = 7.5 Hz, 6H);

13

C NMR (100

MHz; CDCl3): 158.04, 152.19, 134.73, 131.53, 73.88, 17.04, 15.29, 14.68, 12.41, 11.22;
HRMS (ESI): m/z Calcd for C19H27BFN2O (M+-F): 329.2200; found: 329.2167.; UV/vis
(CH2Cl2) λmax (ε) 508 nm (27500).

5-Chloro-2,4,7,9-tetramethyldipyrromethene hydrochloride 65: Dipyrrylketone 59
(314 mg, 1.45 mmol) was dissolved in CHCl3 (100 ml) and excess phosgene in toluene
solution was added and stirred at room temperature for 1 h. When the reaction was
complete according to UV-visible spectra and TLC, nitrogen gas was passed through
solution to purge it of excess phosgene that was directed into an aqueous NaHCO 3
solution trap. Solvent was then removed in vacco and the red solid was recrystallized
from CHCl3/petroleum ether to give 65 as a red solid (306 mg, 90%). Mp > 260 °C. 1H
NMR (400 MHz; CDCl3): 12.93 (s, 2H), 6.23 (s, 2H), 2.59 (s, 6H), 2.34 (s, 6H);

13

C NMR

(CDCl3): 153.70, 144.35, 139.63, 128.18, 120.71, 16.27, 14.38; HRMS (ESI): Calcd m/z
for C13H16ClN2: 235.0997, found: 235.0992. UV/vis (CH2Cl2) λmax(ε) 485 nm (23500).
5-Chloro-3,8-diethyl-2,4,7,9-tetramethyldipyrromethene hydrochloride 66. Yield:
392 mg, (93%). Mp >300 °C. 1H NMR (400 MHz; CDCl3): 12.50 (s, 2H), 2.35 (s, 6H),
2.15 (s, 6H), 2.40 (q, 4H), 1.05 (t, 6H).

13

C NMR (CDCl3): 152.41, 138.81, 137.68,

133.13, 128.08, 17.44, 14.28, 12.72, 12.63 HRMS (ESI): Calcd m/z for C17H24ClN2
291.1623, found: 291.1635. Anal. Calcd for C 17H24Cl2N2: C, 62.4; H, 7.3; N, 8.6; found: C,
62.7; H, 7.5; N, 8.8%. UV/vis (CHCl3) λ max(ε) 509 nm (57500).
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BODIPY 69: Method A: 5-Chloro-dipyrrin 65 (100 mg, 0.37 mmol) was dissolved in
CHCl3 (40 mL) and 1.0 M EtMgBr in THF (1.30 mL, 1.30 mmol) was added dropwise at
0 °C; the mixture was left stirring for 1 h at 0 °C and then for another 2 h at room
temperature. Then the solution was poured into ice/water to destroy excess EtMgBr and
it was extracted with CHCl3. The organic layers were combined and washed with water,
brine and then dried over anhydrous Na 2SO4. After evaporation, the residue in CHCl3 (30
mL) and DIEA (0.45 ml, 7 equiv, 2.58 mmol) in an ice bath was treated with BF 3.OEt2
(0.53 ml, 12.0 equiv, 4.3 mmol) and the mixture was stirred overnight. The solvent was
removed and the residue was purified on a silica gel column (eluted with CH2Cl2/hexane)
to give BODIPY 69. Yield: 20.1 mg, 19.6%.

Method B: ChloroBODIPY 74 (56.4 mg, 0.2 mmol) was dissolved in anhydrous THF (30
ml) and 1.0 M EtMgBr in THF (0.5 mL, 0.5 mmol) was added dropwise to the solution at
- 70 °C with vigorous stirring. When the reaction was complete according to TLC and
spectrophotometry, the solution was poured into ice/water to destroy the exess Grignard
reagent. Then the mixture was extracted 3 times with CHCl 3 and the organic phases
were combined and washed with water, brine and then dried over anhydrous Na 2SO4.
The solvent was evaporated and the residue was purified by silica gel column
chromatography (eluted with CH2Cl2/hexane) to give the product 69 as an orange-red
solid (40 mg, 75%); Mp. 214-216 °C; 1H NMR (400 MHz; CDCl3): 6.05 (s, 2H), 3.01 (q, J
= 7.5 Hz, 2H), 2.52 (s, 6H), 2.44 (s, 6H), 1.32 (t, J = 7.5 Hz, 3H);

13

C NMR (100 MHz;

CDCl3): 153.87, 147.87, 140.30, 131.20, 121.55, 21.29, 16.30, 15.45, 14.45; HRMS
(ESI): m/z calcd for C15H19BF2N2: 276.1718; found: 276.1713; UV/vis (CH2Cl2) λmax (ε)
499 nm (56200). The meso-unsubstituted BODIPY was also eluted from the column (6.0
mg, 10%); Mp. 185-187 °C; 1H NMR (400 MHz; CDCl3): 7.04 (s, 1H), 6.05 (s, 2H), 2.53
(s, 6H), 2.25 (s, 6H);

13

C NMR (100 MHz; CDCl3): 156.75, 141.20, 133.41, 120.07,
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119.02, 14.67, 11.28; HRMS (ESI): m/z Calcd for C13H15BF2N2: 248.1405; found:
248.1404; UV/vis (CH2Cl2) λmax (ε) 507 nm (19600).

Methyl 3,5-dimethylpyrrole-2-carboxylate 72: Chlorodipyrrin hydrochloride 65 (47.0
mg, 0.17 mmol) was dissolved in CHCl3 and 0.5 M NaOMe in MeOH (1.0 mL, 0.5 mmol)
was added at room temperature; the mixture was stirred overnight and the reaction was
monitored by TLC and spectrophotometry. The solution was washed with water, brine
and then dried over anhydrous Na2SO4. The solvent was removed and the product was
purified by silica gel column chromatography (eluted with MeOH/CH 2Cl2); Yield: 21 mg,
80.8%; Mp 93-95 °C (lit.44 98-99 °C); 1H NMR (400 MHz; CDCl3): 9.27 (s, 1H), 5.79 (s,
1H), 3.83 (s, 3H), 2.30 (s, 3H), 2.25 (s, 3H);

13

C NMR (100 MHz; CDCl3): 163.43, 132.97,

129.14, 117.53, 111.34, 50.92, 12.96, 12.82. HRMS (ESI): m/z Calcd for C8H12NO2
(M+H+): 154.0868; found: 154.0870.

Ethyl 3,5-dimethylpyrrole-2-carboxylate 73: This compound was prepared as
described for pyrrole 72 (above) except that sodium ethoxide was used as the base in
ethanol. Yield: 19.0 mg, 66.2%. Mp. 118-119 °C (lit.45 125 °C); 1H NMR (400 MHz,
CDCl3): 8.68 (s, 1H), 5.79 (s, 1H), 4.31 (q, J = 7.1 Hz, 2H), 2.30 (s, 3H), 2.24 (s, 3H),
1.34 (t, J = 7.1 Hz, 3H);

13

C NMR (100 MHz; CDCl3): 161.69, 132.28, 129.02, 117.78,

111.35, 59.68, 14.57, 13.07, 12.77; HRMS (ESI): m/z Calcd for C9H14NO2 (M+H+):
168.1019; found: 168.1016

BODIPY 74: Chloro-dipyrrin hydrochloride 65 (235 mg, 0.87 mmol) was dissolved in
CHCl3 and DIEA (8 mmol, 9.0 equiv) was added before the mixture was stirred for 30
min. Then BF3.OEt2 (14 mmol, 16 equiv) was added. The resulting mixture was stirred
overnight at room temperature. The solution was washed with saturated aq NaHCO3,
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brine and then dried over anhydrous Na 2SO4. The solvent was evaporated and the
residue was purified by chromatography on a silica gel column (eluted with
CH2Cl2/hexane) to give the BODIPY 74 (230 mg, 94%); Mp. 235-237 °C; 1H NMR (400
MHz; CDCl3): 6.09 (s, 2H), 2.52 (s, 6H), 2.45 (s, 6H);

13

C NMR (100 MHz; CDCl3):

155.26, 142.84, 136.54, 129.72, 121.36, 16.68, 14.54; HRMS (ESI): m/z Calcd for
C13H15BClF2N2: 282.1016; found: 282.1010; UV/vis (CH 2Cl2) λmax (ε) 503 nm (61700).

BODIPY 75: This BODIPY was prepared using the same procedure, from 5-chlorodipyrrin hydrochloride 66 (yield: 325 mg, 96%). Mp. 173-175 °C; 1H NMR (400 MHz;
CDCl3): 2.50 (s, 6H), 2.41 (m, 10H), 1.05 (t, J = 7.6 Hz, 6H); 13C NMR (100 MHz; CDCl3):
153.36, 138.10, 135.16, 133.20, 129.16, 17.11, 14.75, 13.82, 12.49; HRMS (ESI): m/z
Calcd for C17H22BClFN2 (M+-F): 319.1549; found: 319.1550; UV/vis (CH 2Cl2) λmax (ε) 527
nm (31600).

BODIPY 76: 1.0 M Ethyl magnesium bromide (1.0 ml, 1.0 mmol) in THF was added to
chloro-BODIPY 65 (56.4 mg, 0.2 mmol) in THF (20 ml) at room temperature and stirred
for 1 h; the reaction was quenched by addition of aqueous NH 4Cl and then extracted
with CHCl3. The organic extract was washed with water, brine and then dried over
anhydrous Na2SO4. The BODIPY 76 was isolated as the sole product using silica gel
column chromatography (eluted with CH2Cl2/hexane). Yield: 49 mg, 83%; Mp. 135-137
°C; 1H NMR (400 MHz; CDCl3): 6.08 (s, 2H), 3.07 (q, J = 7.5 Hz, 2H), 2.46 (s, 6H), 2.44
(s, 6H), 1.31 (t, J = 7.5 Hz, 3H), 0.79 (m, 4H), 0.30 (m, 6H);

13

C NMR (100 MHz; CDCl3):

150.08, 135.52, 131.77, 122.06, 21.34 16.97, 16.39, 15.93, 9.00, 1.02;

11

B-NMR (128

MHz; CDCl3): δ = 1.37; HRMS (ESI): m/z Calcd for C19H30BN2: 296.2533; found:
296.2507; UV/vis (CH2Cl2) λmax (ε) 499 nm (15800).
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BODIPYs 77 and 78: 8-Chloro-BODIPY 65 (56.4 mg, 0.2 mmol) was dissolved in MeOH
(30 ml) in an ice bath and NaOMe (16.5 mg, 0.3 mmol) was added; the mixture was
stirred for 45 min and the reaction was monitored by TLC and spectrophotometry. The
solvent was removed in vacuo and the residue was taken up in CHCl 3 and washed with
water, brine and then dried over anhydrous Na 2SO4. The product was purified by silica
gel column chromatography (eluted with CH 2Cl2/hexane). The major fraction was the
desired BODIPY product 77. Yield: 37.1 mg, 67%; Mp. 160-161 °C; 1H NMR (400 HMz;
CDCl3): 6.03 (s, 2H), 3.98 (s, 3H), 2.51 (s, 6H), 2.40 (s, 6H);

13

C NMR (100 MHz; CDCl3):

159.95, 154.76, 138.33, 128.30, 119.56, 64.32, 49.12, 14.47, 13.76; HRMS (ESI): m/z
Calcd for C14H18BF2N2O: 278.1511; found: 278.1504; UV/vis (CH 2Cl2) λmax (ε) 487 nm
(89100). The monomethoxy-boron substituted BODIPY 78 was also separated as a
minor fraction from the column (Yield: 12.0 mg, 21%); 1H NMR (400 MHz; CDCl3): 6.02
(s, 2H), 3.97 (s, 3H), 2.89 (s, 3H), 2.51 (s, 6H), 2.37 (s, 6H);

13

C NMR (100 MHz; CDCl3):

159.95, 154.76, 138.33, 128.30, 119.56, 64.24, 49.12, 14.47, 13.76;

11

B NMR (128 MHz;

CDCl3): δ = 1.58; HRMS (ESI): m/z Calcd for C14H17BFN2O (M+-OMe): 259.1418; found:
259.1392. A small amount of the dimethoxyboron-BODIPY 79 was also isolated from the
column, but in insufficient quantity to characterizeit from this reaction.

BODIPY 79: 8-Chloro-BODIPY 74 (56.4 mg, 0.2 mmol) was dissolved in MeOH (30 ml)
and NaOMe (54.0 mg, 0.75 mmol) was added before the solution was refluxed under
argon for 12 h. The solvent was removed and the residue was taken up in CHCl 3 and
washed with water, brine and then dried over anhydrous Na 2SO4. The product was
separated by silica gel column chromatography (eluted with MeOH/CH 2Cl2). Yield: 38
mg, 65%; Mp. 93-95 °C; 1H NMR (400 HMz; CDCl3): 6.01 (s, 2H), 3.97 (s, 3H), 2.86 (s,
6H), 2.48 (s, 6H), 2.41 (s, 6H);

13

C NMR (100 MHz; CDCl 3): 159.92, 154.87, 137.38,

129.02, 119.33, 64.13, 49.04, 14.41, 13.81;

11
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B NMR (128 MHz; CDCl3): 2.39; HRMS

(ESI): m/z Calcd for C16H23BN2NaO3 (M++Na): 324.173; found: 324.1719; UV/vis
(CH2Cl2) λmax (ε) 487 nm (46800). The monomethoxy-boron substituted BODIPY (see
earlier) was also separated as a minor fraction from the column (Yield: 9.3 mg, 16%).

BODIPY 80: 8-ChloroBODIPY 74 (56.4 mg, 0.2 mmol) was dissolved in THF (30 ml) in
an ice bath and sodium phenoxide (34.8 mg, 0.3 mmol) was added; the mixture was
stirred for 2 h at room temperature and monitored by TLC and spectrophotometry. The
solvent was removed in vacuo and the residue was taken up in CHCl 3 and washed with
water, brine and then dried over anhydrous Na2SO4. The product was purified by column
chromatography (eluted with CH2Cl2/hexane). Yield: 55 mg, (81%). Mp. 188-190 °C 1H
NMR (400 HMz; CDCl3): 7.33-7.29 (m, 2H), 7.08-7.06 (m, 1H), 7.01-6.99 (m, 2H), 5.99
(s, 2H), 2.55 (s, 6H), 2.04 (s, 6H); 13C NMR (CDCl3): 157.52, 155.78, 151.59, 140.42,
130.08, 127.62, 122.84, 119.99, 114.70, 14.60, 14.14; HRMS (ESI): Calcd m/z for
C19H20BF2N2O: 340.1668, found: 340.1662. λmax (CH2Cl2) 491 nm (ε 51286).

BODIPY

81: A solution

of 8-chloro-BODIPY 74

(56.4

mg, 0.2

mmol), 2-

mercaptobenzothiozole (40.0 mg, 0.24 mmol) and K 2CO3 (41.5 mg, 0.3 mmol) in THF
(30 ml) was stirred at room temperature for 12 h or until the starting material was
completely consumed. The solvent was removed in vacuo and the residue was taken up
in CHCl3 and washed with water, brine and then dried over anhydrous Na 2SO4. The
product was purified by silica gel column chromatography (eluted with CH 2Cl2/hexane).
Yield: 46.1 mg, 56%; Mp. 208-210 °C. 1H NMR (400 HMz; CDCl3): 7.90 (dt, J = 8.4, 0.9
Hz, 1H), 7.68 (m, 1H), 7.44 (ddd, J = 8.4, 7.3, 1.3 Hz, 1H), 7.31 (ddd, J = 8.3, 7.3, 1.2 Hz,
1H), 6.10 (s, 2H), 2.58 (s, 6H), 2.46 (s, 6H);

13

C NMR (100 MHz; CDCl3): 166.56, 158.25,

153.59, 144.75, 135.37, 134.42, 128.70, 126.46, 124.76, 123.07, 122.00, 121.08, 17.26,
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14.97; HRMS (ESI): m/z Calcd for C20H18BFN3S(MW -F): 394.1019; found: 394.1010;
UV/vis (CH2Cl2) λmax (ε) 539 nm (49000).

BODIPY 82: A solution of chloroBODIPY 4a (56.4 mg, 0.2 mmol), p-carborane thiol
(45.6 mg, 0.24 mmol) and K 2CO3 (41.5mg, 3.0 mmol) in THF (30 ml) was stirred at
room temperature for 12 h or until the starting material was consumed, The solvent was
removed in vacuo and the residue was taken up in CHCl 3 and washed with water, brine
and then dried over anhydrous Na 2SO4. The product was purified by silica gel column
chromatography (eluted with CH2Cl2/hexane) and was obtained as a red solid. Yield: 80
mg, (92%). Mp 150-152 °C. 1H NMR (400 MHz; CDCl3): 6.06 (s, 2H), 2.95 (s, 2H), 2.51
(s, 3H), 2.49 (s, 3H), 2.17-1.68 (m, 11H);

13

C NMR (CDCl3): 156.14, 143.51, 136.84,

134.23, 122.50, 59.04, 46.04, 31.91, 16.91, 14.68. HRMS (ESI): Calcd m/z for
C16H26B11F2N2S: 437.2808, found: 437.3033. . λmax (ε)(CH2Cl2) 529 nm (17000).
BODIPY 83: yield :94%1H NMR (400 MHz; CDCl3): 6.15 (s, 2H), 2.57 (s, 6H),2.49 (s,6H),
2.20-1.70 (m, 11H); 13C NMR (CDCl3): 158.91, 143.66, 129.61, 123.83, 135.66, 60.07,
17.15, 15.10; HRMS (ESI): m/z Calcd for C19H20BF2N2: 423.2882; found: 423.2871.
BODIPY 84: yield 92% 1H NMR (400 MHz; CDCl3): δ 6.05 (s, 2H), 5.25 (s, 1H), 4.19 (q,
2H), 2.51 (s, 3H), 2.47 (t, 1H), 2.42 (s, 3H).

BODIPY 85: Method A: In a Suzuki coupling reaction, 8-chloro-BODIPY 74 (56.4 mg,
0.2 mmol), Pd(PPh3)4 (10.0 mg, 5% mmol ), phenylboronic acid (24.4 mg, 0.2 mmol) and
K2CO3 (41.5mg, 0.3 mmol) were added to THF or DME (30 ml). The reaction flask was
evacuated and filled with argon several times. Then the solution was refluxed overnight
under argon. The solvent was removed and the residue was taken up in CHCl 3 and
washed with water, brine, and dried over anhydrous Na 2SO4. The solvent was removed
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and the product was purified by chromatography on a silica gel column (eluting with
CH2Cl2/hexane), The product is the major fraction from the column. (yield: 30.3 mg,
46%).

Method B: In a Stille coupling reaction, 8-chloro-BODIPY 74 (56.4 mg, 0.2 mmol),
Pd(PPh3)4 (10.0 mg, 5% mmol) and tributylphenyl tin (80.0 mg, 0.24 mmol) were added
to a round-bottomed flask. The flask was flushed with argon and then anhydrous toluene
(20 ml) was added. The mixture was refluxed for 5 h after which the reaction was
completed; the toluene was then removed and the residue was taken up in CH2Cl2 and
washed with water, brine and then dried over anhydrous Na 2SO4. The crude product
was purified by silica gel column chromatography (eluting with CH 2Cl2/hexane). Yield:
60.1 mg, 93%; Mp. 165-166 °C. 1H NMR (400 MHz; CDCl3): 7.49-7.47 (m, 3H), 7.297.27(m, 2H), 5.98 (s, 2H), 2.56 (s, 6H), 1.37 (s, 6H);

13

C NMR (100 MHz; CDCl3): 154.90,

142.19, 140.52, 131.14, 123.79, 121.11, 17.24, 14.55; HRMS (ESI): m/z Calcd for
C19H20BF2N2: 324.1718; found: 324.1717. UV/vis (CH2Cl2) λmax (ε) 501 nm (57500).

BODIPY 86: Method A: In a Sonogashira coupling reaction, 8-chloro-BODIPY 74 (56.4
mg, 0.2 mmol), Pd(PPh3)2Cl2 (7.0 mg, 5% mmol ), ethynyltrimethylsilane (21.6 mg, 0.22
mmol), TEA (10.0 ml) and THF (10.0 ml) were mixed together and the reaction flask was
flushed with argon several times. Then the solution was refluxed overnight under argon.
Before the solvent was removed, the residue was taken up in CHCl 3 and washed with
water, aqueous 1 M HCl, water and brine, and then the organic layer was dried over
anhydrous Na2SO4. The solvent was removed and the product was purified by silica gel
column chromatography (eluting with CH2Cl2/hexane), and the product was isolated as a
deep red solid (22.6 mg, 35%).
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Method B: In a Stille coupling reaction,8-chloro-BODIPY 74 (25.0, 0.088 mmol),
Pd(PPh3)4 (4.6 mg, 5% mmol) and TMS-ethynyltin (41.0 mg, 0.11 mmol) were added to
a round-bottomed flask. The flask was flushed with argon and then anhydrous toluene
(20 ml) was added and the mixture was refluxed for 5 h, after which the reaction was
completed; the toluene was then removed and the residue was taken up in CH2Cl2 and
washed with water, brine and then dried over anhydrous Na 2SO4. The crude product
was purified by silica gel column chromatography (eluting with CH2Cl2/hexane).Yield:
(21.7 mg, 71%); Mp. dec. ~250 °C; 1H NMR (400 MHz; CDCl 3): 6.06 (s, 2H), 2.52 (s, 6H),
2.46 (s, 6H), 0.29 (s, 9H);

13

C NMR (100 MHz; CDCl3): 154.40, 142.23, 133.05, 120.78,

120.05, 115.01, 110.44, 15.54, 14.61, 0.68; HRMS (ESI): m/z Calcd for C18H23BFN2Si:
325.1708 (M+-F); found: 325.1699; UV/vis (CH2Cl2) λmax (ε) 545 nm (42500).

BODIPY 87: 8-Chloro-BODIPY 74 (25 mg, 0.088 mmol) and Pd(PPh 3)4 (5.0 mg, 5%
mmol) was dissolved in anhydrous THF (20 ml). Then the mixture was cooled to 0 oC
and 1 M phenylethynyl magnesium bromide (0.264 mmol, 0.26 ml) was added and the
reaction was refluxed for 5 min and the entire solution turned red. The mixture was
cooled to room temperature and quenched with aqueous NH4Cl solution and then
extracted with CH2Cl2 or CHCl3 (three times) and the combined organic layers were
washed with water, brine and dried over anhydrous Na2SO4, The solvent was removed
and the product was purified by silica gel column chromatography (eluting with
CH2Cl2/hexane) to give the product. 1H NMR (400 MHz; CDCl3): 7.39-7.19 (m, 15H),
6.18 (s, 2H), 2.88 (s, 6H), 2.62(s, 6H).

General procedure for Stille coupling reactions
8-Chloro-BODIPY 74 (56.4 mg, 0.2 mmol), Pd(PPh3)4 (10.0 mg, 5% mmol) and
organotin reagent (2.4-3.0 mmol) were added to a round bottom flask. The flask was
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flushed with argon and then anhydrous toluene was added, followed by injection of the
Stille reagents. The mixture was refluxed for 5 h after which the reaction was completed;
the toluene was then removed and the residue was taken up in CH 2Cl2 and washed with
water, brine and then dried over anhydrous Na2SO4. The crude product was purified by
column chromatography on silica gel (eluting with CH 2Cl2/hexane).

BODIPY 88: Yield: 50.7 mg, 97%; Mp 245-247 °C; 1H NMR (400 MHz; CDCl3): δ = 6.05
(s, 2H), 2.56 (s, 6H), 2.51 (s, 6H), 2.40 (s, 3H);

13

C NMR (100 MHz; CDCl3): δ = 153.59,

141.43, 141.01, 132.06, 121.25, 17.31, 16.37, 14.43; HRMS (ESI): m/z Calcd for
C14H18BF2N2: 262.1562; found: 262.1556; UV/vis (CH2Cl2) λmax (ε) 487 nm (66000).

BODIPY 89: Yield: 50.7 mg, 97%; Mp 245-247 °C; 1H NMR (400 MHz; CDCl3): δ = 6.05
(s, 2H), 2.56 (s, 6H), 2.51 (s, 6H), 2.40 (s, 3H);

13

C NMR (100 MHz; CDCl3): δ = 153.59,

141.43, 141.01, 132.06, 121.25, 17.31, 16.37, 14.43; HRMS (ESI): m/z Calcd for
C14H18BF2N2: 262.1562; found: 262.1556; UV/vis (CH2Cl2) λmax (ε) 487 nm (66000).

BODIPY 90: Yield: 59.1 mg, 93%; Mp. 105-107 °C; 1H NMR (400 MHz; CDCl3): δ = 6.03
(s, 2H), 4.46 (d, J = 2.9 Hz, 1H), 4.37 (d, J = 2.8 Hz, 1H), 3.89 (q, J = 7.0 Hz, 2H), 2.52
(s, 6H), 2.23 (s, 6H), 1.39 (t, J = 7.0 Hz, 3H);

13

C NMR (100 MHz; CDCl3): δ = 155.97,

153.56, 142.50, 134.98, 131.29, 88.11, 63.67, 14.65, 14.34; HRMS (ESI): m/z Calcd for
C17H22BF2N2O: 318.1824; found: 318.1817; UV/vis (CH2Cl2) λmax (ε) 513 nm (40700).

BODIPY 91: Yield: 16.8 mg, 31%; Mp. > 260 °C; 1H NMR (400 MHz; CDCl3): δ = 6.07 (s,
2H), 3.92 (s, 1H), 2.53 (s, 6H), 2.45 (s, 6H);

13

C NMR (100 MHz; CDCl3): δ = 155.07,

142.61, 133.28, 121.06, 118.92, 94.42, 79.19, 15.47, 14.63; HRMS (ESI): m/z Calcd for
C15H16BF2N2: 272.1405; found: 272.1380; UV/vis (CH2Cl2) λmax (ε) 544 nm (37200).
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BODIPY 92: Yield: 62.1 mg, 95%; Mp 179-181 °C; 1H NMR (400 MHz; CDCl3): δ = 6.77
(dd, J = 2.7, 1.7 Hz, 1H), 6.21 (dd, J = 3.6, 2.7 Hz, 1H), 6.07 (dd, J = 3.6, 1.7 Hz,1H),
6.01 (s, 2H), 3.40 (s, 3H), 2.55 (s, 6H), 1.50 (s, 6H);

13

C NMR (100 MHz; CDCl3): δ

156.14, 143.34, 133.13, 131.73, 124.64, 122.47, 121.01, 109.34, 108.84, 33.84, 14.67,
12.68; HRMS (ESI): m/z calcd for C18H21BF2N2: 327.1827; UV/vis (CH2Cl2) λmax (ε) 513
nm (53700).

BODIPY 93: Yield: 69.8 mg, 99%; Mp 197-199 °C; 1H NMR (400 MHz; CDCl3): δ = 7.50
(dd, J = 5.0, 1.3 Hz, 1H), 7.13 (dd, J =5.1, 3.5 Hz, 1H), 6.99 (dd, J = 3.5, 1.3 Hz, 1H),
6.00 (s, 2H), 2.55 (s, 6H), 1.58 (s, 6H);

13

C NMR (100 MHz; CDCl3): δ = 156.07, 143.50,

134.64, 133.99, 132.41, 127.81, 127.61, 127.41, 121.50, 14.64, 13.55; HRMS (ESI): m/z
Calcd for C17H17BF2N2NaS (M++Na): 352.1102; found: 352.1094; UV/vis (CH2Cl2) λmax (ε)
514 nm (74100).
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4.5 Supporting Information

1

H-NMR spectra of pyrroles 44 and 54 in CDCl3 at 400 MHz
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1

H-NMR spectra of pyrroles 41 and 43 in CDCl3 at 400 MHz
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1

H- and 13C-NMR spectra of dipyrrothione 55 in CDCl3
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1

H- and 13C-NMR spectra of dipyrroketone 59 in CDCl3
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1

H- and 13C-NMR spectra of dipyrrothione 58 in CDCl3
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1

H- and 13C-NMR spectra of dipyrroketone 60 in CDCl3
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1

H- and 13C-NMR spectra of meso-chloro-dipyrrin 65 in CDCl3
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1

H- and 13C NMR spectra of dipyrrothione 66 in CDCl3
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1

H- and 13C-NMR spectra of BODIPY 74 in CDCl3
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1

H- and 13C-NMR spectra of BODIPY 75 in CDCl3
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1

H- and 13C-NMR spectra of BODIPY 63 in CDCl3
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1

H- and 13C-NMR spectra of BODIPY 64 in CDCl3
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1

H- and 13C-NMR spectra of unexpected pyrrole 72 in CDCl3
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1

H- and 13C-NMR spectra of unexpected pyrrole 73 in CDCl3
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1

H- and 13C-NMR spectra of BODIPY 69 in CDCl3
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1

H- and 13C-NMR spectra of BODIPY 76 in CDCl3
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1

H- and 13C-NMR spectra of BODIPY 77 in CDCl3
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1

H- and 13C-NMR spectra of BODIPY 78 in CDCl3
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1

H- and 13C-NMR spectra of BODIPY 80 in CDCl3
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1

H- and 13C-NMR spectra of BODIPY 79 in CDCl3
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11

B-NMR spectra of BODIPYs 78 and 79 in CDCl3
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1

H- and 13C-NMR of BODIPY 81 in CDCl3
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1

H- and 13C-NMR of BODIPY 82 in CDCl3
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1

H- and 13C-NMR of BODIPY 83 in CDCl3
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1

H- and 13C-NMR of BODIPY 86 in CDCl3
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1

H- and 13C-NMR of BODIPY 85 in CDCl3
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1

H- and 13C-NMR of BODIPY 88 in CDCl3

219

1

H- and 13C-NMR of BODIPY 89 in CDCl3
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1

H- and 13C-NMR of BODIPY 90 in CDCl3

221

1

H- and 13C-NMR of BODIPY 91 in CDCl3
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1

H- and 13C-NMR of BODIPY 92 in CDCl3
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1

H- and 13C-NMR of BODIPY 93 in CDCl3
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1

H- and 13C-NMR of meso-unsubstituted BODIPY in CDCl3
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1

H-NMR spectra of dipyrrothione 56 and BODIPY 84 in CDCl3 at 400 MHz

226

1

H-NMR spectrum of BODIPY 87 in CDCl3 at 400 MHz
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Chapter 5: Syntheses of Symmetrical and Asymmetrical BODIPYs Through
Functionalization of Halogenated BODIPYs
5.1 Introduction
4,4-Difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) is a class of very versatile
fluorophore recognized in the last several decades and that are used widely as labeling
reagents, sensors, and photoelectronic devices. 1-3 Compared with other fluorophores,
BODIPY has a lot of advantages, such as strong absorption and fluorescent bands in the
visible region, relatively high thermal and photochemical stability, and easy
functionalization, thus enabling variations in properties such as absorption wavelength
and amphiphilicity.4 Due to their relatively low molecular weight, BODIPY conjugates
with biomolecules tend to have good permeability to living cells. Another advantage of
BODIPY dyes is their low tendency for self–association, which means they have
negligible aggregation because of the lack of intermolecular interactions.
Various methods have been developed to functionalize BODIPYs to change their long
wavelength absorption or hydrophobicity and hydrophilicity. These methods include
coupling reactions, replacement reactions and Knoevenagel reactions.5-9 Coupling
reactions and Knovenagel reactions are usually used to increase the absorption
wavelength by introducing extended conjugation into the BODIPYs, while replacement
reactions are used to modify the amphiphilicity by introducing heteroatom-based groups.
Halogenated BODIPYs are very versatile substrates for functionalization purposes and
applicable halogens include iodide, bromide and chloride which have already been
introduced into all the positions of BODIPYs11-17 (Figure 5.1). Coupling and replacement
reactions were explored on these BODIPYs since different positions of the BODIPY core
have different reactivity toward coupling reagents and nucleophiles. The coupling
reactions explored on BODIPYs5 include palladium-catalyzed Suzuki, Stille, Sonogashira
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and Heck coupling reactions, all of which worked at the 3,5-positions of the BODIPY;
Heck coupling reactions have not yet worked on the 8-position. For the 2,6-positions,
Suzuki and Stille coupling reactions have been reported. 16 These coupling reactions
significantly facilitated the functionalization of BODIPYs and a number of compounds
were synthesized using these methods.

Figure 5.1: The halogenated BODIPYs.
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5.2. Syntheses of Halogenated BODIPYs
In Chapter 4, we initially used pyrroketones 10 and 11 as starting material to synthesize
BODIPYs; however, the reactions such as chlorination using various chlorinating
reagents did not work on these two pyrroketones due to the presence of the two
electron-withdrawing ester groups on the α-positions. To avoid this problem, we
switched from these two pyrroketone to alkylated pyrroketones possessing no electron
withdrawing groups and as a result the halogenation reactions worked very well. When
we came back to reinvestigate at the reactions of these two pyrroketones 10 and 11, we
devised another strategy to make them useful by elimination of the two ester groups and
subsequent introduction of some other functional groups such as halogens. It was
surmised that if the chlorination reaction works on pyrroketone 12, we can introduce
halogens to the 3, 5, and 8-positions of BODIPYs at the same time, or maybe even
sequentially(Scheme 5.1).
Based on this idea, the pyrroketone 10 was subjected to hydrogenation using Pd/C as
catalyst in THF, and the dipyrroketone dicarboxylic acid was obtained in 90% yield. Then
an electrophilic iodination reaction 15 under basic conditions using iodine gave
diiodopyrroketone 12 in 75% yield. Diiodopyrroketone 12 was treated with phosgene 18 in
chloroform and the reaction was monitored by UV/visible absorption spectroscopy. A
peak around 480 nm indicated the fully conjugated dipyrromethene was obtained.
Complexation with BF3.OEt2 using DIEA as base gave a reddish solution, which had an
absorption maximum at 538 nm. This absorption wavelength is a little lower than
expected for 3,5-diiodo-BODIPYs.15 Chromatographic separation showed the product to
a mixture of di-and tri-chloro-BODIPYs 15 and 16, and this conclusion was confirmed by
an X-ray crystal structure (Scheme 5.2).
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Scheme 5.1: The strategy to access halogenated BODIPYs.
10 R = PMe, 11 R = Me
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Scheme 5.2: Synthesis of halogenated BODIPYs 15 and 16, and X-ray crystal structure
of 15.
5.3. Global and Selective Stille Coupling Reactions
According to the resonance structure of BODIPY, the meso-position is more electrophilic
than the other positions such as the 3,5 or 2,6-postions; a computational study of the
BODIPY by Mulliken charge distribution, and reactivity studies also reached same
conclusion.19 Therefore, the 8-chloro-position is more reactive than the 3,5-positions of
BODIPY 15 and selective coupling reactions on 8-position over 3,5-position are possible
in this case. Since we found that the Stille coupling reaction is very efficient on mesochloro-BODIPYs (Chapter 4), we hoped that selective and global coupling reactions
could both work if stoichiometric amounts of excess coupling reagents are used.
The global coupling reaction was tried first with excess organotin reagents including 2(tributylstannyl)thiophene, tributylphenylstanne and trimethyl[(tributylstannyl)ethynyl]silane (Scheme 5.3). A typical reaction procedure followed the Stille coupling reaction
conditions we used in Chapter 4. In all cases, when the solutions were heated to 110 oC,
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the reaction solution started to change color and became deeper in color with time. The
reactions were monitored with UV/visible spectrophotometry and TLC; when the starting
material was all used according TLC and the UV/visible spectrum showed a strong peak
around 600 nm, the reactions were stopped. The global coupling reactions were usually
left stirring overnight. The tri-thiophene-BODIPY prepared in this way with 2(tributystannyl)thiophene has an absorption at 592 nm and tri-TMS-ethynyl-BODIPY has
a very red shifted absorption at 648 nm while the corresponding tri-phenyl-BODIPY has
a slight red shift at 546 nm. The 2-(tributystannyl)thiophene is the most reactive among
the three reagents investigated, and gave the highest yield (83%), followed by TMSethynyltin, which gave a 79% yield. the phenyltin r,eagent was the least reactive one,
giving a 60% yield. 1H NMR spectra of these compounds showed different chemical
shifts for the same group on the meso-position and 3,5-positions. For example, tri-TMSethynyl-BODIPY has different chemical shifts for the TMS groups at 0.30 and 0.28 ppm,
although the tri-thiophene and triphenyl BODIPYs showed multiple aromatic peaks
beween 7.56-7.09 ppm and 7.53-7.38 ppm, respectively. Structures of all these new
BODIPYs were confirmed by mass spectrumometry with m/z at 639.1429 (MW+H), and
681

2970

(MW+H)

for

BODIPYs

17

and

19,

respectively.

1-Methyl-2-

(tributylstannyl)pyrrole was also tried on the tri-chloro-BODIPY 15; the product showed a
peak in its UV/visible spectrum at 582 nm, but it was not possible to successfully
separate the tin reagent from the product.
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Scheme 5.3: The global Stille coupling reactions of tri-chloro-BODIPY 15, and the X-ray
structure of BODIPY 17 and 19.

Regioselective coupling reactions were tried with the three organotin reagents above,
using a reagent ratio of 1:1 (Scheme 5.4). The solutions were refluxed for five hours
instead of overnight and the slight color change, compared with the tri-chloro-BODIPY,
indicated that only the meso-chloro group was selectively coupled. For 2(tributylstannyl)thiophene, the BODIPY 20 has absorption at 545 nm, a slightly red
shifted compared with starting material at 538 nm. The meso-phenyl-BODIPY 21 is
slightly hypsochromically shifted with an absorption at 533 nm, there is a 5 nm difference
from the starting tri-chloro-BODIPY. The TMS-ethynyl-BODIPY 22 has a significant
bathochromic shift at 584 nm, which is due to the conjugation of the triple bond of TMSethynyl group with the BODIPY core. 1H NMR spectroscopy showed resonances at 7.117.58 ppm for the meso-thiophene group, 7.38-7.50 ppm for meso-phenyl group, and
0.30 ppm for the TMS-ethynyl. The structures of the three new BODIPYs were also
confirmed by mass spectrometry, which showed peaks at m/z 523.0836 (MW+H) for the
meso-thiophene-BODIPY 20 and 517.1238 (MW+H) for the meso-phenyl-BODIPY 21
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Scheme 5.4: The selective Stille coupling reactions on meso-position of BODIPY 15, and
X-ray scrystal strucyures of BODIPYs 20 and 21.
For the three new meso-substituted BODIPYs, different functional groups were
introduced at the 3,5-positions using 2.4 equivalents of organotin reagents (Scheme 5.5).
For meso-thiophene-BODIPY 20, pheny and TMS-ethynyl groups were introduced to
yield the symmetrical BODIPYs 23 and 24, which have UV/visible absorption maxima at
562 and 608 nm. 1H NMR spectroscopy showed that these two compounds have
chemical shift at 7.10-7.59 ppm for BODIPY 23, which overlapped with meso-thiophene
group, and 0.33 ppm for TMS group of BODIPY 24. The identities of these two product
were also confirmed with their mass spectra, with m/z at 607.2238 (MW-F) and
667.2473 (MW+H), respectively.
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Scheme 5.5: Cross-coupling reaction on 3,5-positions of BODIPYs 23 and 24.

Similarly, using the meso-TMS-ethynyl-BODIPY 22, phenyl and thiophene groups were
introduced at the 3,5-positions to given the BODIPYs 25 and 26. These two BODIPYs
have UV/visible absorption maxima at 601 and 631 nm, respectively.

1

H NMR

spectroscopy showed the aromatic areas at 7.36-7.45 ppm and 7.11-7.54 ppm for
BODIPYs 25 and 26, and these two products were structurally confirmed by mass
spectrometry, with m/z at 651.1888 (MW+H) and 663.2634 (MW+Na). For the mesophenyl-3,5-dichloro-BODIPY 21, the thiophene group and TMS-ethynyl group have not
been efficiently introduced due to the low yields observed in the reaction. We are
optimizing the conditions to achieve better yield for the selective coupling reaction of
meso-chloro-BODIPY 21.
Syntheses of unsymmetric BODIPYs through Stille coupling reactions were also
attempted (Scheme 5.6). When two equivalents of organotin reagents were used, the
meso-position and one of α-positions (3 or 5-positions) could react with the organotin
reagent but leave the other α-position untouched and available for introduction of a third
(different) group using a different organotin reagent. However, the generated disubstituted product could continue to react with organotin reagent to give a trisubstituted product as a side product, which should be a minor one due to the electronic
and steric effect compared with meso-substituted BODIPY intermediate. Therefore, we
tried TMS-ethynyltin first, and the di-substituted product 27 was the major product, a
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small fraction was separated and was proven to be tri-substituted product. The BODIPY
27 has an absorption at 615 nm in its UV-visible spectrum. 1H NMR spectroscopy
showed two different chemical shifts for the two TMS groups at 0.27 and 0.30 ppm. The
identity of the product was also confirmed with its mass spectrum, with m/z at 619.2185
(MW+H).

Scheme 5.6: Synthesis of asymmetric BODIPYs through Stille coupling reactions of
BODIPY 15.

5.4. Conclusion
Tri-chloro-BODIPY 15 was synthesized by phosgenation of di-iodopyrroketone 12, and
with this cmpound global and regioselective Stille coupling reactions were explored.
Coupling reactions can take place selectively on meso-position (over the 3,5-positions)
of BODIPYs. Therefore, the same group can be introduced to the 8, 3, and 5-positions of
a BODIPY once, or one group can be selectively introduced to the meso-position,
followed by the different groups on the 3 and 5-postions. We also explored the synthesis
of asymmetric BODIPYs through Stille coupling reactions by introducing the same group
to the meso and one of α-positions simultaneously, followed by introduction of a different
group on the one remaining α-position. Some new products were synthesized and
characterized by 1H NMR,

13

C NMR and mass spectrometry. The results above indicate

that it should be possible to introduce one Stille substituent to the meso-position,
followed by another to an α–position, and yet a third to the second (remaining) α –
position (see below).
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5.5 Near Future and Future Work
1. Syntheses of asymmetric BODIPYs by Stille coupling reactions.
We already tried the synthesis of asymmetric BODIPYs by changing the ratio between
tri-chloro-BODIPYs and organotin reagents (1:2). Another way to synthesize asymmetric
BODIPY is to introduce three different groups to 8, 3, and 5-positions one by one
accordingly. For example, the meso-position could be substituted by introduction of a
pheny group first, followed by introducing a thiophene group to the 3-position, and then
the 5-position could be substituted with a TMS-ethynyl group. All these three steps
should use one equivalent of organotin reagents. Another route to synthesize
Method I
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asymmetric BODIPY is by using dichloro-BODIPY 16; two groups can be introduced to
the BODIPY, followed by halogenation (such as bromination) on the 5-position; then
another Stille coupling reaction can be performed on the molecule.
Method II

2.

Replacement reactions

Selective or global replacement reactions by using various nucleophiles could be
explored on tri-chloro-BODIPYs to see if there is selectivity between the meso-position
and the 3 and 5-positions of BODIPYs.

243

3. Introducing carboranes to BODIPYs.
We already synthesized several BODIPYs which contained TMS-ethynyl group at
different postions; the TMS-protective groups can be cleaved and then reacted with
decarborane to introduce carboranes to BODIPYs. In this way, one, two or three
carboranes could be introduced onto the BODIPY core, and their potential as BNCT
reagents can be investigated. The In addition, an ester group can be functionalized to
introduce biomolecules such as lysine, etc, polyamines and PEFs to improve their
biological properities.
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5.6 Experimental Part
Dimethyl3,3'-(2,2'-carbonylbis(5-iodo-4-methyl-1Hpyrrole3,2diyl))dipropanoateCompound 12: Dipyrromethane 17 (6.14 g, 0.01 mol)
was dissolved in 300 ml THF, and then 5% Pd/C (350 mg) catalyst was added. The
suspension was stirred under a H2 atmosphere overnight. After TLC showed that
reaction was complete, it was stopped and the reaction solution was passed through a
Celite cake to remove the catalyst. The sticky solid on the top of Celite cake was
redissolved and neutralized in water with aqueous ammonia and the solution was
passed through the Celite cake again. The filtrate was acidified with acetic acid and a
precipitate appreared from the aqueous solution. The solid was collected by filtration.
The THF part was evaporated and combined with the solid to give total (4.0 g, 92%) of
debenzylated product. Then the dicarboxylic acid was suspended in a solution of H 2O
(250 ml)/MeOH (100 ml) and NaHCO 3 (4.48 g, 51.2 mmol) was added to the solution,
which was sonicated to form a slurry, and then a clear solution. Then a solution of I2
(3.84 g, 14.72 mmol) in methanol (60 ml) was added to the mixture dropwise at room
temperature with vigorous stirring and some brown solid was formed during the addition.
When the addition of iodine was finished, the stirring was continued for another 2 h and
the precipitate was filtered and washed with water, saturated aqueous NaHCO 3 and
water, followed by hexane to remove excess I2 to obtain a yellowish solid. The product
was left to air dry or dissolved in CH2Cl2 and dried over anhydrous Na 2SO4 before
removal of the solvent to give di-iodopyrroketone 10 (4.2 g, 75%). 1H NMR (400 MHz;
CDCl3): 9.47 (s, 2H), 3.65 (s, 6H), 2.70 (t, 4H), 2.61 (t, 4H), 2.04 (s, 6H);

13

C NMR (100

MHz; CDCl3): 173.81, 173.48, 132.72, 128.49, 126.44, 51.78, 33.91, 20.89, 12.19;
HRMS (ESI): m/z Calcd for C19H23I2N2O5 (MW+H+): 612.9691; found: 612.9697
BODIPYs 15 and 16:
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Diiodopyrroketone 12 (1.0 g, 1.63 mmol) was dissolved in CHCl 3 (150 ml) and excess
phosgene in toluene solution was added to the reaction solution, which turned deep red
with time; the reaction was monitored by UV/visible spectrophotometry and the reaction
was stopped when a sharp peak appeared at about 480 nm. Then nitrogen gas was
passed through solution to purge it of excess phosgene into an aqueous NaHCO 3
solution trap. Solvent was removed in vacuo to give a reddish solid, which was dissolved
in 150 ml of CHCl3, followed by addition of DIEA (2 ml, 7.0 equiv). The solution was
stirred for 30 min, then BF3.OEt2 (2.1 ml, 10 equiv) was added and the solution turned
bright red with a yellow fluorescent under UV long wavelength light. The reaction was
monitored by UV/visible spectroscopy which showed a sharp peak at 538 nm. The
mixture was left stirring for 24 h before being washed with water, saturated NaHCO 3 and
brine, and then dried over anhydrous Na 2SO4 to give a red solid. The product was
purified by silica gel column chromatography, eluting with ethyl acetate/hexane (1:4) to
give the product 15 as the major fraction and 16 as a minor product. BODIPY 15: 1H
NMR (400 MHz; CDCl3): 3.72 (s, 6H), 3.20 (t, 4H), 2.57 (t, 4H), 2.05 (s, 6H);

13

C NMR

(100 MHz; CDCl3): 172.50, 143.99, 142.31, 134.94, 128.45, 127.33 51.97, 33.80, 22.78,
8.87; HRMS (ESI): m/z Calcd for C19H19 BCl3F2N2O4 (MW-H+): 493.0581; found:
493.0574; BODIPY 16: 1H NMR (400 MHz; CDCl3): 7.57 (s, 1H), 3.71 (s, 3H), 3.71 (s,
3H), 3.20 (m, 4H), 2.58 (m, 4H), 2.07 (s, 3H), 2.04 (s, 3H);

13

C NMR (100 MHz; CDCl3):

172.50, 172.54, 143.54, 142.59, 142.39, 136.82, 130.12, 129.12, 128.67, 127.33, 126.83,
51.95, 51.89, 33.94, 33.87, 22.78, 22.19, 9.86, 8.87; HRMS (ESI): m/z Calcd for
C19H121BCl3FN2O4 (MW-F): 441.0955; found: 441.0935.

General Procedure for Stille Coupling Reactions:
Global coupling reactions: BODIPY 15 (15 mg, 0.03 mmol) and Pd(PPh 3)4 (3.0-5.0 mg,
8%) and were added to a round bottomed flask. The flask was flushed with argon and
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then anhydrous toluene (15 ml) was injected, followed by injection of the organotin
reagent (0.045 mmol). The solution was refluxed for 12 h until the starting material
disappeared from TLC and the UV/visible spectrum gave a sharp peak around 600 nm.
Then toluene was removed and the residue was taken up in CH 2Cl2 and washed with
water, brine and then dried over anhydrous Na 2SO4. The crude product was purified by
chromatography to give the fully (tri-) substituted products.
BODIPY 17: 1H NMR (400 MHz; CDCl3): 7.56-7.49 (m, 5H), 7.20-7.09 (m, 4H), 3.63 (s,
6H), 2.33-2.22 (m, 6H), 2.00 (s, 6H), 1.94-1.86 (m, 2H);

13

C NMR (100 MHz; CDCl3):

172.53, 149.74, 142.43, 134.43, 133.20, 132.97, 131.69, 129.72, 128.78, 128.02, 127.35,
127.23, 51.63, 35.08, 21.41, 10.62. HRMS (ESI): m/z Calcd for C31H30BF2N2O4S3
(MW+H+): 638.146; found: 638.143.
BODIPY 18: 1H NMR (400 MHz; CDCl3): 1H NMR (400 MHz; CDCl3): 7.53-7.38 (m, 15H),
3.60 (s, 6H), 2.12 (t, 4H), 2.00 (m, 4H), 1.80 (s, 6H).
BODIPY 19: 1H NMR (400 MHz; CDCl3): 3.69 (s, 6H), 3.25 (t, 4H), 2.25 (t, 4H), 2.08 (s,
6H). 0.32 (s, 9H), 0.28 (s, 9H);

13

C NMR (100 MHz; CDCl3): 172.84, 140.51, 135.96,

134.72, 132.80, 118.30, 113.96, 113.33, 99.15, 96.43, 51.67, 34.20, 21.39, 14.11, 9.52;
HRMS (ESI): m/z Calcd for C34H48BF2N2O4Si3 (MW+H+): 680.3014; found: 680.680.3001.

Selective Stille Coupling Reactions:
The selective coupling reactions followed the procedure of general coupling reactions.
The only difference was that 1.0 equiv of organotin reagent was used instead of excess
organotin reagents.
BODIPY 20: 1H NMR (400 MHz; CDCl3): 7.56 (dd, 1H), 7.15 (dd, 1H), 7.09 (dd, 1H),
3.62 (s, 6H), 2.28-2.02 (m, 6H), 1.96 (s, 6H), 1.89-1.83 (m, 2H);

13

C NMR (100 MHz;

CDCl3): 172.14, 145.04, 143.34, 133.48, 132.80, 130.97, 129.12, 128.48, 127.41, 126.92,

248

51.72, 34.84, 21.45, 8.83; HRMS (ESI): m/z Calcd for C23H23BCl2FN2O4S (MW-F):
523.0833; found: 523.0836
BODIPY 21: 1H NMR (400 MHz; CDCl3): 7.56-7.38 (m, 5H), 3.58 (s, 6H), 2.04 (t, 4H),
1.95 (m, 10H);

13

C NMR (100 MHz; CDCl3): 171.93, 144.35, 143.17, 141.09, 133.25,

130.07, 129.90, 129.03, 128.11, 126.49, 51.59, 34.29, 21.35, 8.74; HRMS (ESI): m/z
Calcd for C25H25BCl2F2N2O4 : 517.1268; found: 517.1278.
BODIPY 22: 1H NMR (400 MHz; CDCl3): 3.71 (s, 6H), 3.30 (t, 4H), 2.59 (t, 4H), 2.04 (s,
6H), 0.30 (s, 9H);

13

C NMR (100 MHz; CDCl3): 172.58, 143.02, 142.12, 131.69, 126.43,

119.32, 114.82, 98.36, 51.76, 34.15, 21.65, 8.78.

Cross Stille Coupling Reactions:
BODIPY 23 (10 mg, 0.018 mmol) and Pd(PPh 3)4 (2.0 mg, 10%) were added to a round
bottomed flask and flushed with argon several times. Anhydrous toluene (10 ml) was
added, followed by injection of tributylphenyltin (17 µl, 3.0 equiv); the solution was
refluxed for 12 h until a sharp peak appeared in the UV/visible spectrum at 562 nm in
CH2Cl2. The reaction was stopped and the toluene was removed; the residue was taken
up in CH2Cl2 and washed with water, brine and the dried over anhydrous Na 2SO4. The
crude product was purified by silica gel column chromatography, eluting with ethyl
acetate/hexane (1:4) to give the product as a purple-red solid. All the other cross Stille
coupling reaction followed this procedure.
BODIPY 23: 1H NMR (400 MHz; CDCl3): 7.59-7.14 (m, 13H), 3.65 (s, 6H), 2.29-2.27 (m,
6H), 2.07-1.96 (m, 2H), 1.86 (s, 6H);

13

C NMR (100 MHz; CDCl3): 172.61, 157.21,

142.46, 134.46, 132.27, 131.85, 129.63, 128.85, 128.67, 128.33, 127.89, 127.78, 127.19,
51.61, 35.08, 21.48, 9.81; HRMS (ESI): m/z Calcd for C35H33BFN2O4S (MWF) :607.2238 ; found: 607.2234.
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BODIPY 24: 1H NMR (400 MHz; CDCl3): 7.54 (dd, 1H), 7.14 (dd, 1H), 7.08 (dd, 1H),
3.63 (s, 6H), 2.19 (m, 6H), 2.02 (s, 6H), 1.90 (m, 2H), 0.33 (s, 18H);

13

C NMR (100 MHz;

CDCl3): 172.39, 141.68, 137.79, 133.96, 133.58, 133.24, 129.01, 128.07, 127.21, 113.65,
96.17,

51.58,

34.87,

21.19,

9.54,

0.25;

HRMS

(ESI):

m/z

Calcd

for

C33H42BF2N2O4SSi2 :667.2465 ; found: 667.2473.
BODIPY 25: 1H NMR (400 MHz; CDCl3): 7.54 (dd, 1H), 7.50 (dd, 1H), 7.11(dd, 1H), 3.72
(s, 6H), 3.39 (t, 4H), 2.64 (t, 4H), 2.09 (s, 6H), 0.32 (s, 18H); );

13

C NMR (100 MHz;

CDCl3): 172.98, 147.91, 141.22, 133.78, 131.87, 131.72, 129.13, 128.72, 127.30, 119.21,
113.57, 99.39, 51.66, 34.38, 31.59, 21.61, 10.58, 1.10; HRMS (ESI): m/z Calcd for
C32H35BFN2O4S2Si (MW-F) :633.1885 ; found: 633.1883.
BODIPY 26: 1H NMR (400 MHz; CDCl3): 7.45-7.36 (m, 10H), 3.72 (s, 6H), 3.39 (t, 4H),
2.67 (t, 4H), 1.89 (s, 6H), 0.33 (s, 9H);

13

C NMR (100 MHz; CDCl3): 173.04, 155.46,

141.29, 133.06, 131.91, 129.68, 128.78, 128.09, 127.72, 113.28, 99.30, 51.62, 34.42,
21.70, 9.74, 1.09; HRMS (ESI): m/z Calcd for C36H39BFN2O4Si (MW-F) :621.2756 ; found:
621.2757.
Synthesis of asymmetric BODIPY 27: BODIPY 15 (15 mg, 0.03 mmol) and Pd(PPh3)4
(3.0-5.0 mmg, 8%) and were added to a round bottomed flask. The flask was flushed
with argon and then anhydrous toluene (15 ml) was injected, followed by injection of the
organotin reagent trimethyl[(tributylstannyl)ethynyl]silane (22.3 µl, 0.06 mmol). The
mixture was refluxed until the starting material disappeared as observed by TLC and the
UV/visible spectrum showed a sharp peak around 615 nm. Then the toluene was
removed and the residue was taken up in CH 2Cl2 and washed with water, brine and then
dried over anhydrous Na 2SO4. The crude product was purified by silica gel column
chromatography to give the fully substituted products. 1H NMR (400 MHz; CDCl3): 3.68
(s, 3H), 3.68 (s, 3H), 3.25 (m, 4H), 2.56 (m, 4H), 2.07 (s, 3H), 2.02(s, 3H), 0.30 (s, 9H),
0.27 (s, 9H);

13

C NMR (100 MHz; CDCl3): 172.79, 172.67, 143.97, 142.12, 140.47,
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135.15, 133.30, 132.94, 126.60, 118.91, 114.44, 113.05, 98.73, 96.03, 51.76, 51.72,
34.24, 34.11, 21.67, 21.40, 9.53, 8.82, 0.32, 1.17; m/z Calcd for C29H39BClF2N2O4Si2
(MW+H) :619.2198; found: 619.2185.
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5.7. Supporting Information

1

H and 13C NMR spectra of dibenzyl 5,5'-carbonylbis(4-(3-methoxy-3-oxopropyl)-3methyl-1H-pyrrole-2-carboxylate) in CDCl3.
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1

H and 13C NMR spectra of dimethyl 3,3'-(2,2'-carbonylbis(5-iodo-4-methyl-1H-pyrrole3,2-diyl))dipropanoate 12 in CDCl3.
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1

H and 13C NMR spectra of BODIPY 15 in CDCl3.
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1

H and 13C NMR spectra of BODIPY 16 in CDCl3.
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1

H and 13C NMR spectra of BODIPY 17 in CDCl3.
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1

H and 13C NMR spectra of BODIPY 19 in CDCl3.
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1

H and 13C NMR spectra of BODIPY 20 in CDCl3.
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1

H and 13C NMR spectra of BODIPY 21 in CDCl3.
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1

H and 13C NMR spectra of BODIPY 22 in CDCl3.
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1

H and 13C NMR spectra of BODIPY 23 in CDCl3.

261

1

H and 13C NMR spectra of BODIPY 24 in CDCl3.
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1

H and 13C NMR spectra of BODIPY 25 in CDCl3.
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1

H and 13C NMR of BODIPY 26 in CDCl3.
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1

H and 13C NMR of BODIPY 27 in CDCl3.
265

1

H NMR spectrum of BODIPY 18 in CDCl3 at 400 MHz.
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